Engineered multi-component system for identifying and characterizing T cell receptors and T cell antigens

Through a multi-component system, including engineered antigen presenting cells and genomic receiving sites, the problem of difficulty in identifying T cell receptor and antigen diversity in the prior art is solved, and rapid and high-throughput antigen and TCR sequence recognition is achieved. , improving the efficiency and accuracy of clinical diagnosis and treatment.

CN118931845APending Publication Date: 2024-11-12GENOVIE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411032748.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-11-07
Filing Date
2017-11-07
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing technology is difficult to quickly and high-throughput recognition and characterize the diversity of T cell receptors (TCRs) and antigens, especially in clinical diagnosis and immunotherapy, resulting in difficulty in identifying antigen targets and controlling immune responses. .

Method used

A multi-component system has been developed, including engineered antigen presenting cells (eAPCs), genomic receiving sites and matching genetic donor vectors, for rapid and high-throughput production of stable derivative cells, presenting multiple forms of antigens molecules that recognize and characterize these antigens and homologous TCR sequences. The system invalidates eAPC for surface presentation of HLA and antigen presenting molecules through genome editing and contains genome receiving sites for ORF and antigen molecules used to insert antigen presenting molecules, designed to target the genetics of genome receiving sites of APC Donor vector, achieving efficient antigen presentation and TCR recognition.

Benefits of technology

Achieve highly standardized systematic assembly and efficient antigen presentation, reducing cell preparation cycles and costs, enabling rapid identification and characterization of T cell antigens and homologous TCRs, providing potential targets for immunotherapy and diagnosis, and improving the The understanding of antigenic targets and the ability to control immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004970325030000322
    Figure BDA0004970325030000322
  • Figure BDA0004970325030000332
    Figure BDA0004970325030000332
  • Figure BDA0004970325030000341
    Figure BDA0004970325030000341
Patent Text Reader

Abstract

The present invention relates to a multi-component system in which a first component is an engineered antigen presenting cell (eAPC), referred to as component A, and a second component is a genetic donor vector, referred to as component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and / or an analyte antigen molecule (aAM), wherein component Aa. Lacks endogenous surface expression of at least one family of aAPX and / or aAM and b. Comprises at least two genomic reception sites, referred to as component B and component D, each for integrating at least one ORF encoding at least one aAPX and / or aAM, and component C is matched to component B, and wherein component C is designed to deliver c. A single ORF encoding at least one aAPX and / or aAM, or d. Two or more ORFs encoding at least one aAPX and / or aAM, wherein the genomic reception sites B and D are synthetic constructs designed for recombinant protein mediated exchange (RMCE).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of PCT application PCT / EP2017 / 078376, filed on November 7, 2017, with the invention name “Engineered multi-component system for identifying and characterizing T cell receptors and T cell antigens”. The date on which the PCT application entered the Chinese national phase is May 6, 2019, and the application number is 201780068369.8. Field of the Invention

[0002] The present invention relates to the construction, assembly and use of a multi-component system comprising at least three components, namely, engineered antigen presenting cells (eAPCs), engineered genomic receptor sites and matched genetic donor vectors. The present invention is used to rapidly and high-throughput generate stable derivative cells that present multiple forms of antigen molecules for the identification and characterization of these antigens and cognate TCR sequences.

[0003] Introduction of the Invention

[0004] Immune surveillance by T lymphocytes (T cells) is a core function of adaptive immunity in all jawed vertebrates. Immune surveillance by T cells is achieved through rich functional diversity between T cell subtypes, which is used to eliminate pathogen infections and tumor cells and coordinate adaptive immune responses to invading pathogens, symbiotic microorganisms, symbiotic non-self factors such as molecular components of food, and even maintain self-immune tolerance. In order to respond to various foreign and self factors, T cells must be able to specifically detect the molecular components of these foreign and self factors. Therefore, T cells must be able to detect a large area of ​​self and non-self molecules encountered by individuals, with sufficient specificity to cause effective responses against pathogenic organs and diseased self, while avoiding causing such responses against healthy self. When considering the almost infinite diversity of foreign and self molecules, the highly complex nature of this task becomes clear, and pathogens are under evolutionary pressure to escape T cell detection.

[0005] T cell receptor (TCR)

[0006] T cells are mainly defined by the expression of T cell receptors (TCRs). TCRs are components of T cells that are responsible for interacting with and sensing the target of T cell adaptive immunity. In general, TCRs are composed of heterodimeric protein complexes presented on the cell surface. Each of the two TCR chains consists of two extracellular domains, namely variable (V)-regions and constant (C)-regions, both of which are immunoglobulin superfamily (IgSF) domains, forming antiparallel β-sheets. They are anchored in the cell membrane by type I transmembrane domains, which are adjacent to short cytoplasmic tails. The quality of T cells that adapt and detect different molecular components comes from the variation of TCR chains produced during T cell occurrence. This variation is produced by somatic recombination in a manner similar to that of antibodies in B cells.

[0007] TCR chain diversity

[0008] The T cell pool consists of several functionally and phenotypically heterogeneous subsets. However, T cells can be broadly classified as αβ or γδ based on the somatically rearranged TCR form they express on their surface. There are two forms of TCR chain pairs; TCRα (TRA) and TCRβ (TRB) pairs; and TRCγ (TRG) and TCRδ (TRD) pairs. T cells expressing the TRA:TRB pair are called αβ T cells, while T cells expressing the TRG:TRD pair are usually called γδ T cells.

[0009] The αβ and γδ forms of TCR are responsible for the recognition of different ligands or 'antigens', and each T cell generates αβ or γδ receptor chains de novo during T cell maturation. These de novo TCR chain pairs achieve diversity of recognition by generating receptor sequence diversity in a process called somatic V(D)J recombination, in which each T cell expresses a copy of a single, distinctly rearranged TCR. At the TRA and TRG loci, many discrete variable (V) and functional (J) gene segments are available for recombination and juxtaposed with constant (C) gene segments, hence the name VJ recombination. The recombination at the TRB and TRD loci additionally includes a diversity (D) gene segment and is referred to as VDJ recombination.

[0010] Each recombinant TCR has the potential for unique ligand specificity, which is determined by the structure of the ligand binding site formed by the α and β chains in the case of αβT cells or by the structure of the ligand binding site formed by the γ and δ chains in the case of γδT cells. The structural diversity of TCRs is mainly limited to three short hairpin loops on each chain, called complementary determining regions (CDRs). Three CDRs are contributed from each chain of the receptor chain pair, and these six CDR loops are co-located at the membrane-distal end of the TCR extracellular domain to form an antigen binding site.

[0011] Sequence diversity in each TCR chain is achieved in two modes. First, the random selection of gene segments for recombination provides base sequence diversity. For example, TRB recombination occurs between 47 unique V, 2 unique D and 13 unique J germline gene segments. Typically, the V gene segment contributes both CDR1 and CDR2 loops and is therefore germline encoded. The second mode for generating sequence diversity occurs within the hypervariable CDR3 loop, which is generated by randomly deleting template nucleotides and adding non-template nucleotides at the junction between the recombinant V, (D) and J gene segments.

[0012] TCR:CD3 complex

[0013] Mature αβ and γδTCR chain pairs are presented on the cell surface of the complex with many auxiliary CD3 subunits (expressed as ε, γ, δ and ζ). These subunits are combined with αβ or γδTCR into three dimers (εγ, εδ, ζζ). The TCR:CD3 complex forms a unit that starts the cell signaling reaction when αβ or γδTCR engages with the cognate antigen. The CD3 auxiliary associated with the TCR:CD3 complex contributes a signal motif known as an activation motif (ITAM) based on immunoreceptor tyrosine. CD3ε, CD3γ and CD3δ each contribute a single ITAM, and CD3ζ homodimers contain 3 ITAMs. Therefore, three CD3 dimers (εγ, εδ, ζζ) assembled with TCR contribute 10 ITAMs. After TCR ligation with cognate antigen, phosphorylation of tandem tyrosine residues generates paired docking sites for proteins containing Src homology 2 (SH2) domains, such as the critical zeta chain-associated protein of 70 kDa (ZAP-70). The re-recruitment of these proteins initiates the formation of the TCR:CD3 signaling complex, which is ultimately responsible for T cell activation and differentiation.

[0014] αβT cells

[0015] αβT cells are usually more abundant in humans than their γδT cell counterparts. Most αβT cells interact with peptide antigens presented by the HLA complex on the cell surface. These peptide-HLA (pHLA) recognition T cells are the first to be described and are the best characterized so far. More rare forms of αβT cells have also been described. Mucosal-associated invariant T (MAIT) cells appear to have relatively limited α and β chain diversity and recognize bacterial metabolites rather than protein fragments. Invariant natural killer T cells (iNKT cells) and germline-encoded mycoacyl reactive T cells (GEMT cells) are limited to recognizing glycolipids cross-presented by non-HLA molecules. iNKT cells are mainly thought to interact with glycolipids presented by CD1d, while GEMT cells interact with glycolipids presented by CD1b. It is believed that other forms of T cells interact with glycolipids in the context of CD1a and CD1c, however, these cells have not yet been characterized in significant detail.

[0016] Conventional αβT cells

[0017] A key feature of most αβ T cells is the recognition of peptide antigens in the context of HLA molecules. These are often referred to as "conventional" αβ T cells. Within an individual, self-HLA molecules present peptides of self and foreign proteins to T cells, providing the necessary basis for adaptive immunity against malignancies and foreign pathogens, and adaptive tolerance to commensal organisms, food, and self. The HLA loci encoding HLA proteins are the most gene-dense and polymorphic regions of the human genome, and more than 12,000 alleles have been described in humans. The high degree of polymorphism in the HLA loci ensures diversity in peptide antigen presentation between individuals, which is important for group-level immunity.

[0018] HLA class I and class II

[0019] There are two forms of classical HLA complexes: HLA class I (HLAI) and HLA class II (HLAII). There are three classical HLAI genes: HLA-A, HLA-B, HLA-C. These genes encode transmembrane α chains, which associate with constant β2-microglobulin (β2M) chains. The HLAI α chain consists of three domains with immunoglobulin folds: α1, α2 and α3. The α3 domain is near the membrane and is mostly constant, while the α1 and α2 domains form a polymorphic membrane-distal antigen binding cleft together. There are six classical HLAII genes: HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA and HLA-DRB1. These genes encode paired DP, DQ and DR heterodimer HLA complexes containing α chains and β chains. Each chain has two major structural domains with an immunoglobulin fold, of which the α2 and β2 domains contain a membrane-proximal and largely invariant module similar to the HLA Iα3 domain. The HLA II α2 and β2 domains together form the membrane distal antigen-binding cleft and are a region of high polymorphism.

[0020] The antigen binding cleft of HLA I and HLA II contains two antiparallel α-helices on the platform of eight antiparallel β-sheets. In this cleft, peptide antigens bind and exist in an extended conformation. The peptide contact residues in HLA I and HLA II are the positions of most sequence polymorphisms, which constitute the molecular basis of the various peptide libraries presented by different HLA alleles. The peptide is widely in contact with the antigen binding cleft and the result is that each HLA allele imposes different sequence restrictions and preferences on the presented peptides. Therefore, a given peptide only binds a limited number of HLAs, and accordingly each allele only adapts to a specific part of the peptide set from a given protein. A group of HLA I and HLA II alleles present in each individual is called HLA haplotype. The polymorphism of HLA I and HLA II genes and the codominant expression of genetic alleles drive the very large diversity of HLA haplotypes in the population, and when coupled with the huge sequence diversity of αβ TCR, a high degree of standardization of the analysis of these HLA antigen-TCR interactions is presented.

[0021] αβTCR engagement of HLA I and HLA II

[0022] αβTCR recognizes peptides as part of a mixed pHLA binding interface formed by residues of HLA and peptide antigens (altered self). HLAI complexes are presented on the surface of almost all nucleated cells and are generally considered to present peptides derived from endogenous proteins. Therefore, T cells can interrogate the endogenous cell proteome of HLAI presenting cells by sampling the pHLAI complex of interacting cells. The engagement of HLAI requires the expression of TCR co-receptor CD8 by interacting T cells, so HLAI sampling is limited to CD8+αβT cells. In contrast, the surface presentation of HLAII complexes is mainly limited to professional APCs, and is generally considered to present peptides derived from proteins exogenous to presenting cells. Therefore, interacting T cells can interrogate the proteome of the extracellular microenvironment where presenting cells are located. The engagement of HLAII requires the expression of TCR co-receptor CD4 by interacting T cells, so HLAII sampling is limited to CD4+αβT cells.

[0023] Thymic selection of αβTCR

[0024] The role of the αβTCR as described above is to detect the pHLA complex so that the TCR presenting T cell can improve the response that is closely related to the role of the T cell in establishing immunity. It should be considered that the αβTCR library generated within an individual must take into account the huge and unforeseen diversity of all foreign antigens that may be encountered in a specific haplotype background and before it actually occurs. This result is achieved on such a background, in which extremely diverse and numerous αβTCRs are generated in a quasi-random manner, with the potential to recognize unspecified pHLA complexes, while being specifically instructed only to avoid strong interactions with self-pHLA. This is carefully planned during T cell maturation in a process called thymic selection.

[0025] During the first step of T cell maturation in the thymus, T cells carrying αβTCRs that cannot interact with self-pHLA complexes with sufficient affinity are deprived of survival signals and eliminated. This step, called positive selection, ensures that surviving T cells carry a TCR library that is at least potentially able to recognize foreign or altered peptides presented in the correct HLA context. Subsequently, αβTCRs that strongly interact with self-pHLA and therefore have the potential to drive autoimmunity are actively removed by a negative selection process. This combination of positive and negative selection results in only T cells carrying αβTCRs with low affinity for self-pHLA, thus filling the periphery. This establishes an αβT cell library that is self-limiting but not self-reactive. The highly personalized nature of this T cell occurrence for HLA haplotypes emphasizes the challenges in standardized analysis of αβTCR-antigen-HLA interactions. In addition, it forms the basis for graft rejection and graft-versus-host disease, as well as the general principle that an αβTCR identified in one individual may have a completely different effect in a second individual, which has a clear impact on TCR- and T cell-based therapeutic and diagnostic strategies that appear in clinical practice.

[0026] Unconventional αβ T cells

[0027] Non-HLA restricted or "unconventional" forms of αβT cells have very different molecular antigen targets. These unconventional αβT cells do not engage the classical HLA complex, but engage conserved HLA-like proteins, such as the CD1 family or MR1. The CD1 family includes four forms (CD1a, b, c and d) that participate in antigen cross-presentation. These cell surface complexes have an α-chain similar to HLA I, which forms a heterodimer with β2-M. The small hydrophobic pocket presented at the distal surface of the membrane of the α chain forms a binding site for pathogen-derived lipid-based antigens. Innate-like NK T cells (iNK T cells) form the best understood example of lipid / CD1 family recognition, and GEM T cells represent another prominent example. It is known that 'type I' iNK T cells interact strongly with lipid α-GalCer in the context of CD1d. These iNK T cells display very limited TCR diversity, with fixed TCR α chains (Vα10 / Jα18) and a limited number of β chains (with restricted vβ usage), and they have been likened to innate pathogen-associated molecular patterns (PAMPS) recognizing receptors such as Toll-like and Nod-like receptors. In contrast, ‘type II’ NK T cells present a more diverse TCR repertoire and appear to have more diverse CD1d-lipid complex engagement patterns. GEM T cells recognize mycobacterium-derived glycolipids presented by CD1b, however, the molecular details of antigen presentation by CD1a, b and c and their T cell recognition are only beginning to be understood.

[0028] MAIT cells predominantly express invariant TCR α chains (TRAV1-2 linked to TRAJ33, TRAJ20, or TRAJ12) that are capable of pairing with a range of TCR β chains. Rather than peptides or lipids, MAIT TCRs can bind pathogen-derived folate- and riboflavin-based metabolites presented by the HLA I-like molecule MR1. The limited but significant TCR diversity observed on MAIT TCRs appears to be able to recognize diverse but related metabolites in the context of a conserved MR1.

[0029] It is not clear how nonclassical HLA-restricted αβ T cell TCRs are selected in the thymus during maturation. However, it appears that the basic processes of negative and positive selection outlined above still apply, and some evidence suggests that this occurs in a specialized microenvironment within the thymus.

[0030] γδ T cells

[0031] Compared to the detailed mechanistic understanding of αβ TCR development and pHLA engagement, relatively little is known about the antigenic targets and context of their γδ T cell counterparts. This is partly due to their relatively low abundance in the circulating T cell compartment. However, it is widely accepted that γδ T cells are not strictly HLA-restricted and, unlike antibodies, appear to recognize surface antigens more freely. Additionally, it has recently been recognized that γδ T cells can innervate the resident T cell compartment of epithelial tissues, the major interaction site of the immune system with foreign antigens. Furthermore, various mechanisms of γδ T cell tumor immunosurveillance and other forms of dysregulated self-surveillance are beginning to emerge in the literature. The specific antigenic targets of innate-like and adaptive γδ T cells remain poorly defined, but the tissue distribution and rapid recognition of PAMPs suggest that γδ T cells play a fundamental role in the early stages of the response to foreign antigens and early in life when the adaptive immune system is still maturing.

[0032] The diverse functions of γδ T cells appear to be based on the use of different VγVδ gene segments and can be broadly understood in two main categories, where γδ T cells with a largely invariant TCR mediate innate-like recognition of PAMPs very early during infection. In addition to PAMPs, these types of γδ T cells are also thought to recognize self molecules, including phosphoantigens that can provide very early signatures of cellular stress, infection, and potential tumor development. The recognition of PAMPs and so-called danger-associated molecular patterns (DAMPS) as well as the large number of tissue-restricted innate-like γδ T cells strongly suggest that these cells are adapted to respond rapidly to antigenic challenge without prior activation, homing, and clonal expansion.

[0033] The second form of γδ T cells is thought to be more adaptive in nature, with a highly diverse γδ TCR repertoire and the ability to direct peripheral circulation and access lymphoid tissues. Antigen-specific γδ T cells of this type have been described against common human pathogens such as CMV, and they appear to form memory responses. However, it has also been observed that γδ T cells show only relatively limited clonal proliferation after activation, and there are few data on the extent of TCR diversity and the specific responses of γδ T cells in the peripheral circulation or tissues. Furthermore, although it is generally believed that γδ TCRs do not interact with the pHLA complex and therefore do not engage peptide antigens in this context, only a few antigenic targets of γδ T cells have been characterized, and the underlying molecular framework is only poorly understood.

[0034] The low frequency of peripheral γδT cells and the difficulty in studying human tissue-resident T cells have limited our understanding of how important and diverse T cells are in the adaptive immune response. This emerging area of ​​research requires more reliable techniques to capture and characterize rare γδT cells, isolate their TCR pairs, and recognize their cognate antigens.

[0035] Antigens and antigen presenting cells

[0036] In the context of T cells and TCR, antigens can be defined as any molecule that can engage with TCR and cause signal transduction in T cells. The most fully characterized T cell antigens are peptides presented in HLA I and HLA II complexes, and they are engaged by conventional αβ T cells. However, in recent years, it has become clear that unconventional αβ T cells and γδ T cells are able to engage a wide range of biomolecules as antigens, including lipids, lipopeptides, glycopeptides, glycolipids, and a series of metabolites and catabolites. In addition, it has been found that γδ T cells may be able to directly engage fully folded proteins in an antibody-like manner. Therefore, in the past two decades, the view that T cell antigens are largely limited to peptides presented by HLA has been extended to include almost any biomolecule. Considering this concept, it is relevant to define what can be considered as antigen presenting cells (APC).

[0037] As defined in the above part, HLA I and HLA II have completely different expression profiles across cell types. It is widely accepted that almost all nucleated cells present HLA I complexes on the cell surface, so peptide antigens for T cell sampling can be presented. On the contrary, HLA II has a limited expression profile, and at least under steady-state conditions, it is only expressed on the cell surface with expert effects in antigen presentation, including dendritic cells (DC), macrophages and B cells. These expert cell types are generally referred to as full-time APC. For the purpose of this document, the term APC is used to describe any nucleated cell that can present antigens for α β or γ δ T cell sampling. Such antigens are not limited to those presented as "cargo" in specific antigen presenting complexes (such as HLA and HLA-like molecules), but can also include any cell surface presentation that can engage with cells carrying α β or γ δ TCR.

[0038] Therapeutic uses of TCRs

[0039] Adoptive transfer of primary T cells was first tested in clinical settings in the early 1990s, beginning with polarization of ex vivo expanded T cells toward viral antigens to confer viral immunity in immunocompromised patients. Similar approaches followed soon after in trials for the treatment of malignancies using primary T cells expanded ex vivo against specific cancer antigens. A limitation of these early approaches that remains a challenge today is the lack of understanding of the nature and diversity of T cells, conflicting with the need to finely optimize their composition in therapeutic products. Currently, with the exception of a few initiatives using primary T cells specific for viral antigens, the pharmaceutical industry has largely abandoned the use of ex vivo expanded primary T cells.

[0040] In recent years, the ability to reliably introduce genetic material into primary human cells has led to the emergence of various experimental genetically modified T cell therapeutics. Such therapeutic cell products are intended to control the ability of T cell responses and redirect T cell specificity to disease-related antigen targets, such as antigens uniquely expressed by malignant cells. These rely heavily on transferring chimeric antigen receptors (CARs) into recipient T cells, rather than actual TCR chain pairs. CAR represents a targeting portion (most commonly a single-chain antibody element that targets surface-expressed proteins of malignant cells), which is transplanted to a signaling receptor element, such as the ζ-chain of the CD3 complex, to produce a synthetic chimeric receptor that mimics CD3-TCR function. To date, these so-called CAR T cell (CAR-T) products have achieved varying success in clinical trials, although their potential is not easily converted beyond tumors with inherent unique molecular targets (such as B cell malignancies). Alternatively, the transfer of full-length TCR chain pairs ORFs into T cells is a new interest. Such TCR-engineered T cell therapies are currently limited by challenging manufacturing methods and, like CAR-T products, lack effective antigen targets and targeting constructs. To date, this has focused on using αβ TCRs to recognize peptide antigens presented by HLA I on malignant cells, and a fundamental challenge of this approach is the need for antigens that are specific to malignant cells.

[0041] It has been thought that natural TCRs may not be optimal for TCR-engineered T cell therapies because the TCR-pHLA interaction has a relatively low affinity. Several methods have been designed to affinity mature TCRs in vitro in a manner very similar to single-chain antibody affinity maturation. These TCR affinity maturation methods also typically use a single-chain format, in which the V region of one chain is fused to the V region of another chain to prepare a single polypeptide construct. This single polypeptide can then be used in a phage or yeast display system adapted to the antibody engineering workflow and selected by rounds based on target binding. In terms of generating functional TCR chain pairs, there are two inherent limitations in this single-chain TCR approach. First, the selection is based on binding affinity to the target. However, it has been well documented that TCR affinity is not always associated with the strength or ability of TCR signal transduction output. Second, the selection of affinity-based single-chain constructs, once reconstructed into full-length receptors, does not always translate into equivalent affinity.

[0042] In the therapeutic context, affinity-matured TCRs present additional and critical limitations. That is, given that their sequences have been altered, by definition, the resulting constructs are no longer subject to thymic selection, with TCRs that strongly react to self-antigens missing from the library. Therefore, these modified TCRs have an inherent risk of self-reactivity, which is difficult to exclude in vitro using existing methods. For the same reason, any selected or engineered TCR for therapeutic application needs to be personalized. If the TCR is artificially engineered or natural TCR is applied to an individual, cross-reactivity must be excluded based on the HLA haplotype and the peptide library presented for each specific individual to avoid potentially catastrophic autoimmunity. This is because thymic selection is performed on the background of all available HLA molecules, which are specific only to a given individual. The possibility of such cross-reactions is unclear. However, the ability of the TCR library to recognize pHLA complexes of other individuals of the same species as the foreign source is a fundamental property of adaptive immunity and supports graft rejection and graft-versus-host disease. Recent clinical trials using mature TCR chains against cancer-specific melanoma-associated antigens (MAGE) have highlighted potential problems in bypassing thymic selection. When autologous T cells carrying mature TCRs were infused back into two cancer patients, these patients rapidly developed fatal heart disease. Subsequent studies determined that the MAGE-specific mature TCRs cross-reacted with peptides presented by HLA I from the cardiac protein titin. This strongly suggests that cross-reactivity is a distinct possibility in the therapeutic use of TCRs.

[0043] A different approach to utilizing TCRs for therapeutic purposes is to use them as affinity agents in much the same way as antibody therapeutics. Single-chain TCR molecules have been tested for delivery of conjugated drug substances to specific HLA antigen-expressing cell populations. This approach is generally considered safer than CAR-T or TCR-engineered T cell therapeutics because administration of the drug can simply be withdrawn. However, the potential for unpredictable cross-reactivity and off-target effects remains a potential limitation in this setting.

[0044] TCR Repertoire Detection in Clinical Diagnosis

[0045] On a related note, interest has emerged in using the abundance detection of specific TCR sequences for clinical diagnostic purposes. Particularly with the rise of deep sequencing approaches, it is possible to capture the full TCR diversity within an individual globally, and the matched αβ pairs in a specific context. This could be a means of diagnosing specific conditions and disease states simply by detecting the abundance of expanded T cell clones as a proxy readout of the immune response established to disease-associated antigens in patients. However, such global approaches are currently limited to very robust immune responses with defined clinical time points, and there are potential difficulties in identifying the specific antigenic targets of any particular TCR identified by sequencing.

[0046] Therapeutic and diagnostic uses of T cell antigens

[0047] The fundamental advantage of controlling the adaptive immune response translates into a core technical challenge, as the precise specificity of the TCR-antigen interaction requires detailed knowledge of the antigens specifically associated with each pathogen, cancer cell, or autoimmune disease. In addition, each antigen can be presented by a specific antigen presenting complex or its alleles, allowing antigen discovery for each relevant HLA gene and allele. For several infectious diseases such as HIV, influenza, and CMV, which are associated with strong adaptive immune responses and generally show a conserved hierarchy of epitope responses, the most important epitopes have been mapped in the context of a few common HLAs. Similarly, the fields of cancer, allergy, and autoimmunity have seen increased and systematic efforts to map relevant T cell antigens. However, these are challenging procedures, and efforts to systematically characterize T cell antigens relevant to different clinical contexts are hampered by the lack of efficient, robust, rapid, and scalable protocols.

[0048] Cancer cells, in particular, represent a challenging and important aspect, as most peptides presented on the surface of malignant cells are self-antigens or very similar to self-antigens. As a result, TCRs that can strongly recognize these peptides will be missing by thymic selection, while tumors have evolved to evade immune recognition. This means that effective immune responses against established tumors are relatively rare and difficult to predict or find targets. However, these responses do exist and, importantly, are often associated with better outcomes. The targets of such responses, tumor-associated antigens (TAAs), will in most cases have features that distinguish them from self and will be derived from proteins that are overexpressed during cancer development, are otherwise not present in the cell type at this stage of development or are specifically altered by genetic mutations or post-translational modifications such as phosphorylation.

[0049] When available, knowledge of these epitopes makes it possible to interrogate the relevant T cell responses for basic discovery, diagnostic purposes, and, for example, as a test of vaccine efficacy. Importantly, they also provide highly specific targets for T cell tolerance in allergy and autoimmunity, and, crucially, point to valuable targets for specific immunotherapy and against malignant cells. Malignant tumors represent particularly valuable targets, as the promise of cellular immunotherapy and progress in T cell manipulation has been slowed by the lack of validated target TAAs beyond the few cases where specific markers for the cancer type happen to be available.

[0050] Given the potential of cell-based therapies and the lack of effective targets, the identification of promising TCR antigens remains one of the most pressing bottlenecks for TCR-based immunotherapy, particularly in efforts to treat cancer.

[0051] Technical aspects of TCR and T cell antigen analysis

[0052] Overall, the development of TCR-based therapeutics is still in its early stages and has had limited success. Despite its great potential, diagnostic methods are rarely used in controlled clinical studies designed to assess patients' disease status or response to therapy. Undeveloped technologies for reliable capture of native TCR chain pairs and systematic analysis of TCR-antigen interactions in the functional context of high-throughput and cell-cell communication have been major obstacles to the development of TCR-based therapeutics and diagnostics.

[0053] Deep sequencing approaches have led to an improved understanding of T cell receptor diversity in health and disease. However, these approaches have typically focused on short stretches spanning the CDR3 region, primarily the TCRβ chain. Most studies have overlooked the contribution of the TCRα chain, and few have attempted to analyze paired αβ chains as well as the antigen specificity of the TCR identified as being of interest. Recent workflows using single-cell encapsulation and genetic barcoding have enabled the analysis of paired and full-length sequences of native TCRαβ or γδ chain pairs, however, such workflows remain experimental.

[0054] Isolated TCR chain pairs can be analyzed for antigen specificity in either biophysical or functional modes. Biophysical analysis requires recombinant production of the TCR as well as a soluble form of the analyte antigen. In the case of HLA-restricted TCRs, this would require the generation of all individual TCRs as well as the cognate pHLA complex. This is technically highly challenging, slow, and has extremely low throughput. Furthermore, such analysis only provides interaction affinity, which does not correlate well with functional characteristics in a predictable manner.

[0055] Until recently, detailed functional analysis of isolated TCR sequences in a cellular context was limited to transfection of analyte TCR chain pairs into primary T cells or immortalized T cell lines and detection of cellular responses by conventional flow cytometric analysis of cell activation, or cumbersome protocols for detection of secreted factors from transfected cells after antigen challenge. In a recent publication by Guo et al., rapid cloning, expression, and functional characterization of paired TCR chains from single cells were reported (Molecular Therapy-Methods and clinical development (2016) 3: 15054). In this study, the analyte human αβTCR pair was expressed in a reporter cell line lacking αβTCR expression and containing a green fluorescent protein (GFP) reporter system linked to the Nur77 promoter activated after TCR stimulation. Due to the lack of standardized TCR integration into the reporter cell line genome, this system remains inefficient and does not provide a systematic way for APC elements to respond to cell-bound antigen challenge.

[0056] Similar to the workflow used to identify TCRs against known T cell antigens, the de novo discovery of novel T cell antigens in health and disease remains very challenging. Most approaches remain biophysical in nature and are aimed at generating candidate antigens that can be tested in immunization protocols, or by identifying cognate TCRs as described above. There is little or no standardization in the field of T cell antigen discovery, and the field is largely limited to academic research.

[0057] With the increasing interest in TCRs and their homologues for therapeutic and diagnostic uses, and the advent of means to capture large numbers of natural TCR αβ and γδ chain pairs, there is still a lack of reliable high-throughput and standardized technologies for the systematic analysis of TCR-antigen interactions. Importantly, there is a lack of standardized systems for the functional analysis of TCR chain pairs in the natural context of cell-cell communication, where both the TCR and antigen are presented by living cells. In addition, there is a lack of systematic means to provide large candidate antigen libraries for analysis of TCR-bearing cells or reagents.

[0058] Therapeutic uses of T cell antigens

[0059] With the rapid development of knowledge of T cell biology, there is increasing interest in the use of T cell antigens in therapeutic preparations. Mainly this takes the form of some type of immunization strategy. Most prominently, a large number of such mutagenized sequences can be identified in tumor cells using next-generation sequencing methods. Such sequences can represent potential T cell antigens specific to cancer cells and therefore can represent immunogens for personalized therapeutic vaccines against sequenced tumors. However, due to the large number of gene mutations that can be observed, there is no high-throughput way to analyze the ability of these potential T cell antigens to be presented by the patient's HLA library and whether these antigens are immunogenic. Currently, predictions of mutant peptide binding are calculated from a very small number of HLA alleles. These predictive models loosely inform whether a given peptide sequence will bind to HLA and generally do not predict the potential immunogenicity of the bound antigen. In addition, these computational models are unreliable for antigens that do not have canonical "anchor" residues relative to the HLA alleles that are being analyzed.

[0060] Other immunization approaches require detailed knowledge of T cell antigens, including, for example, tolerance therapy for allergic and autoimmune syndromes, and prophylactic vaccination against pathogens. In the case of the latter prophylactic vaccines, knowledge of T cell antigens from common pathogens, with the exception of a few HLA alleles, remains surprisingly poor. Systematic approaches are needed to expand this knowledge to develop effective vaccines against both common and emerging pathogens. DETAILED DESCRIPTION OF THE INVENTION

[0062] The present invention is dedicated to meeting the above needs. In particular, the present invention relates to the construction, assembly and use of a multi-component system, which comprises at least three components, namely engineered antigen presenting cells (eAPC), engineered genomic receiving sites and matching genetic donor vectors. The present invention is used to quickly and high-throughput produce stable derivative cells that present various forms of antigen molecules for identifying and characterizing these antigens and homologous TCR sequences. Specifically, eAPC is engineered by genome editing to render APC ineffective for cell surface presentation of human leukocyte antigen (HLA) molecules, HLA-like molecules and different forms of antigen presenting molecules and antigen molecules. In addition, the eAPC as part of the multi-component system contains antigen presenting molecules for inserting an encoding open reading frame (ORF), and optionally inserting a genomic receiving site for a genetically encoded analyte antigen. The system also includes a genetic donor vector designed for targeting the genomic receiving site of the APC to rapidly deliver the ORF encoding the analyte antigen molecule and / or the antigen presenting complex. The multi-component system can be used as an analytical system in clinical immunodiagnostics. Furthermore, the present invention relates to the use of multi-component systems to identify and characterize T cell antigens and cognate TCRs for the generation of immunotherapeutic and immunodiagnostic agents.

[0063] The present invention enables a highly standardized system to assemble various analyte eAPC forms in a systematic manner. This standardization and systematization is achieved by highly defined and controllable genomic integration of antigen presenting complexes and antigen molecule ORFs with matching donor vector / genomic receiving site subsystems. This controllable and predictable system provides significant efficiency for the process of generating eAPC groups, reducing the cycle time and cost of such processes. Previous systems relied on random integration using non-guided genomic integration and / or viral methods. In addition, the system is designed in part to ensure a controllable copy number of integrated ORFs, usually single copies, which allows strict control of the achievable expression level of the integrated ORF product. More importantly, the ability to integrate ORFs with a single copy from a vector pool allows so-called "shotgun integration", in which each cell integrated with a donor vector can receive only a single ORF from a vector pool that may encode different groups of ORFs. This enables the ORF library encoded in the donor vector to be transformed into an eAPC library that expresses a single desired analyte ORF in each cloned eAPC subpopulation; essentially representing a cell-based array system, similar to a phage or yeast display system. Such an array system can facilitate the identification of unknown analyte antigen sequences in a library of sequences (based on their TCR or other affinity reagent reactivity when presented by eAPCs), followed by recovery of the unknown "reactive" sequences from the carrier eAPCs. Furthermore, shotgun integration allows for efficient production of each analyte antigen within the target cell. Compared to transient transfection of a large pool of analyte antigen sequences (which would result in trace levels of transcripts available for any given analyte antigen), each cell in the eAPC library generated by shotgun integration will robustly express a single analyte for surface presentation by the eAPCs, facilitating recognition of said analyte antigen by various means.

[0064] The present invention relates to providing an engineered multi-component system whose components are used to prepare one or more analyte eAPCs. These analyte eAPCs are then combined with one or more analyte TCRs (collectively referred to as eAPC:TCR systems, eAPC:T) to obtain one or more outputs, wherein the analyte TCR can be provided as a soluble or immobilized reagent, presented on the cell surface or presented by non-cell-based particles (NCBP). The eAPCs provide candidate analyte antigens to the analyte TCRs.

[0065] The multi-component system in its smallest form comprises a first component, referred to as component A, which is an eAPC, a second component, component B, which is a genomic receiving site, and a third component, which is a genetic donor vector, referred to as component C. Figure 1 ).

[0066] The eAPC represents a fundamental component of a multi-component system to which all other components of the system are related. Thus, the eAPC contains certain characteristics, either natural or engineered, that make the eAPC suitable for use in the creation of analyte eAPC populations and their uses.

[0067] In this paper, eAPC, component A

[0068] i. lack of endogenous surface expression of at least one family of antigen presenting complexes (aAPX) and / or analyte antigen molecules (aAM),

[0069] ii. Contains at least one genomic receptor site, called component B

[0070] wherein i) can be obtained by selecting a naturally occurring cell population lacking said expression of aAPX and / or aAM, or can be engineered to lack such expression, and ii) is synthetic and can be introduced by means of targeted or non-targeted genomic integration.

[0071] Selection of eAPC cell candidates that lack the desired aAPX and / or aAM expression from a naturally occurring cell population can be achieved by methods well known in the art. This can be achieved directly by staining target cells with an affinity reagent specific for the aAPX and / or aAM that is desired to be lacking by eAPC, and selecting cells that lack the target aAPX and / or aAM expression.

[0072] Engineering of cells lacking aAPX and / or aAM expression can be accomplished by both non-targeted and targeted means. Non-targeted mutagenesis of cells can be accomplished by providing chemical, radiological or other mutagen to the cells and then selecting for cells lacking expression of the target aAPX and / or aAM. Targeted mutation of genomic loci can be accomplished by various means, including but not limited to site-directed mutagenesis via the following

[0073] i. Zinc finger nuclease

[0074] ii. CRISPR / Cas9-mediated targeting

[0075] iii. Synthetic transcription activator-like effector nucleases (TALENs)

[0076] The site-directed nuclease induces site-specific DNA repair error mutagenesis at the target locus, after which mutant cells are obtained by selecting cells lacking expression of the target aAPX and / or aAM.

[0077] Component A, eAPCs may optionally include additional T cell co-stimulatory receptors, wherein these features allow for robust or differential communication of analyte eAPCs with analyte TCR presenting cells (analyte TCs), wherein the tunable communication is associated with recognition or characterization of specific analyte TCRs and / or analyte antigens. In the present context, differential CD28 ligation on analyte TCs may be facilitated by inclusion of one or more of CD80, CD86, and / or other B7 family proteins.

[0078] Component A, eAPC, may optionally further include an introduced cell surface adhesion molecule component, or ablation of endogenous cell surface adhesion molecules, to promote engagement of the eAPC with the analyte TC and formation of immune synapses, respectively, or to avoid close association and formation of clustered deleterious cells in the combined eAPC:T system. Such adhesion molecules, which may be introduced as additional ORFs into component A or genetically eliminated from A, may be selected from the integrin family of adhesion proteins.

[0079] eAPCs may optionally possess the ability to process and load antigens as cargo into aAPXs (referred to as aAPX:aAM) via the native processing and loading machinery. eAPCs that possess the ability to process and load antigens as cargo into aAPXs via the native processing and loading machinery will also process and load cargo molecules (CMs) native to the eAPCs or culture systems containing them, wherein aAPXs loaded with CMs are referred to as aAPX:CM complexes ( Fig.17 ).

[0080] The second component of the minimal multi-component system is a genetic donor vector, component C, which is used to integrate at least one ORF encoding at least one aAPX and / or aAM ( Figure 1 ).

[0081] Component C is a genetic donor vector that is coupled to a genomic receiving site of component B contained within the genome of an eAPC, component A. Component C is designed to integrate one or more ORFs encoding aAPX and / or aAM encoded in the genetic donor vector into the genomic receiving site B, wherein the integration results in expression of aAPX and / or aAM by the target eAPC.

[0082] In this context, a paired genetic donor vector and genomic recipient site are described as an integration coupling.

[0083] In an expanded form of the multi-component system, component A eAPC can further contain a second genome receiving site (referred to as component D), which is coupled to a second genome donor vector (referred to as component E), which is also added to the system ( Figure 2 ). The multi-component system may further include one or more additional integration pairs.

[0084] Multi-component system comprising eAPC and one or two integration pairs for preparing derivative eAPC forms

[0085] i.eAPC-p

[0086] ii.eAPC-a

[0087] iii.eAPC-pa

[0088] Each genetic donor vector may contain one or more ORFs encoding one or more aAPXs and / or aAMs, such that the ORFs are integrated into coupled genomic receiving sites such that i) at least one aAPX is expressed, ii) at least one aAM is expressed, and iii) at least one aAPX and at least one aAM are expressed. Figure 3 ).

[0089] The genetic donor vector and the genomic recipient locus are integrated as a multi-component system. The genetic donor vector must first be combined with the target ORFs so that the base donor vector now encodes those target ORFs. The assembled primed donor vector is then introduced into the target eAPC to exchange the target ORFs into the genomic recipient locus, thereby integrating the target ORFs into the coupled recipient locus of the target cell ( Figure 4 ).

[0090] A multi-component system comprising genetic donor vector components C and / or E can be combined with at least one ORF encoding at least one aAPX and / or aAM to obtain components C' and / or E', wherein the combination is defined as the ligation of the genetic material into the correct coding frame and to the genetic donor vector in the correct orientation.

[0091] The combination of one or more ORFs into genetic donor vectors C and / or E can be performed multiple times with a pool of unique ORFs as follows: i. A single discrete reaction to obtain a discrete pool of C' and / or E' vectors encoding multiple ORFs

[0092] ii. Single reaction to obtain a pooled library of C' and / or E' vectors encoding multiple ORFs

[0093] Wherein discrete libraries can be combined with component A multiple times to obtain discrete libraries of eAPCs having unique ORFs encoding unique aAPXs and / or aAMs, or combinatorial libraries can be combined with component A as a single event to obtain pooled libraries of eAPCs, each library having a unique ORF encoding a unique aAPX and / or aAM.

[0094] Efficient integration of one or more ORFs at a predictable copy number into a genomic recipient site is highly advantageous for the operation of standardized eAPCs, where analyte eAPC populations can be rapidly prepared and characterized. Therefore, the genomic recipient site and the coupled donor vector are critical to the function of the eAPC. In addition, it is strongly desirable to have eAPCs in which components B and D are insulated from each other, such that the donor vector component C cannot integrate in component B and vice versa. In addition, it is also desirable that component B and / or component D be suitable for a method of preparing eAPCs, in which the introduction of a single defined aAPX and / or aAM-containing construct is rapid and reproducible, with a high probability of correct integration and delivery of a single analyte.

[0095] The genomic receiving site can be selected from the following

[0096] i. Design of synthetic constructs for recombinase-mediated cassette exchange (RMCE)

[0097] ii. Design of synthetic constructs for site-directed homologous recombination

[0098] iii. Natural genomic site for site-directed homologous recombination

[0099] Among them, i) is preferred. The RMCE method can employ selected heterologous specificity sites specific to individual recombinases, so that each component B and D possesses an isolated specificity.

[0100] The genomic receiving site, component B and / or component D comprises at least one of the following genetic elements

[0101] i. Heterologous specific recombinase site

[0102] ii. Homology arms

[0103] iii. Eukaryotic promoter

[0104] iv. Eukaryotic conditional regulatory elements

[0105] v. Eukaryotic terminator

[0106] vi. Select marker

[0107] vii. Splice acceptor site

[0108] viii. Splice donor site

[0109] ix. Non-protein coding genes

[0110] x.Insulator

[0111] xi. Mobile genetic elements

[0112] xii. Meganuclease recognition sites

[0113] xiii. Internal Ribosome Entry Site (IRES)

[0114] xiv. Viral self-cleaving peptide element

[0115] xv. Kozak consensus sequence.

[0116] The preferred genomic recipient site will include two different arrangements using the following selected elements from the previously described element list. The first arrangement is to receive a single ORF encoding one or more aAPX and / or aAM and / or an integrated selectable marker via RMCE integration, wherein the arrangement is

[0117] 5'-[A][B][C][D][E][F]-3'

[0118] in,

[0119] A) is element iii) a constitutive or inducible eukaryotic promoter

[0120] B) is element i) heterologous specific recombinase site 1

[0121] C) is element xv) Kozak consensus sequence

[0122] D) is a component vi) encoding a protein marker that is FACS and / or MACS compatible

[0123] E) is element i) heterologous specific recombinase site 2

[0124] F) is element v) a eukaryotic terminator.

[0125] The second arrangement is to receive two ORFs encoding one or more aAPX and / or aAM and / or an integrated selectable marker via RMCE integration, wherein the arrangement is

[0126] 5'-[A][B][C][D][E][F][G][H][I]-3'

[0127] in,

[0128] A) is element iii) a constitutive or inducible eukaryotic promoter

[0129] B) is element i) heterologous specific recombinase site 1

[0130] C) is element xv) Kozak consensus sequence

[0131] D) is a component vi) encoding a protein marker that is FACS and / or MACS compatible 1

[0132] E) is an element v) a eukaryotic bidirectional transcription terminator

[0133] F) is a component vi) encoding a protein marker that is FACS and / or MACS compatible 2

[0134] G) is element xv) Kozak consensus sequence

[0135] H) is element i) heterologous specific recombinase site 2

[0136] I) is an element iii) a constitutive or inducible eukaryotic promoter;

[0137] Furthermore, in this second arrangement, elements F, G and I are encoded in the antisense orientation.

[0138] Components C and / or E contain at least one of the following genetic elements

[0139] i. Heterologous specific recombinase site

[0140] ii. Homology arms

[0141] iii. Eukaryotic promoter

[0142] iv. Eukaryotic conditional regulatory elements

[0143] v. Eukaryotic terminator

[0144] vi. Select marker

[0145] vii. Splice acceptor site

[0146] viii. Splice donor site

[0147] ix. Non-protein coding genes

[0148] x.Insulator

[0149] xi. Mobile genetic elements

[0150] xii. Meganuclease recognition sites

[0151] xiii. Internal Ribosome Entry Site (IRES)

[0152] xiv. Viral self-cleavage f element

[0153] xv.kozak consensus sequence

[0154] xvi. Integrated Selectable Markers

[0155] xvii. Antibiotic resistance cassette

[0156] xviii. Bacterial Origin of Replication

[0157] xix. Yeast Origin of Replication

[0158] xx. Cloning site

[0159] In a preferred embodiment of the Genetic Donor Vector, component C and / or component E will comprise two different possible arrangements using the following selected elements from the previously described list of elements.

[0160] The first arrangement is the delivery of a single ORF encoding one or more aAPX and / or aAM and / or an integrated selectable marker via RMCE integration, wherein the arrangement is

[0161] 5'-[A][B][C][D][E]-3'

[0162] in,

[0163] A) is element i) heterologous specific recombinase site 1

[0164] B) is element xv) Kozak consensus sequence

[0165] C) is the cloning site for a single ORF of element xx) encoding one or more aAPX and / or aAM and / or a selectable marker for integration of element xvi)

[0166] D) is element i) heterologous specific recombinase site 2

[0167] E) is element xvii) an antibiotic resistance cassette and element xviii) a bacterial origin of replication, in no particular orientation. Additionally, elements viii and / or xiv can be used to link multiple aAPXs and / or aAMs and / or element xvi together.

[0168] The second arrangement is to deliver two ORFs encoding one or more aAPX and / or aAM and / or an integrated selectable marker via RMCE integration, wherein the arrangement is

[0169] 5'-[A][B][C][D][E][F]-3'

[0170] in,

[0171] A) is element i) heterologous specific recombinase site 1

[0172] B) is element xv) Kozak consensus sequence

[0173] C) is a cloning site for the introduction of two or more ORFs of element xx) with a eukaryotic terminator encoding one or more aAPX and / or aAM and / or a selectable marker for the integration of element xvi)

[0174] D) is element xv) Kozak consensus sequence (antisense direction)

[0175] E) is element i) heterologous specific recombinase site 2

[0176] F) is element xvii) antibiotic resistance cassette and element xviii) bacterial origin of replication, in no particular orientation

[0177] Furthermore, elements viii and / or xiv can be used to link multiple aAPXs and / or aAMs and / or element xvi together within each ORF.

[0178] Preparation of analyte eAPCs using a multi-component system

[0179] The multi-component system described above can be used in a variety of ways to prepare different forms of analyte eAPCs or libraries thereof, which are used to present analytes aAPX, aAM, aAPX:aAM and aAPX:CM to analyte TCRs in an operating combined eAPC:T system (see Fig. 27 ).

[0180] eAPC-p can be prepared in one step from component A using a multi-component system comprising a single integration coupling, by providing component C' in combination with the ORF of aAPX, such that the aAPX integrates into site B to produce B'. The resulting cell line expresses the provided aAPX and presents it on the cell surface ( Figure 5 ).

[0181] A multi-component system comprising two integration pairs can be used to prepare eAPC-p from component A in one step by providing component C' in combination with the ORF of aAPX such that the aAPX integrates into site B to produce B'. The resulting cell line expresses the provided aAPX and presents it on the cell surface. The second integration pair D / E remains unchanged and can be used for downstream integration steps ( Figure 6 ).

[0182] eAPC-a can be prepared in one step from component A using a multi-component system comprising a single integration pair, by providing component C' in combination with the ORF of aAM, such that the aAM integrates into site B to produce B'. The resulting cell line expresses the provided aAM and presents it on the cell surface or retains it intracellularly ( Figure 7 ).

[0183] A multi-component system comprising two integration pairs can be used to prepare eAPC-a in one step from component A by providing component C' in combination with the ORF of aAM so that the aAM integrates into site B to produce B'. The resulting cell line expresses the provided aAM and presents it on the cell surface or is retained intracellularly. The second integration pair D / E remains unchanged and can be used for downstream integration steps ( Figure 8 ).

[0184] eAPC-pa can be prepared in one step from component A using a multi-component system comprising a single integration pair, by providing component C' in combination with two ORFs (one encoding aAPX and the other encoding aAM) such that both aAPX and aAM integrate into site B to produce B'. The resulting cell line expresses the provided aAPX and aAM and can present aAPX:aAM ( Fig. 9 ).

[0185] eAPC-pa can be prepared from component A in one step using a multi-component system comprising two integration pairs, by providing component C' in combination with two ORFs (one encoding aAPX and the other encoding aAM) such that both aAPX and aAM integrate into site B to produce B'. The resulting cell line expresses the provided aAPX and aAM and can present aAPX:aAM on the cell surface. The second integration pair D / E remains unchanged and can be used for downstream integration steps ( Fig.10 ).

[0186] eAPC-pa can be prepared from component A in one step using a multi-component system comprising two integration pairs, by providing components C' and E' each in combination with an ORF encoding aAPX or aAM, such that both aAPX and aAM are integrated into site B or D to produce B' and D'. The resulting cell line expresses the provided aAPX and aAM and can present aAPX:aAM ( Fig.11 ).

[0187] eAPC-p a can be prepared from component A in two steps using a multi-component system comprising two integration pairs, first providing component C' in combination with an ORF encoding aAPX such that the aAPX integrates into site B to produce B'. The resulting cell line expresses the provided aAPX and presents it on the cell surface (eAPC-p intermediate). The second integration pair D / E remains unchanged. In a second step, E' is provided, in which a donor vector is combined with an ORF encoding aAM such that the aAM integrates into site E to produce E'. The resulting cell line expresses the provided aAM and this can be processed in aAPX and loaded as cargo to form an aAPX:aAM complex on the cell surface ( Fig.12 ).

[0188] eAPC-pa can be prepared from component A in two steps using a multi-component system comprising two integration pairs, by first providing component C' in combination with an ORF encoding aAM such that the aAM integrates into site B to produce B'. The resulting cell line expresses the provided aAM (eAPC-a intermediate). The second integration pair D / E remains unchanged. In the second step, E' is provided, wherein a donor vector is combined with an ORF encoding aAPX such that the aAPX integrates into the E site to produce E'. The resulting cell line expresses the provided aAPX, which is presented on the cell surface. The aAM integrated in the first step can be processed and loaded into aAPX as cargo to form an aAPX:aAM complex on the cell surface ( Fig.13 ).

[0189] In the above example of preparing analyte eAPC-p, eAPC-a and eAPC-pa populations from eAPC, a multi-component system is used to provide known aAPX and aAM candidates in a defined manner to prepare discrete populations of analyte eAPC expressing defined aAPX and / or aAM. Such a process can be repeated multiple times to construct libraries of eAPC-p, eAPC-a and eAPC-pa to provide a combined eAPC:T system in the operation of the system. Another approach is to combine a pool of candidate aAPX and / or aAM ORFs with a genetic donor vector and integrate them into a single reaction to obtain a pool of analyte eAPC-p, eAPC-a or eAPC-pa expressing multiple aAPX, aAM and / or aAPX:aAM. The process of converting a vector pool to an eAPC-p, -a and / or -pa pool will be referred to as shotgun integration. This is particularly useful when analyzing large libraries of candidate aAMs against fixed aAPXs, and vice versa.

[0190] eAPC-pa can be prepared from component A in two steps using a multi-component system comprising two integration pairs, by first providing component C' combined with an ORF encoding aAPX so that the aAPX integrates into site B to produce B'. The resulting cell line expresses the provided aAPX (eAPC-p intermediate) on the cell surface. The second integration pair D / E remains unchanged. In the second step, a library of multiple E' is provided, wherein the donor vector library comprises a pool of vectors, each vector combined with a single ORF encoding aAM so that each aAM integrates into the E site to produce E' within a single cell. The resulting cell pool comprises a collection of cells, each of which has integrated a single random aAM ORF from the original vector pool. The aAM integrated in the second step can be processed and loaded as cargo into the aAPX integrated in the first step to form an aAPX:aAM complex on the cell surface ( Fig.14 ).

[0191] eAPC-pa can be prepared from component A in two steps using a multi-component system comprising two integration pairs, by first providing component C' combined with an ORF encoding aAM so that the aAM integrates into site B to produce B'. The resulting cell line expresses the provided aAM, i.e., the eAPC-a intermediate. The second integration pair D / E remains unchanged. In the second step, a library of multiple E's is provided, wherein the donor vector library comprises a pool of vectors, each vector being combined with a single ORF encoding aAPX so that each aAPX integrates into site E to produce E' in a single cell. The resulting cell pool contains a collection of cells, each of which has integrated a single random aAPX ORF from the original vector pool. The aAM integrated in the first step can be processed and loaded as cargo into the aAPX integrated in the second step to form an aAPX:aAM complex on the cell surface ( Fig.15 ).

[0192] eAPC-pa can be prepared from component A in one step using a multi-component system comprising two integration pairs, by first providing components C' and E', which are each combined with an ORF library encoding aAPX library or aAM library, such that both aAPX and aAM integrate into site B or D to produce B' and D'. The resulting cell pool contains a collection of cells, each of which has integrated a single random aAPX ORF and a single random aAM ORF from the original vector pool. Within each cell in the pooled library, the integrated aAM can be processed and loaded as cargo into an aAPX integrated into the same cell to form an aAPX:aAM complex on the cell surface. Such a combined library will contain all possible combinations of aAPX:aAM from the provided aAPX and aAM collections ( Fig.16 ).

[0193] In the above-described shotgun integration method for providing a pooled library of eAPC-pa, the robustness of the system relies on a single copy of the genomic receiving site. This is to ensure that a single analyte can be introduced into each cell through the integration pair. This single copy genomic receiving site is an optional aspect of the eAPCS, as multiple copies of the same genomic receiving site may be beneficial to provide an integration step in which multiple "alleles" from a provided vector library can be obtained in the prepared eAPC.

[0194] In this article, you can choose aAPX from one of the following

[0195] i. One or more members of HLA class I

[0196] ii. One or more members of HLA class II

[0197] iii. One or more non-HLA antigen presenting complexes.

[0198] In this article, you can choose aAPX from one of the following

[0199] i. Peptide or polypeptide complex provided as analyte antigen

[0200] ii. Peptides derived from a polypeptide provided as an analyte antigen

[0201] iii. Peptides provided as analyte antigens

[0202] iv. Metabolites provided as analyte antigens

[0203] v. A polypeptide or polypeptide complex translated from the ORF of the analyte antigen molecule

[0204] vi. Peptides derived from polypeptides translated from the ORF of the analyte antigen molecule

[0205] vii. Peptides Derived from Altered Component A Proteome

[0206] viii. Polypeptides Derived from Altered Component A Proteome

[0207] ix. Metabolites derived from altered component A metabolites.

[0208] Contacting the analyte eAPC with the analyte TC

[0209] The present invention relates to providing an engineered multi-component system. Component A and one or more components C' and / or one or more components E' are used to prepare one or more analyte eAPC populations. These analyte eAPCs are then combined with one or more analyte TCRs to edit an eAPC:TCR analysis system (eAPC:T) to obtain one or more outputs ( Fig. 27 ), wherein the analyte antigen is provided in the eAPC and wherein the analyte TCR can be represented as:

[0210] i. TCR molecules and / or

[0211] ii. a molecule having affinity for the analyte antigen, and

[0212] The analyte TCR can be presented to the eAPC in different modes within the eAPC:T system, represented by:

[0213] i. Analyte TCR presenting cells (TC) and / or

[0214] ii. Soluble or immobilized affinity reagents and / or

[0215] iii. Non-cell-based particles (NCBP),

[0216] Where i) analyte TCR presenting cells (TCs) are considered to be any TCs capable of presenting analyte TCRs to eAPCs; ii) affinity reagents are considered to be any reagents prepared as analytes to detect TCR binding and / or stimulation on the surface of eAPC cells in the eAPC:T system. These reagents will typically represent analyte TCR multimer reagents (e.g., TCR'tetramers') for staining eAPCs. Affinity reagents in this context may also represent antibodies or similar entities; iii) non-cell-based particles (NCBPs) act in a similar manner to affinity reagents, because particles present analyte TCRs or other entities that will be assessed for analyte antigen engagement on the surface of eAPCs within the eAPC:T system. However, NCBPs are considered to be larger entities that can further carry genetic or other information, either directly or by proxy, as identifiers for the presented analyte TCRs or other binding entities. A typical example of NCBP is a phage in a phage display scheme, where the phage can display antibody fragment antigen binding (FAB). Positively labeled eAPCs can be recovered along with phage and sequenced to identify FABs specific for the analyte antigen on the surface of the eAPCs.

[0217] Furthermore, cellular presentation of the analyte TCR can be in any of the following forms

[0218] i. Primary T cells

[0219] ii. Recombinant T cells

[0220] iii. Engineered TCR presenting cells

[0221] iv. Engineered cells that present molecules with affinity for the analyte antigen

[0222] They are collectively referred to as analyte TC.

[0223] The analytical eAPC:T system consists of one or more analyte eAPC populations and a collection of more analyte TCRs ( Fig. 27 Analyte eAPC populations were prepared using the multi-component system described above ( Figures 3 to 16 ). The eAPC:T system is provided in a form that allows physical contact between the analyte eAPC and the analyte TCR, wherein such contact allows complex formation between one or more analyte antigens presented by the analyte eAPC and the analyte TCR.

[0224] The analyte antigen represents any entity that the analyte TCR can putatively engage the eAPC:T system and can be represented by;

[0225] i. aAPX (analyte antigen presenting complex) and / or

[0226] ii. aAM (analyte antigen molecule) and / or

[0227] iii. aAPX:aAM (analyte antigen presenting complex, presenting analyte antigen molecule) and / or

[0228] iv. CM (non-analyte cargo molecules) and / or

[0229] v.aAPX:CM (analyte antigen presenting complex, presenting cargo molecule)

[0230] where aAPX represents the complex capable of presenting aAM; aAM is any molecule that is directly recognized by the TCR or loaded into aAPX; aAPX:aAM is aAPX with loaded aAM; CM is a cargo molecule that can be loaded into aAPX but is not the analyte and can therefore be derived from the analyte antigen presenting cell (APC) or the assay system itself; and aAPX:CM is aAPx loaded with CM.

[0231] In the context of this article, the eAPC:T system consists of:

[0232] i. Input of a single analyte eAPC; or

[0233] ii. Input of pooled analyte eAPC library

[0234] and combined with one of the following:

[0235] iii. Input of a single analyte TC; or

[0236] iv. input of a single analyte affinity reagent; or

[0237] v. Input of a single analyte NCBP; or

[0238] vi. Input of a pooled analyte TC library; or

[0239] vii. Input of a pooled library of analyte affinity reagents; or

[0240] viii. Input of the pooled analyte NCBP library

[0241] Contact in buffer system

[0242] The contact between the analyte eAPC and the analyte TC is performed in a permissive cell culture system or buffered medium, wherein the system comprises a medium that permits the function of the analyte eAPC and the analyte TC cells or the analyte affinity reagent or the analyte NCBP.

[0243] Contact between soluble analyte TCR, immobilized analyte TCR and / or analyte NCBP and analyte eAPC can be performed in a permissive buffered system, wherein the system includes a buffered medium that allows both the analyte TCR and analyte eAPC cells to function.

[0244] Labeling of eAPC with Affimer or NCBP

[0245] The analyte eAPC obtained from the multi-component system can be used to characterize the analyte antigen presented by the eAPC. Such characterization can be performed by contacting the analyte eAPC with an immobilized or soluble affinity reagent or NCBP, thereby labeling the eAPC ( Fig.24 ).

[0246] Labeling of eAPCs may be considered to be detected by direct visualization of the label by methods such as flow cytometry, microscopy, spectroscopy or luminescence, or alternatively by capture using immobilized affinity reagents or NCBP for recognition of the analyte antigen.

[0247] Signal Response Definition

[0248] Analyte eAPCs prepared from the multi-component system are used to characterize the signal response of the analyte eAPCs to the analyte TCR, wherein such signal response can be binary or gradual and can be measured as eAPC ( Fig.21 ) and / or analyte TC( Fig. 20 Such signals may be detected by methods such as flow cytometry, microscopy, spectrometry or luminescence, or other methods known to those skilled in the art.

[0249] General Approach - Selecting eAPC

[0250] A method of selecting one or more analyte eAPCs from an input analyte eAPC or a library of analyte eAPCs to obtain one or more analyte eAPCs from a combinatorial eAPC:T system wherein the expressed analyte antigen binds to one or more analyte TCRs comprises

[0251] i. combining one or more analyte eAPCs with one or more analyte TCRs, resulting in contact between the analyte antigen and the analyte TCR, and at least one

[0252] ii. measuring the formation of a complex (if any) between one or more analyte antigens and one or more analyte TCRs and / or

[0253] iii. measuring the signal from the labeled analyte TCR and / or

[0254] iv. measuring the signal response of the analyte eAPC induced by complex formation between one or more analyte antigens and one or more analyte TCRs (if any) and / or

[0255] v. measuring the signal response (if any) of the analyte TC induced by complex formation between one or more analyte antigens and one or more analyte TCRs and / or

[0256] vi. Selecting one or more analyte eAPCs based on steps ii, iii, iv and / or v, wherein the selection is performed by positive and / or negative measurements

[0257] Among them, i, iv and vi or i, v and vi comprise preferred arrangements.

[0258] General Approach - Selecting Analyte TCR

[0259] A method for selecting one or more analyte TCRs from an input analyte TCR or a library of analyte TCRs to obtain one or more analyte TCRs wherein an expressed analyte antigen binds to the one or more analyte TCRs comprises

[0260] i. combining one or more analyte APCs with one or more analyte TCRs, resulting in contact between the analyte antigen presented by the analyte APCs and the one or more analyte TCRs and

[0261] ii. measuring the formation of a complex (if any) between one or more analyte antigens and one or more analyte TCRs and / or

[0262] iii. measuring the signal from the labeled analyte TCR and / or

[0263] iv. measuring a signal response (if any) in one or more analyte TCs induced by complex formation between the analyte TCR and the analyte antigen and / or

[0264] v. measuring the analyte APC measurement signal response (if any) induced by the formation of a complex between one or more analyte TCRs and one or more analyte antigens and

[0265] vi. Selecting one or more analytes APC from steps ii, iii, iv and / or v, wherein the selection is performed by positive and / or negative measurement

[0266] Among them, i, iv and v comprise preferred arrangements.

[0267] General Methods for Signal Response

[0268] The method of selecting an analyte eAPC and / or an analyte TC and / or an affinity agent and / or a NCBP from a combined eAPC:T system based on a reported signal response comprises

[0269] i. Determine the native signaling response and / or

[0270] ii. If the eAPC contains such a response circuit, and / or if the analyte TC contains an equivalent synthetic reporter circuit, the synthetic signaling response is determined.

[0271] Measuring the induced natural or synthetic signaling response inherent to the APC and / or analyte TC by detecting an increase or decrease in one or more of the following:

[0272] i. Secreted biomolecules

[0273] ii. Secreted Chemicals

[0274] iii. Intracellular biomolecules

[0275] iv. Intracellular Chemical Substances

[0276] v. Surface expressed biomolecules

[0277] vi. Cytotoxic effect of analyte TC on analyte eAPC

[0278] vii. The paracrine effect of the analyte TC on the analyte eAPC, so as to induce a signal response in the analyte APC, and is determined by detecting any one of the increase or decrease of i to v

[0279] viii. Proliferation of Analyte TC

[0280] ix. Immune synapse between analyte TC and analyte eAPC

[0281] Wherein the detected signal response is compared to a non-induced signal response state inherent to the analyte eAPC and / or analyte TC, and then the combined eAPC:T system and / or parallel assembled combined systems are assembled, wherein the analyte eAPC and / or analyte TC can present a control analyte antigen and / or analyte TCR species and / or a soluble analyte antigen that is known not to induce a signal response within the combined eAPC:T system in use.

[0282] Selection methods by labeling and / or signal response

[0283] Methods for selecting analyte eAPCs and / or analyte affinity reagents and / or analyte NCBPs from a combined eAPC:T system based on measurable labeling of eAPCs by said affinity reagents or NCBPs include:

[0284] i. Determine the marker of eAPC by affinity reagent or NCBP, and may also include

[0285] ii. Determine the native signaling response and / or

[0286] iii. If the eAPC contains such a response circuit, the resultant signaling response is determined.

[0287] Wherein selecting eAPC and / or affinity agent and / or NCBP by detecting a marker of the eAPC may include detecting a surface marker of the eAPC by the affinity agent and / or NCBP via including a detectable marker on the affinity agent and / or NCBP. Such a detectable marker may be a fluorescent, luminescent, spectral, chemical, radiochemical or affinity moiety. Thus, such selection of eAPC may be performed based on FACS, MACS or equivalent high throughput screening and selection methods.

[0288] Overview

[0289] In a combined eAPC:T system, measuring the signal response in one or more analyte eAPCs or one or more analyte TCs or markers of eAPCs is critical to selecting the primary system output ( Fig. 27 Step v), the signal response may be mediated by the formation of a complex between the analyte antigen and the analyte TCR ( Fig. 27 Step iv), wherein the primary system output is a single cell or a pool of cells, and / or a single affinity agent or a library of affinity agents and / or a single NCBP or a pool of NCBPs. Wherein the selection of cells or agents can be performed based on the presence or absence of a reported signal response in either and / or both of the contacted analyte eAPCs or analyte TC cells, or by measuring a measurable marker of the eAPCs with the affinity agent or NCBP

[0290] Get primary system output from the eAPC:T system

[0291] The present invention is directed to providing an engineered multi-component system. Component A and one or more components C' and / or one or more components E' are used to prepare one or more analyte eAPC populations. These analyte eAPCs are then combined with one or more analyte TCRs via the eAPC:T system to obtain one or more outputs. The analyte TCRs are provided as soluble or immobilized reagents, presented on the cell surface or presented by non-cell-based particles (NCBPs). Cellular presentation of the analyte TCRs can be in any of the following forms:

[0292] i. Primary T cells

[0293] ii. Recombinant T cells

[0294] iii. Engineered TCR presenting cells

[0295] iv. Engineered cells that present molecules with affinity for the analyte antigen

[0296] They are collectively referred to as analyte TC.

[0297] The system consists of one or more analyte eAPC populations and a collection of more analyte TCRs ( Fig. 27 Analyte eAPC populations were prepared using the multi-component system described above ( Figures 3 to 16 ). The eAPC:T system is provided in a form that allows physical contact between an analyte eAPC and an analyte TCR, wherein such contact allows complex formation between one or more analyte antigens presented by the analyte eAPC and the analyte TCR, wherein the analyte antigen is any of the following

[0298] i.aAPX and / or

[0299] ii.aAM and / or

[0300] iii.aAPX:aAM and / or

[0301] iv.CM and / or

[0302] v.aAPX:CM

[0303] and wherein the analyte TCR is provided for presentation by the analyte TC, or presented by a soluble or immobilized analyte affinity reagent, or presented by the analyte NCBP, for potential engagement with the analyte antigen presented by the analyte eAPC, such that complex formation can result in stabilization of such complex and wherein resulting labeling of the eAPC and / or induction of signaling within the analyte eAPC and / or analyte TC can be reported and measured.

[0304] Modes for reporting and / or labeling eAPC responses to inducing signals are described above, and it is precisely these reporter responses and / or labels that need to be measured in order to obtain the primary output of a multi-component system programmed into an eAPC:T system.

[0305] The primary output from the eAPC:T system is a selected cell population and / or a selected affinity reagent or a selected NCBP, wherein the selection is made based on;

[0306] i. Measurable labeling of eAPC and / or

[0307] ii. Signal response detected in eAPC and / or

[0308] iii. Lack of detected signal response in eAPCs and / or

[0309] iv. Signal response detected in analyte TC and / or

[0310] v. lack of detected signal response in analyte TC;

[0311] The primary output may be represented by a single cell, or a pool of cells and / or one or more eAPC-associated affinity reagents or NCBPs.

[0312] The analyte affinity reagent, NCBP or analyte TC and / or analyte eAPC from the combined eAPC:T system can be selected based on the response in the contacted cell. That is, the analyte TC can be selected based on the reported response or lack thereof in the contacted analyte eAPC. Conversely, the analyte eAPC can be selected in the case of the reported response or lack thereof in the contacted analyte TCR, or in the case of the analyte TC being the analyte affinity reagent or NCBP, the analyte affinity reagent or NCBP can be selected from the eAPC response.

[0313] The primary eAPC and / or analyte TC output from the system is selected cells, wherein the selection is based on the presence or absence of a reported signal response in the analyte TC or eAPC, and these cells can include one or more of the eAPC and / or one or more analyte TC, wherein the selected cells can include a single cell, a pool of cells of the same identity, a pool of cells of different identities ( Fig. 27 Step v).

[0314] The primary analyte affinity reagent or NCBP output from the system is selected cells with or without the associated affinity reagent or NCBP, wherein the selection is based on the presence or absence of a signal response of a marker or reporter of the analyte eAPC, wherein the selected affinity reagent or NCBP may comprise a single affinity reagent or NCBP, a pool of affinity reagents or NCBPs of the same identity, a pool of affinity reagents or NCBPs of different identities ( Fig. 27 Step v).

[0315] Output of binary composition

[0316] Signals reported in analyte eAPCs and / or analyte TCs in a combined eAPC:T system can be used to select analyte cell populations to provide a primary output.

[0317] In the present context, primary output of analyte eAPCs can be achieved in such cases by selecting a desired population of analyte eAPCs labeled with an analyte TCR from a binary system, where the combined eAPC:T system is a binary combination of one or more analyte eAPCs and an analyte TCR (e.g. Fig.24 ).

[0318] Primary output of an analyte affinity reagent or analyte NCBP can be achieved in such cases by selecting a desired analyte eAPC population labeled with an analyte affinity reagent or analyte NCBP from a binary system, wherein the combined eAPC:T system is a binary combination of one or more analyte eAPCs and an analyte affinity reagent or analyte NCBP (e.g. Fig.24 ).

[0319] Primary output of eAPC and / or analyte TC types can be achieved in such cases by selecting the desired analyte APC and / or analyte TC population from a combinatorial culture system, wherein the combinatorial eAPC:T system has immobilized analyte eAPC and pooled library analyte TC properties (e.g. Fig. 22 ), or in cases where the combined eAPC:T system is a pooled library of immobilized analyte TCs and analyte eAPCs (e.g. Fig.23 )nature.

[0320] Primary output of analyte eAPCs can be achieved in situations where the combinatorial eAPC:T system has both fixed analyte TCRs and pooled analyte eAPC library properties (e.g. Fig.24 ), or in cases where the combined eAPC:T system is a pooled library of immobilized eAPCs and soluble analyte affinity reagents or NCBP properties.

[0321] Primary output of analyte affinity reagents or analyte NCBPs can be achieved in situations where the combined eAPC:T system is a library of immobilized soluble analyte affinity reagents or analyte NCBPs and pooled analyte eAPCs (e.g. Fig.24 ) or is achieved in cases where the combined eAPC:T system is an immobilized eAPC and a pooled library of analyte affinity reagents or analyte NCBP properties.

[0322] Get the output mode

[0323] There are several different modes that can be used to obtain the primary output, each of which requires a cell sorting step. Sorting can be achieved by fluorescence activated cell sorting (FACS) and / or magnetic activated cell sorting (MACS) and / or different affinity activated cell sorting methods.

[0324] Primary output eAPCs and / or analyte TC cells, and / or eAPC-associated affinity reagents or NCBPs can be obtained by single cell sorting to obtain single cells and / or by cell sorting of a pool to obtain a pool of cells.

[0325] Primary output eAPCs and / or analyte TC cells may be obtained by single cell sorting to obtain single cells, and optionally subsequently growing out the single cells to obtain a monoclonal pool of selected eAPCs or analyte TC cells.

[0326] Primary output eAPCs and / or analyte TC cells may also be obtained by cell sorting of the pool to obtain a pool of cells, and optionally subsequently growing a bank of cells to obtain a pool of selected eAPCs and / or TC cells.

[0327] Get terminal system output from eAPC:T system

[0328] Following the above method of obtaining a primary output, wherein the primary output analyte eAPC and / or analyte TC and / or analyte NCBP is selected based on a measured signal response or stable complex formation, such that a terminal output from the eAPC:T system can be obtained by further processing the selected eAPC and / or analyte TC and / or NCBP primary output ( Fig. 27 , step vi).

[0329] The terminal output from the multi-component system is the following identity

[0330] i.aAPX and / or

[0331] ii.aAM and / or

[0332] iii.aAPX:aAM and / or

[0333] iv.CM and / or

[0334] v.aAPX:CM and / or

[0335] vi.TCR

[0336] Presented by analyte APC or analyte TC or analyte affinity reagent or analyte NCBP and obtained as a primary output of a multi-component system by selection from the combined eAPC:T system.

[0337] In the eAPC:T system, it is usually the case that the analyte molecules presented by the analyte eAPC and the analyte TC are genetically encoded. It is also possible that the analyte NCBP has a genetically encoded identity, for example, in the case where the NCBP is a bacteriophage. Therefore, in order to identify the analyte molecules presented by the analyte eAPC or the analyte TC or the analyte NCBP, genetic sequencing of the prepared analytes eAPC, TC and NCBP can be performed.

[0338] The selected primary output may be processed to obtain the gene sequence of the genome or transcriptome of the sorted and / or amplified cells to determine the identity of

[0339] i.aAPX and / or

[0340] ii.aAM and / or

[0341] iii.aAPX:AAM

[0342] iv.CM and / or

[0343] v.aAPX:CM and / or

[0344] vi. Analyte TCR

[0345] The obtained identities represent the terminal output from the eAPC:T system.

[0346] NCBPs possessing genetic components can be processed such that the genetic sequence of the genome or transcriptome of the sorted NCBP is obtained to determine the identity of the analyte TCR, wherein the obtained identity represents the terminal output from the eAPC:T system.

[0347] The eAPCs can be processed such that the genetic sequence of component B' and / or component D' of the sorted and / or expanded TC cells is obtained to determine the identity of the analyte antigen, wherein the identity of the analyte antigen obtained represents the terminal output from the eAPC:T system.

[0348] The analyte TCs can be processed such that the genetic sequence of the genome or transcriptome of the sorted and / or amplified TC cells is obtained to determine the identity of the analyte TCR, wherein the identity of the obtained TCR represents the terminal output from the eAPC:T system.

[0349] Genetic sequencing can be achieved in a variety of ways, or by arranging genetic material, with or without specific processing. The sequencing step can be preceded by

[0350] i. Extraction of genomic DNA and / or

[0351] ii. Extracting component B' and / or D' RNA transcripts and / or

[0352] iii. Amplification of DNA and / or RNA transcripts of components B' and / or D' by PCR and / or RT-PCR

[0353] The sequencing step may be destructive to the eAPCs or TCs, NCBp or pools thereof obtained as primary output from the multi-component system.

[0354] If it is desired to obtain a primary output from an eAPC:T system, where the sequencing step is destructive to the primary output eAPCs, the sequence information obtained as the terminal output of the multi-component system can be used to prepare equivalent output eAPCs as analyte eAPCs.

[0355] In the above scenario of genetically encoded analyte molecules, the terminal output of the eAPC:T system can be obtained by obtaining sequence information from components B' and / or D' and / or from the cell genome and / or transcriptome. However, in some embodiments, antigen information will not be genetically encoded. Antigens that have been post-translationally modified, antigens provided to the combined eAPC:T system by non-genetic means, antigens that emerge from an induced or modified state of the analyte eAPC proteome or metabolites, CMs that are inherent to the eAPC:T system, may not be reasonably identified by genetic sequencing means.

[0356] In the important case of aAM that can be non-genetically provided to the eAPC:T system, there are two different modes by which the APC can present the provided aAM as an aAPX:aAM complex. In the first scenario, the aAM is provided in a form that can directly bind to aAPX and form an aAPX:aAM complex on the cell surface ( Fig.18 ). An example of such an aAM is a peptide antigen of the HLA complex. In the second scenario, the aAM is provided in a form that can be received and processed by the analyte eAPC so that it is loaded as cargo in the aAPX and forms an aAPX:aAM complex on the cell surface ( Fig.19 ).

[0357] A method for selecting and identifying an aAM cargo or a CM cargo, wherein the cargo is a metabolite and / or a peptide, which is loaded into an aAPX of an eAPC selected and obtained as a primary output of a multi-component system, the method comprising

[0358] i. Separation of aAPX:aAM or aAPX:CM or cargo aM or cargo CM and

[0359] ii. Identify the cargo being loaded

[0360] The identified load (CM or aAM) represents the terminal output of the multi-component system.

[0361] There are generally two modes by which cargo molecules can be identified from the selected APC. First, forced release of cargo from aAPX:aAM or aAPX:CM results in the detachment of aAM or CM that can be used for subsequent identification ( Fig.25 ). An example of this is acid washing of eAPC to release peptide aAM from the HLA complex. Next, capture of aAPX:aAM or aAPX:CM, for example, by releasing the complex and immunoaffinity separation methods, results in separation of the aAPX:aAM or aAPX:CM complex, allowing identification of aAM or CM ( Fig.26 ).

[0362] Methods for identifying isolated aAM and / or CM directly or from isolated aAPX:aAM or aAPX:CM complexes may include i. mass spectrometry analysis

[0363] ii. Peptide sequencing analysis

[0364] The inclusion of an AM and / or CM identity is the terminal output from the multi-component system.

[0365] Determining the affinity of the analyte TCR for the analyte antigen using the eAPC:T system

[0366] Following the above method of obtaining a primary output (wherein the primary output is an analyte eAPC cell selected based on the measured signal response), the eAPC primary output can be subjected to affinity analysis to determine the affinity of the analyte antigen for the cognate analyte TCR, wherein the analyte antigen is any of the following

[0367] i.aAPX and / or

[0368] ii.aAM and / or

[0369] iii.aAPX:aAM and / or

[0370] iv.CM and / or

[0371] v.aAPX:CM

[0372] and wherein the analyte TCR is provided as a soluble affinity reagent or presented by the analyte TC or the analyte NCBP such that the affinity of the analyte antigen is determined according to

[0373] i. Labeling of selected analyte eAPCs using analyte TCRs across a range of concentrations

[0374] ii. FACS analysis of the stained analyte eAPC in step a

[0375] iii. Determine the fluorescence labeling intensity of the analyte eAPC over the analyte TCR concentration range

[0376] iv. Calculate the affinity of the analyte antigen for the analyte TCR

[0377] In this context, the affinity of the analyte antigen may also be determined by the aforementioned method, but wherein a labeled reference may also be included, so that the affinity is calculated using the ratio of the fluorescence intensity of the analyte antigen to the fluorescence intensity of the reference, wherein the labeled reference is selected from

[0378] i. Analyte eAPC labeled with an affinity reagent for one of the analyte antigens

[0379] ii. Cells or particles presenting labeled reference analyte antigen. BRIEF DESCRIPTION OF THE DRAWINGS

[0380] The invention is further illustrated in the following non-limiting drawings.

[0381] Figure 1 -Single integration of component descriptions of multi-component systems.

[0382] Example of an MCS containing three components. The first component A is the eAPC line itself, with all the desired engineered features of the cell. The eAPC A contains another component B, which is a genomic integration site for aAPX and / or aAM integration. An additional component C represents a genetic donor vector for site-directed integration of the ORF into site B, with arrows indicating the specificity of the coupling. Paired integration site / donor vector pairs can be formatted to integrate a single ORF or a pair of ORFs to introduce APX and / or aAM expression.

[0383] Figure 2 -Dual integration of component descriptions for multi-component systems.

[0384] Example of an MCS containing five components. The first component A is the eAPC line itself, with all the desired engineered features for the cell. eAPC A contains two additional components, B and D, which are genomic integration sites for aAPX and / or aAM integration. The other two components, C and E, represent genetic donor vectors for site-specific integration of ORFs into sites B and D, respectively, with arrows indicating pairing specificity. Each paired integration site / donor vector pair can be formatted to integrate a single ORF or a pair of ORFs to introduce APX and / or aAM expression.

[0385] Figure 3 -Preparation of different analyte antigens presenting eAPC

[0386] MCS begins with eAPCs and uses donor vectors to generate cells that express analyte antigen presenting complexes (aAPX) and / or analyte antigen molecules (aAM) on the cell surface. eAPCs that present aAPX alone are referred to as eAPC-p and can be created by introducing an ORF encoding aAPX into an eAPC (step i). eAPCs that express aAM alone are referred to as eAPC-a, where aAM can be expressed on the cell surface and available for TCR engagement or need to be processed and loaded as cargo into aAPX as an aAPX:aAM complex. eAPC A can be created by introducing an ORF encoding aAM into an eAPC (step ii). eAPCs that present aAM as a cargo in aAPX are referred to as eAPC-pa. eAPC-pa can also be produced; either by introducing ORFs encoding aAM and aAPX into an eAPC at the same time (step iii); or by introducing an ORF encoding aAM into an eAPC-p (step iv); or by introducing an ORF encoding aAPX into an eAPC-a (step v).

[0387] Figure 4 - Manipulation of genetic donor vector and genomic recipient site integration pairs

[0388] The genetic donor vector and the genomic receiving site form an integration pair, wherein one or more ORFs encoded in the genetic donor vector can be specifically integrated into its coupled genomic receiving site. Step 1 in the operation of the integration pair is to introduce one or more target ORFs into the donor vector. The initial donor vector is labeled X and is modified to be a priming donor vector X' by introducing the target ORF. Step 2 requires combining the priming donor vector X' with a cell with a genomic receiving site Y. The introduction of the ORF encoded by the priming donor vector into the receiving site results in the generation of a cell with an integration site Y'.

[0389] Figure 5 - Example of preparing eAPC-p in one step using one integration pair

[0390] eAPC A contains a genomic receptor site B. The primed genetic donor vector C' is coupled to B and encodes aAPx. When the AeAPC is combined with the C' donor vector. The ORF of C' of the resulting cell is exchanged with the B genomic receptor site to generate site B' and introduce aAPX expression. This results in the expression of aAPX on the cell surface and the generation of eAPC-p.

[0391] Figure 6 - Example of preparing eAPC-p in one step with one integration pair and one unused integration site

[0392] eAPC A contains genomic receptor sites B and D. The primed genetic donor vector C' is coupled to B and encodes aAPx. When the AeAPC is combined with the C' donor vector. The ORF of C' of the resulting cell is exchanged with the B genomic receptor site to generate site B' and introduce aAPX expression. This results in the expression of aAPX on the cell surface and the generation of eAPC-p. Genomic receptor site D remains unused.

[0393] Figure 7 - Example of preparing eAPC-a in one step using one integration pair

[0394] eAPC A contains a genomic receptor site B. The primed genetic donor vector C' is coupled to B and encodes aAM. When the AeAPC is combined with the C' donor vector. The ORF of C' of the resulting cell is exchanged with the B genomic receptor site to generate site B' and introduce aAM expression. This results in one of two forms of eAPC-a, expressing aAM on the cell surface or inside the cell.

[0395] Figure 8 - Example of preparing eAPC-a in one step using one integration pair and one unused integration site

[0396] eAPC A contains genomic receptor sites B and D. The primed genetic donor vector C' is coupled to B and encodes aAM. When the AeAPC is combined with the C' donor vector. The ORF of C' of the resulting cell is exchanged with the B genomic receptor site to generate site B' and introduce aAM expression. This results in one of two forms of eAPC-a, expressing aAM on the cell surface or intracellularly. Genomic receptor site D remains unused.

[0397] Fig. 9 - Example of preparing eAPC-pa in one step using an integration pair

[0398] eAPC A contains a genomic recipient site B. Genetic donor vector C' is coupled to B. Donor vector C' encodes aAPX as well as aAM.

[0399] A eAPC is combined with donor vector C'. The resulting cell has ORFs C' exchanged into the B genomic receiving site to create site B' and deliver the ORFs of aAPX and aAM. This results in expression of aAPX on the cell surface, expression of aAM inside the cell, and thus the loading of aAM as cargo in aAPX in the formation of aAPX:aAM complex on the cell surface.

[0400] Fig.10 - Example of preparing eAPC-pa in one step with one integration pair and one unused integration site

[0401] eAPC A contains different genomic receptor sites B and D. Genetic donor vector C' is coupled to B. Donor vector C' encodes aAPX as well as aAM. A eAPC is combined with donor vector C'. The ORF C' of the resulting cell is exchanged with the B genomic receptor site to generate site B' and deliver the ORFs of aAPX and aAM. Genomic receptor site D remains unused. This results in aAPX being expressed on the cell surface, aAM being expressed inside the cell and thus aAM being loaded as cargo in aAPX, forming an aAPX:aAM complex on the cell surface. This creates the eAPC-pa cell line. Genomic receptor site D remains unused.

[0402] Fig.11 - Example of preparing eAPC-pa using two integration pairs in one step

[0403] eAPC A contains different genomic receptor sites B and D. Different genetic donor vectors C' and E' are independently coupled to B and D, respectively. Donor vector C' encodes aAPX and donor vector E' encodes aAM. A eAPC is combined with donor vectors C' and E' simultaneously. The ORF C' of the resulting cell is exchanged with the B genomic receptor site to produce site B' and deliver the ORF of aAPX. At the same time, the ORF of E' is exchanged with the D genomic receptor site to produce site D' and deliver the ORF of aAM. This results in the expression of aAPX on the cell surface, the expression of aAM inside the cell, and thus the loading of aAM as cargo in aAPX, forming an aAPX:aAM complex on the cell surface. This creates the eAPC-pa cell line.

[0404] Fig.12 - Example of preparing eAPC-pa in two steps using two integration pairs via eAPC-p

[0405] eAPC A contains different genomic receptor sites B and D. Different genetic donor vectors C' and E' are independently coupled to B and D, respectively. Donor vector C' encodes aAPX and donor vector E' encodes aAM. In step 1, the eAPC is combined with the C' donor vector. The resulting cell's insert C' is exchanged with the B genomic receptor site to produce site B' and deliver the ORF of aAPX. This results in the expression of aAPX on the cell surface and the production of eAPC-p. The genomic receptor site D remains unused. In step 2, the eAPC-p created in step 1 is combined with the E' donor vector. The resulting cell's insert E' is exchanged with the D genomic receptor site to produce site D' and deliver the ORF of aAM. This results in the expression of aAM as a cargo for the expressed aAPX on the cell surface and the production of eAPC-pa.

[0406] Fig.13- Example of preparing eAPC-pa in two steps using two integration pairs via eAPC-a

[0407] eAPC A contains different genomic receptor sites B and D. Different genetic donor vectors C' and E' are independently coupled to B and D, respectively. Donor vector C' encodes aAM and donor vector E' encodes aAPx. In step 1, A eAPC is combined with the C' donor vector. The resulting cell's insert C' is exchanged with the B genomic receptor site to produce site B' and deliver the ORF of aAM. This results in the expression of aAM on the cell surface and the production of eAPC-a. The genomic receptor site D remains unused. In step 2, the eAPC-a created in step 1 is combined with the E' donor vector. The resulting cell's insert E' is exchanged with the D genomic receptor site to produce site D' and deliver the ORF of aAPX. This results in the expression of aAPX on the cell surface with aAM as cargo and the production of eAPC-pa.

[0408] Fig.14 - Shotgun preparation of eAPC-pa pool from eAPC-p

[0409] eAPC-p contains an exchanged genomic receiving site B' expressing aAPX, and a different genomic receiving site D. A pool of genetic donor vectors E'i-iii is coupled to D. Donor vectors E'i-iii each encode a single aAM gene. eAPC-p is combined with donor vectors E'i, E'ii, and E'iii at the same time. Any insert E'i-iii in multiple independent instances of the resulting cell pool is exchanged with the D genomic receiving site to produce site D'i-iii, each site delivering a single ORF of the aAM gene. The resulting eAPC-pa cell pool contains a mixed population of three different cell cohorts, each expressing B' presented as aAPX:aAM and a discrete combination of any aAM gene contained in the initial vector library.

[0410] Fig.15 - Shotgun preparation of eAPC-pa pool from eAPC-a

[0411] eAPC-a contains an exchanged genomic receptor site B' expressing aAM, and a different genomic receptor site D. A pool of genetic donor vectors E'i-iii is coupled to D. Donor vectors E'i-iii each encode a single aAPX gene. eAPC-a is combined with donor vectors E'i, E'ii, and E'iii simultaneously. In multiple independent instances, any one of the inserts E'i-iii of the resulting cell pool is exchanged with the D genomic receptor site to generate sites D'i-iii, each delivering a single ORF of an aAPX gene. The resulting eAPC-pa cell pool contains a mixed population of three different cell cohorts, each expressing a discrete combination of the aAM encoded in B' and any one of the aAPX genes contained in the initial vector pool.

[0412] Fig.16 - Shotgun preparation of pooled eAPC-pa libraries from eAPCs containing combinatorial pairs of aAM and aAPX genes

[0413] eAPC A contains different genomic recipient sites B and D. Different genetic donor vectors C' and E' are coupled to B and D, respectively. Donor vectors C'i and C'ii each encode a single aAM gene, and donor vectors E'i and E'ii each encode a single aAPX gene. eAPC A is combined with donor vectors C'i, C'ii, E'i and E'ii simultaneously. In multiple independent instances, the insert C'i or C'ii of the resulting cell pool is exchanged with the B genomic recipient site to produce sites B'i and B'ii, each delivering a single ORF of aAM. In multiple independent instances, the resulting cell pool also exchanges the insert E i or E ii with the D genomic recipient site to produce sites E'i and E'ii, each delivering a single ORF of the APX gene. The resulting eAPC-pa cell pool contains a mixed population of four different cell cohorts, each expressing discrete randomized aAPX:aAM pairs consisting of one of each gene contained in the initial vector library on the surface.

[0414] Fig.17 - Generation of eAPC-p:CM from eAPC-p expressing endogenous cargo CM

[0415] In the absence of aAM expression from genomic recombination sites, aAPX molecules on eAPC-p can present the internal cargo molecule CM as aXX:CM complex on the surface.

[0416] Fig.18 - Generation of eAPC-p+aAM from eAPC-p with the addition of soluble, presentable antigen aAM

[0417] eAPC-p contains an exchanged genomic receptor site B' expressing aAPX. The soluble, directly presentable antigen aAM combines with the eAPC-p. This results in the formation of an aAPX:aAM complex on the cell surface and the production of eAPC-p+aAM.

[0418] Fig.19 - Generation of eAPC-p+aAM from eAPC-p and soluble aAM

[0419] eAPC-p contains the exchanged genomic receptor site B' expressing aAPX. The soluble antigen aAM combines with the eAPC-p, which results in the expression of aAPX on the cell surface, the presence of aAM within the cell, and thus the loading of aAM as cargo in aAPX to form an aAPX:aAM complex on the cell surface and generate eAPC-p+aAM.

[0420] Fig. 20 - Operation of the combined eAPC:T system, showing possible analyte TC output states

[0421] The analyte eAPC contains sites C' and E' integrated with one ORF, each of which encodes one aAPX and one aAM, with the aAM being loaded as cargo in the aAPX on the cell surface. The analyte TC expresses TCRsp on the surface. When contacted with the analyte TC and the eAPC-pa population, four analyte TC response states can be achieved, one negative and three positive. The negative state is the resting state of the analyte TC, with no signal intensity indicating failure of the eAPC aAPX:aAM complex to stimulate the TCRsp presented by the analyte TC. The three positive states showing increased signal intensity *, **, and *** represent low, medium, and high signal intensities, respectively, also indicated by the darker shading of the cells. This indicates a graded response of the analyte TCRsp expressed by the analyte TC population to the analyte aAPX:aAM presented by the eAPC-pa.

[0422] Fig.21 - Operation of the combined eAPC:T system, showing possible eAPC-pa output states

[0423] Analyte eAPC-pa contains sites C' and E' integrated with one ORF, each encoding one aAPX and one aAM, with the aAM loaded as cargo in the aAPX on the cell surface. Analyte TC expresses TCRsp on the surface. When the analyte TC and eAPC-pa population are contacted, four eAPC response states can be achieved, one negative and three positive. The negative state is the quiescent state of the analyte eAPC, indicating the failure of the TCRsp chain to stimulate the aAPX:aAM complex presented by the analyte eAPC. The three positive states show increased signal intensity from the contacted aAPX:aAM. The three positive states show increased signal intensity *, ** and ***, representing low, medium and high signal intensities, respectively, also indicated by the darker shading of the cells. This indicates a graded response of the analyte aAPX:aAM to the analyte TCRsp presented by the analyte TC.

[0424] Fig. 22 -Combined operation of the combined eAPC:T system to identify TCR chain pairs reactive with analyte aAPX:aAM from a library of analyte TCs expressing discrete analyte TCRs

[0425] The analyte TC pool expresses different TCRsps on the surface. The analyte eAPC-pa contains sites C' and E' integrated with a set of different ORFs to encode one aAPX and one aAM, where the aAM is loaded as cargo in the aAPX on the cell surface. In this example, only the analyte TC i expresses a TCRsp specific for the aAPX:aAM presented by the analyte eAPC-pa, so when the analyte TC pool and the analyte eAPC-pa population are contacted, only the cohort of cells expressing the analyte TC that are engaged by the TCRsp i are present.

[0426] Fig.23 -Combined operation of the combined eAPC:T system for identification of αAM reactive with analyte TC from a pool of analyte eAPC-pa expressing discrete analyte aAPX:aAM complexes

[0427] The analyte eAPC contains sites C' and E' integrated with different sets of ORFs, each encoding one aAPX and one aAM, which are loaded as cargo on the cell surface in the aAPX. The analyte TC expresses a defined TCRsp on the surface. In this example, only the complex aAPX:aAM i is specific for the TCRsp presented by the analyte TC, so that when the analyte eAPC pool and the analyte TC population are contacted, only the cell population expressing aAM i expresses a different signal*.

[0428] Fig.24- Operation of the combined eAPC:T system for identification of aAPX:aAM complexes reactive with analyte-specific TCRs

[0429] The analyte eAPC-pa pool contains sites C' and E' integrated with different sets of ORFs, each encoding one aAPX and one aAM i-iii, where the aAM is loaded as cargo in the aAPX on the cell surface. The analyte TCR in soluble, immobilized or NCBP form contacts the analyte eAPC-pa pool, which is specific for different aAPX:aAM complexes expressed by subsets of the analyte eAPC-pa pool. In this example, aAPX:aAM i is formed only for the analyte TCR, so that only the cell cohort of the analyte eAPC-pa pool carrying aAM i responds to the analyte TCR (dark gray).

[0430] Fig.25 - Identification of aAM presented by eAPC-p+aAM by forced release of aAM

[0431] eAPC-p+aAM contains the exchanged genomic receptor site B' expressing aAPX and the internalized aAM presented on the surface as aAPX:aAM complex. aAM is released from the aAPX:aAM surface complex by incubation and the released aAM can be used for identification.

[0432] Fig.26 - Identification of aAM presented by eAPC-p+aAM through capture of the aAPX:aAM complex

[0433] eAPC-p+aAM contains the exchanged genomic receptor site B' expressing aAPX as well as the internalized aAM presented on the surface as aAPX:aAM complex. The aAPX:aAM surface complex is captured to recognize the loaded aAM.

[0434] Fig. 27 - Operation of the multi-component system for preparing analyte eAPCs for assembly of combined eAPC:T systems

[0435] The entire system of engineered multi-component cell system (MCS) operation includes contacting the prepared analyte engineered antigen presenting cells (eAPCs) with various analyte TCRs in the assembly of the combined eAPC:T system. Primary outputs are derived from the combined eAPC:T system, and terminal outputs are derived from these primary outputs. The operation of the entire system includes two stages, a preparation stage and an analysis stage. In one aspect of stage 1, the multi-component system is used to prepare analyte eAPCs, and such analyte populations may include eAPC-p, eAPC-a and / or eAPC-pa. Such analyte eAPCs present various forms of antigen moieties; analyte antigen presenting complexes (aAPX); analyte antigen molecules (aAM); aAPX loaded with aAM cargo (aAPX:aAM); cargo molecules (CM); aAPX loaded with CM (aAPX:CM); wherein the analyte antigen represents those whose affinity or signal induction to the analyte TCR is to be tested (step i). On the other hand of stage 1, cells (analyte TCs), non-cell-based particles, soluble reagents, immobilized reagents presenting analyte TCR chain pairs, or other affinity reagents specific for the analyte antigen are prepared, collectively referred to as analyte TCRs (step ii). Stage 2 of the overall system is the contact of the analyte eAPC population and the analyte TCR prepared in stage 1, resulting in the assembly of the combined eAPC:T system (step iii). The contacted analyte eAPCs may bind to the analyte TCR, where such binding may result in the formation of a stable complex. The formation of a stable complex can induce a signal response in the analyte eAPC and / or analyte TC entity, and / or a stable complex can be directly selected. Within the combined eAPC:T system, the output of the analyte eAPC or analyte TC can change their signal state (indicated by * and with darker shading) so that those responsive species can be identified (step iv). The altered state can also be a directly selected form of the eAPC, forming a stable complex with the analyte TCR. Based on the altered signaling states within the eAPC:T system, specific analyte eAPCs and / or analyte TCs can be selected based on their ability to induce a response to each other, or based on an inability to induce such a response, and / or direct selection of the stable complex itself is performed. Selection based on this responsiveness or stable complex generates a primary output of the combined eAPC:T system (step v). By obtaining the analyte cell or analyte TCR from step v, the presented analyte aAPX, aAM, aAPX:aAM, CM, aAPX:CM and / or TCR and / or other affinity reagent specific for the analyte antigen can be identified as a terminal output of the system operation (step vi).

[0436] Fig.28- Selection of cells with targeted mutagenesis of the HLA-A, HLA-B and HLA-C loci in the HEK239 cell line

[0437] A) Compared with HEK293 control cells (dashed histogram), GFP fluorescence signals in two independent cell populations after transfection for 48 hours with plasmids encoding Cas9-P2A-GFP and gRNAs targeting HLA-A, HLA-B and HLA-C loci (gray histogram). Cells with GFP signals in the GFP subset gate are sorted as polyclonal populations. B) When labeled with PE-Cy5 anti-HLA-ABC conjugated antibodies (gray histogram), cell surface HLA-ABC signals are observed on two sorted polyclonal populations. Single cells showing low PE-Cy5 anti-HLA-ABC signals and displayed in the sorting gate are sorted to establish monoclones. Unlabeled HEK293 cells (dashed histogram) and PE-Cy5 anti-HLA-ABC labeled HEK293 cells (full black histogram) are used as controls.

[0438] Fig.29 -HLA-ABC null Phenotypic analysis of monoclonals: Monoclonal populations were stained with PE-Cy5 anti-HLA-ABC conjugated antibodies and analyzed by flow cytometry (grey histograms). Unlabeled HEK293 cells (dashed histograms) and PE-Cy5 anti-HLA-ABC labeled HEK293 cells (full black histograms) were used as controls. All three monoclonal lines showed fluorescence signals matching the unlabeled controls, demonstrating that each line lacked HLA-ABC surface expression.

[0439] Fig.30 -Genetic characterization of a panel of monoclones lacking surface HLA-ABC expression, demonstrating genomic deletion in the targeted HLA allele. PCR amplicons were generated with primers spanning the gRNA genomic target site for the specific HLA allele, and their sizes were determined by electrophoresis. The expected size of the wild-type HLA-A amplicon is 1067 bp, the HLA-B amplicon is 717 bp, and the HLA-C amplicon is 1221 bp.

[0440] Fig.31 - Selection of cells with targeted genomic integration of synthetic component B with or without synthetic component D

[0441] a) GFP fluorescence signal (grey histogram) after 48 hours of transfection with plasmid encoding Cas9-P2A-GFP, gRNA targeting the AAVS1 locus and component B genetic elements flanked by the left and right homologous arms of AAVS1. HEK293 cells were used as GFP negative controls (dashed histograms). Cells with GFP signals in the GFP+ gate were classified as polyclonal groups. b) GFP fluorescence signal (grey histogram) after 48 hours of transfection with plasmid encoding Cas9-P2A-GFP, gRNA targeting the AAVS1 locus and components B and D flanked by the left and right homologous arms of AAVS1. HEK293 cells were used as GFP negative controls (dashed histograms). Cells with GFP signals in the GFP+ gate were sorted as polyclonal groups. c) Maintained BFP but no detectable RFP signal was observed in the polyclonal group sorted by D1. Single cells showing high BFP signals in quadrant Q3 were sorted to establish eAPC containing synthetic component B monoclonal clones. d) Maintained BFP and RFP signals were observed in the polyclonal population sorted in D2. Single cells showing high BFP and RFP signals in quadrant Q2 were sorted to establish eAPC single clones containing synthetic module B and synthetic module D.

[0442] Fig.32 -Phenotypic analysis of eAPC monoclones

[0443] a and b) Monoclonal populations showing sustained expression of BFP indicate integration of synthetic module B. c) Monoclonal populations showing sustained expression of BFP and RFP indicate integration of synthetic modules B and D.

[0444] Fig.33 - Genetic characterization of a panel of single clones integrating component B or components B and D in the AAVS1 locus.

[0445] a) PCR amplicons were generated with primers priming within components B and / or D and sized by electrophoresis. The expected size for a positive amplicon was 380 bp, indicating stable integration of components B and / or D. b) PCR amplicons were generated with primers priming on AAVS1 genomic sequences distal to the regions encoded by the homology arms and the SV40 pA terminator encoded by components B and / or D and sized by electrophoresis. The expected size for a positive amplicon was 660 bp, indicating integration of components B and / or D occurred at the AAVS1 site.

[0446] Fig.34 -Selection of cells with targeted genomic integration of component C' into component B

[0447] a) Plasmid encoding Cas9-P2A-GFP, gRNA targeting the AAVS1 locus and component C' HLA-A*24:02(left) or component C' HLA-B*-07:02 (Right) GFP fluorescence signal 48 hours after transfection. Cells with GFP signal within the GFP+ gate were sorted as polyclonal populations of ACL-303 or ACL-305.

[0448] b) Analyte HLA cell surface expression observed on two sorted polyclonal populations when labeled with PE-Cy5 anti-HLA-ABC conjugated antibodies (grey histograms). Single cells showing high PE-Cy5 anti-HLA-ABC signals and displayed within the right sorting gate were sorted to establish monoclonal clones. null and HLA-DR, DP, DQ null The signal detected by the eAPC cell line (dashed histogram) was used as a control.

[0449] Fig.35 - Phenotypic analysis of eAPC-p monoclones expressing analyte HLA class I proteins on the cell surface

[0450] Monoclonal populations were stained with PE-Cy5 anti-HLA-ABC conjugate antibody and analyzed by flow cytometry (grey histogram). ACL-128, HLA-ABC null and HLA-DR, DP, DQ null The eAPC cell line (dashed histogram) was used as a control. null and HLA-DR, DP, DQ null Compared to the eAPC cell line control, the ACL-321 and ACL-331 monoclonal cell lines showed stronger fluorescence signals, demonstrating that each cell line expressed its analyte aAPX, HLA-A*24:02 or HLA-B*-07:02 ORF, respectively, and was therefore an eAPC-p cell line.

[0451] Figure 36-1 Genetic characterization of a single clone confirmed that it had integrated component C' into its genome, and that integration occurred at the AAVS1 genomic recipient site, generating component B'

[0452] a) PCR amplicon confirms the presence of the HLA insert, the 810 bp band represents the correct CMV promoter amplicon and the 380 bp is the amplicon generated from the SV40pA terminator. b) PCR amplicon was generated with two sets of primers priming on AAVS1 genomic sequences away from the region encoded by the homology arms and one set of primers unique to the SV40pA terminator linked to the analyte HLA ORF. Positive

[0453] The expected sizes of amplicons 1 kb and 1.1 kb indicated the production of component B'.

[0454] Fig.37 -Selection of cells with targeted genomic integration of component C' into component B

[0455] a) Plasmid encoding Cas9-P2A-GFP, gRNA targeting the AAVS1 locus and component C' HLA-DRA*01:01 / HLA-DRB1*01:01 (left) or component C' HLA-DPA1*01:03 / HLA-DPB1*04:01 (Right) GFP fluorescence signal 48 hours after transfection. Cells with GFP signal within the GFP+ gate were sorted as a polyclonal population.

[0456] b) Analyte HLA cell surface expression observed on two sorted polyclonal populations when labeled with Alexa 647 anti-HLA-DR, DP, DQ conjugated antibodies (grey histograms). Single cells showing high Alexa 647 anti-HLA-ABC signal and presenting within the right sorting gate were sorted to establish monoclonals. null and HLA-DR, DP, DQ null Signals detected from the eAPC cell line) (dashed histogram) and the ARH wild-type cell line (full black histogram) were used as controls.

[0457] Fig.38 - Phenotypic analysis of eAPC-p monoclones expressing the analyte HLA class II protein on the cell surface

[0458] Monoclonal populations were stained with Alexa 647 anti-HLA-DR, DP, DQ conjugated antibodies and analyzed by flow cytometry (grey histograms). ACL-128 (HLA-ABC null and HLA-DR, DP, DQ null eAPC cell line) (dashed histogram) and ARH wild-type cell line (full black histogram) were used as controls. null and HLA-DR, DP, DQ null Compared to the eAPC cell line control, the ACL-341 and ACL-350 monoclonal cell lines showed stronger fluorescence signals, demonstrating that each cell line expressed their analytes aAPX, HLA-DRA*01:01 / HLA-DRB1*01:01 or HLA-DPA1*01:03 / HLA-DPB1*04:01, respectively, and were therefore eAPC-p cell lines.

[0459] Fig.39- eAPC-p monoclonals generated by RMCE integration of analyte HLA class I proteins

[0460] a) eAPC-p monoclonal populations ACL-421 and ACL-422 lost BFP fluorescence (grey histograms). Their parental eAPC cell line ACL-385 (full black histograms) and the BFP-negative ARH wild-type cell line (dashed histograms) served as controls.

[0461] b) When stained with PE-Cy5 anti-HLA-ABC conjugate antibody (grey histogram), eAPC-p monoclonal populations ACL-421 and ACL-422 acquired HLA-A*02:01 expression. Their parent ACL-385 HLA-ABC null and HLA-DR, DP, DQ null The eAPC cell line (dashed histogram) and the ARH wild-type cell line (full black histogram) served as negative and positive PE-Cy5 anti-HLA-ABC labeling controls, respectively.

[0462] These results strongly suggest that successful RMCE occurred between the BFP ORF and the HLA-A*02:01 ORF in both ACL-421 and ACL-422 cell lines.

[0463] Figure 40-1 Genetic characterization of monoclonal clones confirmed HLA-A*02:01 integration via RMCE

[0464] The 630 bp amplicon indicated the presence of HLA-A2 in monoclonal ACL-421 and 422, but not in the control line ACL-128.

[0465] Fig.41 - Phenotypic analysis of eAPC-pa monoclones expressing analyte HLA class I proteins on the cell surface and aAM

[0466] a) eAPC-p monoclonal population was stained with PE-Cy5 anti-HLA-ABC conjugated antibody and analyzed by flow cytometry (grey histogram). ACL-128, HLA-ABC null and HLA-DR, DP, DQ null The eAPC cell line (dashed histogram) was used as a control. The ACL-321 and ACL-331 monoclonal cell lines showed stronger fluorescence signals compared to the control, demonstrating that each cell line expressed its analyte aAPX, HLA-A*02:01 or HLA-B*35:01, respectively, and was therefore an eAPC-p cell line.

[0467] b) GFP fluorescence of the monoclonal population of eAPC-pa was assessed by flow cytometry (grey histogram). ACL-128, HLA-ABC null and HLA-DR, DP, DQ null The eAPC cell line (dashed histogram) was used as a control. The ACL-391 and ACL-395 monoclonal cell lines showed stronger fluorescence signals compared to the control, demonstrating that each cell line expressed the analyte aAM selection marker and thus inferred aAM expression in cell lines that also expressed the HLA-LA-A*02:01 or HLA-B*35:01 ORF, respectively. ACL-391 and ACL-395 are therefore eAPC-pa lines.

[0468] Fig.42 - Table 1 and Table 2.

[0469] Table 1: Genetic characterization of single clones containing component B.

[0470] Table 2: Genetic characterization of single clones containing components B and D.

[0471] Fig.43 - eACP-p constructed in one step, where component C' encodes a single HLAIORF.

[0472] eAPC-p were generated by RMCE by electroporating the cell line ACL-402 with a plasmid encoding the expression of the Tyr-recombinase Flp (V4.1.8) together with a plasmid encoding one of the component C's of aAPX selected from HLA-A*02:01 (V4.H.5 or HLA-A*24:02 (V4.H.6). At day 10 after electroporation, single cells were sorted that were positive for HLA I surface expression and for a reduced signal of the fluorescent protein RFP encoded by the component B selection marker. The resulting monoclonal eAPC-p lines were analyzed by flow cytometry in parallel to the parental eAPC lines and two examples are presented. a) Individually grown monoclonal lines (ACL-900 and ACL-963) were analyzed by flow cytometry for the loss of RFP, the presence of BFP and the acquisition of HLA-ABC (aAPX). The left panel shows BFP to RFP, with parental cells having both BFP and RFP (Q2, top panel, 99.2%), while ACL-900 (Q3, middle panel, 99.7%) and ACL-963 (Q3, bottom panel, 99.9%) both lack RFP signals, indicating that an integration pair between component B / C' has occurred. The right panel shows BFP to HLA-ABC (aAPX), with ACL-900 (Q2, top panel, 99.8%) and ACL-963 (Q2, bottom panel, 99.2%) both showing strong signals to HLA-ABC (aAPX), further reinforcing the integration of B / C. Both ACL-900 and ACL-963 have strong BFP signals, indicating that component D remains open and isolated from the component B / C' integration pair. b) To further characterize ACL-900 and ACL-963, as well as a) a third eAPC-p not represented in ACL-907, genomic DNA was extracted and PCR was performed using primers targeting adjacent and internal to component B' (Table 5, 8.B.3, 15.H.2), thereby selectively amplifying only successful integration pair events. This was compared to the unmodified parental line, ACL-3, which lacks component B. Component B'-specific amplicon products were generated for all three eAPC-p monoclones, while no product was detected in the ACL-3 reaction, confirming that specific integration pair events occurred between component B and component C'.

[0473] Fig.44 - eAPC-pa constructed in one step from eAPC-p, wherein component D' encodes a single analyte antigen molecule (aAM) ORF.

[0474] Multiple eAPC-pa were constructed in parallel from the parental eAPC-p (ACL-905), in which the genomic receiving site component D was targeted for integration by the initiated genetic donor vector component E', which contained a single ORF encoding aAM. eAPC-p (ACL-900, Example 8) was independently combined by electroporation with a vector encoding the expression of each component E' of RMCE recombinase (F lp, V4.1.8) and any one of V9.E.6, V9.E.7 or V9.E.8. Ten days after electroporation, a single eAPC-pa was selected and single cell sorting (monocloning) was performed based on the reduction of the signal of the integrated BFP selection marker encoded by component D. The resulting monoclonal eAPC-pa line was analyzed in parallel with the parental eAPC line by flow cytometry, and three examples are presented. In addition, the resulting monoclonal clones were genetically characterized to confirm the integration event. A) Analyze the monoclones of eAPC-pa, ACL-1219, ACL-1227 and ACL-1233, and select the loss of BFP signal and the retention of HLA-ABC signal by flow cytometry. The BFP to SSC diagram shows a BFP-gate. An increase in the number of BFP events compared to the parental eAPC-p was observed, indicating that integration pairs between components D / E' occurred. Select single cells of the BFP-gate, sort and grow. B) ACL-1219, ACL-1227, ACL-1233 monoclones selected by flow cytometry were analyzed to confirm the loss of BFP and the retention of HLA-ABC signals. A BFP to HLA-ABC diagram is presented, in which it can be observed that all three monoclones have lost the BFP signal compared to the parental eAPC-p (rightmost figure), indicating a successful integration pair event. c) To demonstrate that the single clones contained the correct fragment size for the aAM ORF, polymerase chain reaction was performed using primers targeting the aAM ORF (Table 5, 10.D.1, 15.H.4) and representative agarose gels are presented. Results for two single clones representing each aAM ORF are shown. Lane 1: 2_log DNA marker, lanes 2-3: pp28 ORF (expected size 0.8 kb), lane 4: 2_log DNA marker, lanes 5-6: pp52 ORF (expected size 1.5 kb), lane 7: 2_log DNA marker, lanes 8-9: pp65 ORF (expected size 1.9 kb), lane 10: 2_log DNA marker. All single clones analyzed had the expected amplicon size for the corresponding aAM, further indicating that an integration pair had occurred.

[0475] Fig.45 - Shotgun integration of multiple antigens into eAPC-p in one step to generate a pooled eAPC-pa library

[0476] A pooled pool of eAPC-pa was generated from a pool of primed component E vectors (component E') that collectively encoded multiple aAM ORFs (HCMVpp28, HCMVpp52, and HCMVpp65) by integration into parental eAPC-p in a single step, wherein each individual cell integrated a single random analyte antigen ORF derived from the original vector pool at component D', such that each generated eAPC-pa expressed a single random aAM, but the pooled pool of eAPC-pa collectively represented all aAM ORFs encoded in the original pooled vector pool. The eAPC-pa pool was generated by electroporation by combining eAPC-p (ACL-905, aAPX:HLA-A*02:01) with a pooled vector pool consisting of a single vector encoding an ORF of one of HCMVpp28, HCMVpp52, HCMVpp65 (V9.E.6, V9.E.7, and V9.E.8) and mixed at a molecular ratio of 1:1:1. The resulting eAPC-pa population was analyzed and selected by flow cytometry in parallel with the parental eAPC-p line. a) 10 days after electroporation, putative eAPC-pa cells (transfectants) were analyzed and selected by flow cytometry in parallel with the parental line (ACL-905). The figure shows the gating of BFP vs. SSC, BFP- population, where an increase in BFP- cells was observed in the BFP- gate compared to the parental line. A large number of cells were sorted based on the transfectants of the BFP- gate, denoted as ACL-1050. b) After outgrowth, ACL-1050 cells were analyzed by flow cytometry for BFP loss. The figure shown is BFP vs. SSC, where ACL-1050 was enriched to 96.4% BFP- compared to the parental line ~4% BFP-. Subsequently, single cells were sorted from the BFP contamination of ACL-1050. c) To demonstrate that polyclonal ACL-1050 consisted of a mixture of HCMVpp28, HCMVpp52 and HCMVpp65 encoding cells, 12 single clones were randomly selected, grown out and used for genetic characterization. Cells were characterized by PCR using primers targeting the aAM ORF (component D') (Table 5, 10.D.1, 15.H.4) to amplify and detect integrated aAM. All 12 single clones screened by PCR had detectable amplicons with the expected size of one of pp28 (0.8 kb), pp52 (1.5 kb) or pp65 (1.9 kb). In addition, all 3 aAMs were represented in 12 single clones. In contrast, amplicons from three discrete single clones (where known in aAM) were amplified in parallel as controls; all three controls produced amplicons of the correct size for pp28 (0.8 kb), pp52 (1.5 kb) and pp65 (1.9 kb). Therefore, it was determined that the pool consisted of eAPC-pa with each cell harboring a single randomly selected aAM, forming the original pool of three vectors.

[0477] Fig.46 -eAPC-pa-induced antigen-specific outgrowth of primary CD8 cells

[0478] Primary CD8+ T cells were used as analytes TC and three different eAPC cell lines ACL-191 (eAPC-p, aAPX:HLA-A*02:01), ACL-390 (eAPC-pa, aAPX:AM:HLA-A*02:01, HCMVpp65) or ACL-128 (eAPC, HLA-1 null , i.e., without aAPX) were edited with 7 different eAPC:T systems. In addition, the eAPC:T system contained ACL-191 or ACL-128, with exogenously provided aAM (as soluble NLVPMVATV peptide) when applicable. The systems were edited as described below, and after 9 days of co-culture, the cells were analyzed for specific staining with CMV-A.0201-NLVP tetramers (aAPX:aAM) to detect the outgrowth of antigen-specific T cells by flow cytometry. a) Four eAPC:T systems were edited, which included analyte TCs (CD8+ T cells), and 1) ACL-191 without aAM (unpulsed), 2) ACL-191 pulsed with aAM, 3) unpulsed ACL-128, or 4) ACL-128 pulsed with aAM. As described in the Materials and Methods section, the NLVPMVATV peptide (aAM) derived from the HCMVpp65 protein was provided to the system with aAM at a peptide concentration of 1 μM for 4 hours. Flow cytometry graphs showing CD8 vs CMV-A.0201-NLVP, where the graphs represent data for the eAPC:T system (from left to right) 1), 2), 3), 4). Compared to all other eAPC:T systems, Figure 2 A distinct population of CD8+CMV-A.0201-NLVP+ cells (gated) (27%) was observed in ACL-191 cells pulsed with aAM, lacking either aAPX or aAM or both. Figure 1), 3), 4) have positive cells between 0.02-0.12%. Therefore, when exogenous aAM is provided, specific analyte TC can be grown in an antigen-dependent manner through aAPX:aAM presented by eAPC-p cells. b) Editing three eAPC:T systems, which include analyte TC (CD8+T cells), and 1) ACL-128 (eAPC), 2) ACL-191 (eAPC-p), or 3) ACL-390 (eAPC-pa), and no exogenous aAM is provided. ACL-390 has an integrated aAMORF, HCMVpp65. Flow cytometry graphs of CD8 and CMV-A.0201-NLVP are shown, where the graphs represent data from the eAPC:T system (from left to right) 1), 2), 3). In Figure 3 A clear population (4.89%) of CD8+CMV-A.0201-NLVP+ cells (gated) was observed in ACL-390 (with endogenous aAM), compared to other eAPC:T systems lacking aAM or aAPX and aAM. Figure 1 ) and 2), with positive cells between 0.02-0.12%. Therefore, this data supports that eAPC-pa is able to process endogenous aAM ORF into aAM through natural cellular mechanisms and present aAM in complex with aAPX, so that it can stimulate antigen-specific growth of the analyte TC.

[0479] Fig.47 Antigen-specific growth of primary CD4 cells induced by eAPC-p and exogenous aAM

[0480] Two different eAPC:T systems were edited using primary CD4+ T cells as analyte TC and one eAPC-p cell line ACL-341 (aAPX:HLA-DRB1*01:01). In addition, where applicable, exogenous aAM (such as PKYVKQNTLKLAT peptide, SEQ ID NO: 1) was also provided to the system. The system was edited as described below, and after 9 days of co-culture, the cells were analyzed for specific staining with INFL-DRB1*01:01-PKYV tetramer (aAPX:aAM, SEQ ID NO: 2) to detect the outgrowth of antigen-specific T cells by flow cytometry. Two eAPC:T systems were compiled, which included the analyte TC (CD4+ T cells), and 1) ACL-341 without aAM (unpulsed), 2) ACL-341 pulsed with PKYVKQNTLKLAT peptide (aAM, SEQ ID NO: 1), as described in the Materials and Methods section, at a peptide concentration of 1 μM for 2 hours. Flow cytometry graphs of CD4 and INFL-DRB1*01:01-PKYV are shown, where the graphs represent data from eAPC:T systems (from left to right) 1) and 2). Figure 2 A clear population (12%) of CD4+ / INFL-DRB1*01:01-PKYV+ cells (gated) was observed in ACL-341 (pulsed with aAM), whereas a control eAPC:T system lacking aAM, Figure 1 ), with positive cells between 0.06%. Therefore, when exogenous aAM is provided, specific analyte TC CD4+ cells can be grown in an antigen-dependent manner through aAPX:aAM presented by eAPC-p cells.

[0481] Fig.48 - Antigen-specific cytotoxicity of eAPC-pa cells co-cultured with primary CD8 cells

[0482] Primary CD8+ T cells were used as analytes TC and three different eAPC cell lines ACL-191 (eAPC-p, aAPX:HLA-A*02:01), ACL-390 (eAPC-pa, aAPX:AM:HLA-A*02:01, HCMVpp65) or ACL-128 (eAPC, HLA-1 null, i.e. without aAPX) were edited with 7 different eAPC:T systems. In addition, the eAPC:T system contained ACL-191 or ACL-128, and where applicable, an exogenously provided aAM (such as NLVPMVATV peptide, SEQ ID NO: 3) was used. The system was edited as described below, and the cytotoxic effect of the cell co-culture on eAPC-p or -pa was analyzed by staining with AnnexinV and PI to detect dead cells by flow cytometry. a) Four eAPC:T systems were edited, which included the analyte TC (CD8+ T cells), and 1) unpulsed ACL-128, 2) ACL-128 pulsed with aAM, 3) ACL-191 without aAM (unpulsed), and 4) ACL-191 pulsed with aAM. As described in the Materials and Methods section, the NLVPMVATV peptide (aAM) derived from the HCMVpp65 protein was provided to the system with aAM at a peptide concentration of 1 μM for 2 hours. In addition, the systems were edited at ratios of 1:0, 1:1, and 1:8 for eAPC:CD8. The figure is a bar graph of the percentage of dead eAPC cells detected by flow cytometry (CD80+Annexin+PI+). Significant killing of eAPC-p cells was observed only in system 4 (ACL-191+peptide), which consisted of eAPC and CD8+ cells at a ratio of 1:1 or 1:8 (eAPC:CD8). There was no significant increase in death above background observed in systems 1, 2, and 3 without aAPX, aAM, or both. Therefore, eAPC-p pulsed with exogenous aAM can be used to stimulate antigen-specific cytotoxicity in primary CD8+T cells (analyte TC). b) Editing of three eAPC:T systems, including analyte TC (CD8+T cells), and 1) ACL-128 (eAPC), 2) ACL-191 (eAPC-p), or 3) ACL-390 (eAPC-pa), in which no exogenous aAM was provided. ACL-390 has an integrated aAM ORF, HCMVpp65. The figure is a bar graph of the percentage of dead eAPC cells detected by flow cytometry (CD80+Annexin+PI+). Significant killing of eAPC-p cells was only observed in system 3 (ACL-390) composed of eAPC and CD8+ cells at a ratio of 1:1 or 1:8 (eAPC:CD8). No significant increase in death above background was observed in systems 1 and 2 lacking aAM or aAPX:aAM. Therefore, the data support that eAPC-pa is able to process endogenous aAM ORF into aAM through natural cellular mechanisms and present aAM in complex with aAPX so that it can stimulate antigen-specific cytotoxicity by primary CD8+ T cells (analyte TC).

[0483] Fig.49- Identification of analyte antigen molecules from eAPC-pa cells by mass spectrometry

[0484] Mass spectrometry results are provided for peptide fractions derived from the following procedure. Two eAPC-p lines, ACL-900 (aAPX: HLA-A*02:01) and ACL-963 (aAPX: HLA-A*24:02) were pulsed with known antigenic peptides, where each eAPC-p was subjected to four discrete pulses consisting of one of the following aAMs as peptides; NLVPMVATV (APD-2, SEQ ID NO: 3), NLGPMAAGV (APD-21, SEQ ID NO: 4), or VYALPLKML (APD-11, SEQ ID NO: 5), or no peptide. APD-2 is known to complex with HLA-A*02:01, APD-11 is complexed with HLA-A*24:02, and APD-21 is a triple mutant of APD-2 (V3G, T8G, V6A). These mutations abolish the ability of the peptide to complex with HLA-A*02:01. Pulsed cells were harvested and lysed. The clarified lysate was mixed with nickel agarose resin and HLA was pulled down using 6x-His capture. The bound fraction was eluted in 10% acetic acid and ultrafiltered on a 3kD column. The peptide fraction was subjected to liquid extraction and the removed organic phase was subjected to solid phase extraction. The eluted peptide fraction w was subjected to mass spectrometry analysis. The peptides NLVPMVATV (SEQ ID NO: 3), VYALPLKML (SEQ ID NO: 5) and NLGPMVAGV (SEQ ID NO: 4) were successfully identified in their corresponding pulse experiments (ID 2, 3, 11) and were not identified in any other samples. The HLA-mismatched peptides NLVPMVATV (ID 12, HLA-A*24:02, SEQ ID NO: 3) and VYALPLKML (ID 13, HLA-A*02:01, SEQ ID NO: 5) and the triple mutant NLGPAAGV (SEQ ID NO: 4) were not identified. Therefore, capture and enrichment of aAPX:aAM complexes of eAPC-p cells can be used to identify, confirm and / or determine HLA-restricted presentation of analyte antigen molecules in antigen presentation complexes.

[0485] Materials and methods

[0486] Electroporation of ARH-77 cells

[0487] Each reaction was performed using the Gene Pulser Xcell TM 4 × 10 cells were electroporated in 500 μl RPMI 1640 with Glutamax-I (Life Technologies) using the following settings: 6Cells: square wave 285V, pulse length 12.5ms and 2 pulses, 1 second interval. The DNA concentration for Cas9 plasmid V1.A.8 was 10ug / ml and the DNA concentration for gRNA targeting integration site was 7.5ug / ml (V2.I.10 and V2.J.1 were used for integration in HLA endogenous sites and V2.J.6 was used for targeting AAVS1 site) (Table 3).

[0488] The integration vector was electroporated at a concentration of 7.5ug / μl. For HDR integration in the HLA locus, HLA class I V1.C.6 and V1.C.9 plasmids were used. For HDR integration in the AAVS1 locus, HLA class I V1.F.8 and V1.F.10 and HLA class II V1.I.5 and V1.I.7. Variants of the pp65 ORF were integrated into the previously generated HLA monoallelic lines. Plasmids V1.G.9 and V1.H.1 containing a form of pp65 linked to a GFP marker were used for this purpose. To generate an ARH-77HLA-null line with one RMCE site, plasmids with heterologous specific recombinase sites flanking the marker were used, V4.B.2 for RFP, and V4.B.3 for BFP. The same plasmids were co-electroporated to generate a stable line containing two RMCE sites. Monoallelic HLA lines were also generated using RMCE, where the vector V4.D.2 was electroporated into cells containing one RMCE site. After electroporation, cells were incubated in a 37°C, 5% CO medium containing Glutamax-1 + 10% FBS prior to analysis. 2 ) in RPMI 1640 medium for two days.

[0489] Transfection of HEK293 cells

[0490] One day before transfection, cells were plated at 1.2-1.4 × 10 6 The cells were seeded at a density of 10 cells / 60 mm dish in 90% DMEM + 2 mM L-glutamine + 10% HI-FBS (Life Technologies). The following day, a total of 5 ug of DNA and Cells with 65% confluence were transfected with 5% 5% 1% 2% 4% 5% 5% 2% 5% 5% 2% 5% 1% 2% 5 ... The stock solutions of DNA were diluted in sterile 1M NaCl and 150mM NaCl, respectively. The final volume of each solution was equivalent to 50% of the total mixed volume. The PEI solution was then added to the diluted DNA, and the mixture was incubated at room temperature for 15 min. Finally, the DNA / PEI mixture was added to a 60-mm culture dish, taking care not to damage the cell membrane.

[0491] Prior to GFP expression analysis, cells were incubated at 37°C with 5% CO 2 , 55% relative humidity) for 48 hours. To delete HLA class I genes, cells were transfected with 0.42ug of DNA vector encoding Cas9_GFP (V1.A.8), gRNAs targeting HLA-A, B, and C (V2.A.1, V2.A.7, and V2.B.3, respectively), and an empty vector (V1.C.2). To integrate the RMCE site in the AAVS1 locus, 0.5μg of V1.A.8; 0.625ug of gRNA V2.J.6 and 0.75ug of plasmid encoding two markers flanked by RMCE sites (V4.B.2 for RFP and V4.B.3 for BFP) were used to transfect cells, and the empty vector V1.C.2 was used to complete the 5ug DNA.

[0492] Sorting of polyclonal GFP expressing cells

[0493] Cells electroporated or transfected with Cas9-P2A-GFP (V1.A.8) or with a plasmid encoding a GFP selectable marker (V1.A.4) were used Transient GFP expression was sorted using a cell sorter (BD Biosciences). TM HEK 293 cells were harvested with Express trypsin (ThermoFisher Scientific) and resuspended in an appropriate volume of DPBS 1X (Life Technologies) in DMEM 1X medium containing 20% ​​HI-FBS and Anti-Anti 100X (Life Technologies) before cell sorting. ARH-77 cells were washed and resuspended in an appropriate volume of DPBS and then sorted in RPMI 1640 with Glutamax-I containing 20% ​​HI-FBS and Anti-Anti 100X (Life Technologies).

[0494] Isolate polyclonal and monoclonal cells that stably express the component of interest

[0495] To obtain a population of cells constitutively expressing an integral protein or marker, sort cells 7 to 15 days after the first GFP+ selection. For cells expected to express surface proteins, perform antibody staining prior to sorting. For HLA class I genes, use PE-Cy TM 5. Mouse anti-human HLA-ABC antibody (BD Biosciences). HLA-DR and HLA-DP were stained with 647 mouse anti-human HLA-DR, DP, DQ (BD Biosciences). In the case of HEK 293-derived cell lines, TrypLE TM Cells were harvested with ExpressTrypsin (ThermoFisher Scientific) and washed in an appropriate volume of DPBS 1X (LifeTechnologies) and then sorted in DMEM 1X medium containing 20% ​​HI-FBS and Anti-Anti 100X (LifeTechnologies). ARH-77-derived cell lines were washed in a sufficient volume of DPBS and then sorted in RPMI 1640 with Glutamax-I containing 20% ​​HI-FBS and Anti-Anti 100X (Life Technologies).

[0496]

[0497]

[0498] For HLA knockout or integration, cells were selected based on loss or gain of HLA expression, respectively. Cells with integrated RMCE sites were sorted based on expression of BFP and RFP markers, and HLA monoclonals with integrated pp65 mutants were sorted for GFP expression (Table 4). Monoclonal sorting of cells expressing the gene of interest was performed in 96-well plates containing 200ul of growth medium. One to two plates were sorted per sample. Cells were sorted in FACS tubes using the Influx Cell Sorter. TM The remaining cells were immediately subjected to polyclonal sorting using the bidirectional sorting setup in BD Biosciences.

[0499] Phenotypic screening of monoclonal populations

[0500] A sample of 20,000 cells of the grown monoclonal population was transferred to a microtiter plate for analysis, and the cells were resuspended in 250 μl of DPBS 1X (Life Technologies) and plated on an LRS Fortessa TM (BD Biosciences). BFP and RFP expression were detected using PMTs targeting BV421 and PE-Texas Red fluorophores, respectively. For proteins with surface expression, PE-Cy TM 5 mouse anti-human HLA-ABC antibody (BD Biosciences) or Alexa The cells were stained with 647 mouse anti-human HLA-DR, DP, DQ (BD Biosciences). The staining solution was prepared using the recommended antibody volume diluted in 100ul staining buffer (DPBS + 2% FBS). The cells were incubated at 4°C for 1 hour and then washed twice with 500ul staining buffer before analysis. The selected monoclones were maintained in normal growth medium. HEK239 cells were grown in DMEM + 2mML-glutamine + 10% HI-FBS (Life Technologies), and ARH-7 cells were grown in RPMI 1640 with Glutamax-1 + 10% HI-FBS. The confluence of the cells was monitored daily until they reached 10-12x10 6 5 × 10 6 The remaining cells were further expanded and cultured at 3×10 6 Cells were cryopreserved at a density of 10 cells / ml in 70% growth medium + 20% HI-FBS + 10% DMSO.

[0501]

[0502]

[0503] Confirm integration at the correct genomic location

[0504] Single clones with the desired phenotypic characteristics were selected and evaluated at the molecular level by PCR using HotStart High-Fidelity DNA polymerase (NBE) was performed in 20ul reactions using the manufacturer's recommended components and volumes. To determine if the HLA IORF was integrated into the HLA locus, primers 9.C.4 and 9.D.6 were used; correct right homology arm recombination was indicated by a 1 kb amplicon (Table 5). For HLA integration in the AAVS1 locus, four sets of primers were used: 9.C.3 and 9.C.8 to assess correct left homology arm recombination (1.1 kb), 9.C.4 and 9.D.1 to assess right homology arm recombination (660 bp), 1.C.5 and 9.C.5 to amplify the CMV promoter of the internal construct (810 bp), and 1.C.2 and 9.C.10 to obtain an amplicon of the SV40pA terminator of the internal construct (380 bp). Evaluation of RMCE site integration in HEK293 and ARH-77 HLA-null lines was completed using primer sets 2 and 4. To confirm HLA class I deletion in HEK293 cells, specific HLA primers were used as follows: 4.A.3 and 4.A.4 targeting HLA-A, 4.A.7 and 4.B.1 for HLA-B, and 4.B.5 and 8.A.1 for HLA-C. Initially, all components ( Reaction buffer, dNTPs, hot start DNA polymerase, primers Fwd and Rev, 100 ng DNA template and H 2 O) Prepare PCR Master Mix. Use C1000 Touch TM PCR reactions were performed in a thermal cycler (Bio-Rad). PCR products were run on a 1% agarose gel in 1X TAE buffer using PowerPac Basic (Bio-Rad), stained with 10,000-fold diluted sybersafe and analyzed with Fusion SL (Vilber Lourmat).

[0505]

[0506] Identification of gene copy number

[0507] The DNA of the selected monoclones was analyzed by using specific primers targeting the gene of interest and probes that recognized the integrated gene fragment and extended to the homology arms. For HLA class I integration in the HLA locus, primers 4.I.9 and 9.C.4 were used to amplify the gene of interest and 8.B.2 was used as a probe, conjugated to FAM. For constructs integrated in the AAVS1 locus, primers 9.D.6 and 9.D.7 and probe 9.J.2, also conjugated to FAM, were used. In all cases, primers 10.A.9 and 10.A.10 and fluorescent probe 10.B.6 conjugated to HEX were used while a reference gene (TRAC) was screened to determine the copy number. The integrated copy number assumes that ARH-77 cells are diploid and HEK293 cells are triploid for the reference gene (TRAC). Prior to Droplet DigitalPCR, DNA was digested with MfeI (NEB) to separate tandem integrations. According to The protocol of Supermix for Probes (without dUTP) (Bio-Rad) was used. Droplet Reader and Droplet Generator and C1000 Deep Well Thermal Cycler (Bio-Rad), following the reaction setup and cycling conditions. The software acquired data using Ch1 to detect FAM and Ch2 to detect HEX.

[0508]

[0509] Table 7: Summary of ACL cell lines, associated components and aAPX and / or aAM (if applicable) incorporated into Components B / B' and D / D'

[0510]

[0511]

[0512] Flp-mediated integration of HLA-A*02:01 sequences in eAPC cell lines

[0513] eAPC cells were electroporated with a vector encoding Flp, a marker to track the delivered DNA (a vector encoding GFP), and a vector containing HLA-A*02:01. The HLA-A*02:01 sequence also encodes a linker and a 3xMyc-tag at the 3' end. The electroporation conditions used were 258V, 12.5ms, 2 pulses, 1 pulse interval.

[0514] The ratio between each integration vector and Flp-vector was 1:3. Cells electroporated with only GFP vector and non-electroporated cells were used as controls, respectively, so that gates for GFP sorting could be set two days later. On the second day (2 days after electroporation), cells were analyzed and sorted based on GFP expression. Cells were sorted using a BD Influx cell sorter.

[0515] 3 days after electroporation, sorting based on GFP expression was performed to enrich for electroporated cells. 7-8 days after electroporation, cells were harvested and surface stained for HLA-ABC expression. BFP+ve RFP-ve HLA+ve cells were single cells for monoclonal cell sorting.

[0516] To genotype the cells, PCR reactions were performed using 100 ng of DNA as template to check if integration had occurred at the expected integration site. A forward primer targeting the integration cassette (Pan_HLA_GT_F1 (insertion of SEQ ID NO)) and a reverse primer targeting just outside the integration site (SV40pA_GT_R1 insertion of SEQ ID NO) were used and the PCR products were electrophoresed on a 1% agarose gel.

[0517] Flp-mediated integration of HCMV ORF sequences in the eAPC-p cell line

[0518] eAPC-p cells were electroporated with a vector encoding Flp, a marker to track the delivered DNA (a vector encoding GFP), and a vector containing HCMV pp28, pp52, or pp65 aAM-ORF. The HCMV-ORF sequence also encodes a linker and a 3xMyc-tag at the 3' end. The electroporation conditions used were 258V, 12.5ms, 2 pulses, 1 pulse interval.

[0519] The ratio between each integration vector and Flp-vector was 1:3. Cells electroporated with GFP vector alone and non-electroporated cells were used as controls, respectively, to set the gate for GFP sorting two days later. On the second day (2 days after electroporation), cells were analyzed and sorted based on GFP expression. Cells were sorted using a BD Influx cell sorter.

[0520] Flp-mediated shotgun integration of three HCMV ORF sequences in the eAPC-p cell line

[0521] eAPC-p cells were electroporated with a vector encoding Flp, a vector encoding a marker to track the delivered DNA (a vector encoding GFP), and a vector containing HCMVpp28, pp52, or pp65 aAM-ORF. The HCMV-ORF sequence also encodes a linker and a 3xMyc-tag at the 3' end. The electroporation conditions used were 258V, 12.5ms, 2 pulses, 1 pulse interval. For shotgun integration, the vectors containing the HCMV-ORF were combined in a 1:1:1 ratio and the mixture was electroporated into eAPC-p cells. The resulting eAPC-pa cells are polyclonal. Individual monoclonal cells were sorted and genetically characterized to demonstrate that the polyclone consisted of cells containing all three HCMV-ORFs.

[0522] PCR reaction to assess RMCE integration of HCMV ORF into component D

[0523] Primers used to assess integration of HCMV ORF annealed to the linker (forward primer 10.D.1 (insert SEQ ID) and EF1α promoter (reverse primer 15.H.4). Expected sizes are 1.5 for pp28, 0.8 kb for pp52 and 1.9 kb for pp65.

[0524]

[0525]

[0526] Table 9: PCR Cycling Conditions

[0527]

[0528] PCR products were run on 1% agarose gel in 1X TAE buffer using PowerPac Basic (Bio-Rad), stained with 10,000-fold diluted sybersafe and analyzed with Fusion SL (Vilber Lourmat).

[0529] Outgrowth of antigen-specific CD8+ cells

[0530] Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors known to have CMV-A.0201-NLVP-specific CD8+ T cells using Ficoll Paque Plus (GE Healthcare). Cells were stained with surface antibodies against CD markers. Specific T cell populations were sorted using a BD Influx cell sorter, precipitated and resuspended to 200,000 cells / ml in OSG medium + 10% HS.

[0531] Pulsing eAPCs with peptide multimers

[0532] HLA-A*02:01eAPC were pulsed with 1 μM peptide (NLVPMVATV (SEQ ID NO: 3) or in complete OSG medium + 10% HS) for 4 hours. Cells were washed 3 times in phosphate buffered saline (PBS) and resuspended to 100,000 cells / ml in OSG medium + 10% human serum (HS).

[0533] Co-culture of antigen-specific CD8+ and eAPC

[0534] CD8+ cells were co-cultured with eAPCs in a 1:1 ratio in 96-well polystyrene (wp) round-bottom plates, i.e., 5000 cells of each cell type, 10,000 total cells in 100 μL culture volume per well. Re-stimulation was performed on day 9 of culture such that 150 μL culture was maintained and restimulated with 5000 μL of freshly pulsed eAPCs in a volume of 50 μL per well.

[0535] In parallel experiments, CD8+ T cells were co-cultured with eAPC-pa cell line, stably expressing pp65, at a 1:1 ratio in 96wp round bottom, 5.000 cells per cell type => 10,000 cells in 100 μL culture volume per well. Unpulsed HLA null and eAPC-pa cells were included as controls. No restimulation was performed.

[0536] Phenotypic analysis

[0537] Phenotypic analysis was performed on day 14. Phenotypic analysis was performed on 5 replicates and 20 wells per condition. Cells were stained with 100x diluted DCM (Zombie NIR) and then stained with 50x diluted polymers (Table 4) for 10 min, and then surface markers (Table 4) were added in 25 μL / sample for 30-60 min. Cells were resuspended in staining buffer (PBS + 2% FBS) and data were acquired on LSRFortessa and analyzed in FlowJo.

[0538] Outgrowth of antigen-specific CD4+ cells

[0539] Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors known to have CD4+ T cells specific for INFL-DRB1*01:01-PKYV using Ficoll Paque Plus (GE Healthcare). Cells were stained with surface antibodies against CD markers. Specific T cell populations were sorted using a BD Influx cell sorter, pelleted and resuspended to 100,000 or 400,000 cells / ml in OSG medium + 10% HS.

[0540] Pulsing eAPCs with peptide multimers

[0541] HLADRB1*01:01eAPC were pulsed with 1 μM peptide (PKYVKQNTLKLAT (SEQ ID NO: 1) or in complete OSG medium + 10% HS) for 2 hours. Cells were washed 3 times in phosphate buffered saline (PBS) and resuspended to 5000 cells / ml in OSG medium + 10% human serum (HS).

[0542] Co-culture of antigen-specific CD4+ and eAPC

[0543] CD4+ cells were co-cultured with eAPC in 96wp round bottom, i.e. 250 eAPC and 5,000 vs. 20,000 CD4+ cells in 100 μL culture volume. Cultures were maintained in OSG + 10% HS. Some cultures were dosed with 100 U / mL IL-2 on day 1. Cultures without IL-2 addition were dosed with media. Cultures were expanded for 14 days with an additional dose of IL-2 on day 7.

[0544] Phenotypic analysis

[0545] Phenotypic analysis was performed on day 14. Phenotypic analysis was performed on 5 replicates and 20 wells per condition. Cells were stained with 100x diluted DCM (Zombie NIR) and then stained with 50x diluted polymers (Table 4) for 10 min, and then surface markers (Table 4) were added in 25 μL / sample for 30-60 min. Cells were resuspended in staining buffer (PBS + 2% FBS) and data were acquired on LSRFortessa and analyzed in FlowJo.

[0546] Cytotoxicity assay

[0547] Peptide pulsing of eAPCs

[0548] 2×10 6 Cells were pulsed overnight with 1 μM NLVPMVATV (SEQ ID NO: 3) peptide in 2 ml complete Roswell Park Memorial Institute (RPMI) medium, harvested, washed three times with PBS and resuspended in complete RPMI.

[0549] Preparation of antigen-specific CD8+ T cells

[0550] Antigen-specific CD8+ T cells were derived from PBMCs from healthy donors. Cells were stained with surface antibodies against CD markers. Specific T cell populations were sorted using a BD Influx Cell Sorter, counted and stored in liquid nitrogen. The day before the experiment, cells were thawed and allowed to stand overnight in complete OSG medium. Cells were counted and resuspended in complete OSG medium.

[0551] Co-culture of eAPC and antigen-specific CD8+ cells

[0552] Peptide-pulsed and unpulsed eAPCs were co-cultured with cytotoxic CD8+ T cells. 10,000 eAPCs were seeded per well in a 96-well plate (50 μl complete RPMI). eAPCs were co-cultured with CD8+ T cells in increasing ratios. The ratios tested were eAPC alone 1:0 (eAPC:CD8+), 1:1 (eAPC:CD8+), 1:8 (eAPC:CD8+) in a total volume of 100 ul. Cells were co-cultured for 4-5 hours.

[0553] dyeing

[0554] Transfer cells from the wells to microtubes (one well -> one microtube) and add 400 μl RPMI to each tube. Centrifuge the cells at 400 g for 3 min, aspirate the supernatant and resuspend the cell pellet in 25 μl staining mixture or RPMI (unstained control) (staining mixture: AnnexinV BV711 + CD80 APC + CD8 APC-H7) and incubate at room temperature and 450 rpm for 20 min. Terminate the staining by adding 400 μl RPMI to each tube, then centrifuge and remove the supernatant. Staining is described in Table 4. Resuspend the cell pellet in 150 μl RPMI containing 1 μg / ml propidium iodide (stained samples) or 150 μl RPMI (unstained samples), and transfer the sample to a 96-well plate for Fortessa acquisition.

[0555] Metal affinity chromatography

[0556] Peptides used for pulse experiments were purchased from Genscript Biotech.

[0557] APD-2: NLVPMVATV (SEQ ID NO: 3) pp65 is a wild-type peptide and is limited to binding to HLA-A*02:01, APD-21: NLGPMAAGV (SEQ ID NO: 4) pp65 V3G, T8G, V6A ADP-2's triple mutant peptide NLVPMVATV (SEQ ID NO: 3) pp65, APD-11: VYALPLKML (SEQ ID NO: 5) is a wild-type peptide limited to binding to HLA-A*24:02.

[0558] The cells were cultured in RPMI supplemented with 10% FBS at 37 °C and 5% CO. 2 On the day of the experiment, cells were harvested, washed twice in warm PBS 1x, and cultured at 2 × 10 6 Cells were re-seeded at 1 μM peptide / ml and pulsed for 2 hours with 1 μM peptide. Pulsed cells were collected, washed twice with ice-cold PBS, and lysed in ice-cold lysis buffer (150 mM sodium chloride (NaCl), 50 mM Tris pH 8, 1% 3-[(3-cholamidopropyl) dimethylamino]-1-propane sulfonate (CHAPS), 5 mM imidazole, 0.2 mM iodoacetamide and 1x Halt protease inhibitor cocktail (Thermo Scientific)), vortexed and incubated at 4°C for 20 minutes.

[0559] The clarified lysate was mixed with HisPur TM Nickel-nitriloacetic acid (Ni-NTA) resin (Thermo Scientific) was mixed and rotated at 4°C for 2 hours. After removing the unbound fraction of the lysate, the resin was washed twice with high salt buffer (250mM NaCl, 50mMTris pH 8, 25mM imidazole) and twice with low salt buffer (50mM NaCl, 50mM Tris pH 8). The washed beads were harvested in low salt wash buffer and transferred to a spin column (Thermo Scientific). The bound fraction was eluted in 10% acetic acid and ultrafiltered on a 3kD Nanosep Omega column (Pall). The peptide fraction was liquid extracted by mixing 1:1 with water-saturated ethyl acetate, vortexing thoroughly and removing the organic phase. Subsequent solid phase extraction was performed on stage tips assembled with 2 layers of Empore styrene divinylbenzene-reverse phase sulfonate (SDB-RPS) matrix 47mm disk (3M). Before loading the sample, the SDB-RPS membrane was activated with acetonitrile and equilibrated with SDB wash buffer (0.2% TFA, milli-Q, pH ≤ 2). The SDB membrane was then washed twice and the adsorbed peptide fraction was eluted in elution buffer (80% acetonitrile (ACN), 1% NH3, milli-Q, pH ≥ 10). The samples were transferred to HPLC-glass vials, vacuum dried and stored at -20°C prior to LC-MS / MS analysis.

[0560] Mass spectrometry

[0561] Before LC-MS / MS analysis, peptides were resuspended in 10 ul of solvent A (3% ACN, 0.1% formic acid (FA), MQ). Each sample was analyzed on a Q Exactive HF (Thermo Fisher, Germany) connected to a Dionex nano-UHPLC system (Thermo Fisher Scientific) by injecting 8 μl from each sample vial. The UHPLC was equipped with a trap column (Acclaim PepMap100, 75 μm × 2 cm, nanosorbent, C18, 3 μm, Thermo Fisher Scientific) and analytical column (PepMap RSLCC18, 2 μm, 50 μm × 50 cm; Thermo Fisher Scientific) heated to 50 ° C. The mobile phase buffer for nLC separation consisted of solvent A and solvent B (95% ACN, 0.1% FA, MQ). The peptides were eluted during a 30 min gradient and sprayed directly into the mass spectrometer. The flow rate was set to 400 nL / min, and the LC gradient was as follows: 2-5% solvent B in 5 min, 5-40% solvent B in 30 min, 40-47% solvent B in 5 min, 47-100% solvent B in 5 min, and 100% B in 8 min and 2% solvent B in 5 min. Nanospray was achieved using an applied voltage of 1.8 kV.

[0562] The mass spectrometer was programmed in data-dependent acquisition (DDA) mode (first 10 most intense peaks) and configured to perform a Fourier transform survey scan from 400 to 1600 m / z (resolution 60,000 at 200 m / z), AGC target 1e6, and maximum injection time 250 ms. MS2 scans were acquired on the 10 most abundant MS1 ions of charge states 1–7 using a quadrupole isolation window of 1.2 m / z for HCD fragmentation and 30 s of dynamic exclusion.

[0563] Data analysis

[0564] MaxQuant (version 1.5.6.5) was used to search the raw MS files against peptide fasta files including the peptides used in the experiment, supplemented with a list of common LC-MS / MS contaminants. Digestion specificity was set to nonspecific, and peptide variable modifications were set to allow oxidation (M), first search tolerance was set to 20 ppm and FDR was set to 1%. Example

[0565] Example 1: Deletion of the APX gene family by targeted mutagenesis

[0566] Herein, we describe how to achieve targeted mutagenesis of a family of genes encoding an antigen presenting complex (APX) to generate a first trait of engineered antigen presenting cells (eAPCs). The trait is the lack of surface expression of at least one member of the APX family.

[0567] In this example, the targeted APX contains three members of the major HLA class I family, HLA-A, HLA-B, and HLA-C, in the HEK293 cell line. HEK293 cells are derived from human embryonic kidney cells, which display endogenous surface expression of HLA-ABC. Cytogenetic analysis showed that the cell line has a nearly triploid karyotype, so that HEK293 cells encode three alleles of each HLA-A, HLA-B, and HLA-C gene.

[0568] Targeted mutagenesis of the HLA-A, HLA-B, and HLA-C genes was performed using an engineered CRISPR / Cas9 system, in which Cas9 nuclease activity was targeted to the HLA-A, HLA-B, and HLA-C loci by synthetic guide RNAs (gRNAs). Four to five unique gRNAs were designed to target conserved nucleotide sequences at each HLA locus, and the target site was biased toward the beginning of the gene coding sequence because this is more likely to produce null alleles. The efficiency of the gRNAs in inducing mutations at their target loci was determined, and the most efficient gRNA was selected to produce null alleles for HLA-A, HLA-B, and HLA-C (HLA-ABC). null )HEK293 cell line.

[0569] Plasmids encoding optimal gRNAs targeting HLA-A, HLA-B, and HLA-C loci were transfected into HEK293 cells together with a plasmid encoding Cas9-P2A-GFP as described in the methods. Two days after transfection, cells positive for Cas9-P2A-GFP plasmid uptake were FAC-sorted based on GFP fluorescence ( Fig.28 a). GFP sorted cells were further expanded for more than 5 days to allow sufficient time for gene editing events to occur and, in the case of deleterious mutations, loss of expression of the remaining endogenous HLA I proteins. After this growth period, cells were stained with pan-HLA-ABC antibodies, resulting in identification of cells with reduced expression of HLA-ABC on their surface ( Fig.28 b) The absence of pan-HLA-ABC antibody staining suggests that each of the HLA-A, HLA-B, and HLA-C alleles is mutated. Individual HLA-ABC negative cells are sorted and expanded to represent a monoclonal collection.

[0570] Confirmation of HLA-ABC by lack of surface expression of HLA-ABC nullMonoclonal. A subset of monoclonals have been shown to lack surface expression of HLA-ABC, including three example monoclonals, ACL-414, ACL-415, and ACL-416. Fig.29 Further genetic characterization of the single clones lacking HLA I surface expression was performed by determining whether the cell line harbored potential genetic mutations in all alleles of the HLA-A, HLA-B, and HLA-C genes ( Fig.30 ). Genetic characterization is performed by PCR with primers spanning the gRNA gene target site to detect amplicon size changes and / or to serve as a template for sequencing. Fig.30 HLA-ABC null Single clones were selected that contained genetic deletions in alleles of the HLA-A, HLA-B, and HLA-C genes detected by shorter PCR amplicons compared to the amplicon size of established cell lines (eg, ACL-414).

[0571] In summary, genetically modified HEK293 cell lines, including ACL-414, ACL-415, and ACL-416, were demonstrated to lack surface expression of HLA-ABC, thus possessing the first traits of engineered antigen-presenting cells (eAPCs).

[0572] Example 2: Generation of eAPCs containing component B

[0573] This article describes how component B is stably integrated into HLA-ABC null The monoclonal line ACL-414 is used to generate a second trait of the eAPC. The second trait comprises at least one genomic receptor site for integration of at least one ORF, wherein the genomic receptor site is a synthetic construct designed for recombinase-mediated cassette exchange (RMCE).

[0574] In this embodiment, the genomic integration site, component B, is composed of selected genetic elements. Two unique heterologous specific recombinase sites, FRT and F3, are flanked by ORFs encoding selection marker blue fluorescent protein (BFP). The 5' of the encoded FRT site is the EF1a promoter, and the 3' of the F3 site is the SV40 polyadenylation signal terminator. The benefit of positioning non-coding cis-regulatory elements outside the heterologous specific recombinase site is that they are not required in the matching genetic donor vector C component. Therefore, after the cell delivery of the genetic donor vector, transient expression of the encoded ORF was not observed. This makes the selection of successful RMCE more reliable, because the cellular expression of the ORF from the genetic donor vector is likely to occur only when it is correctly integrated into component B, because it now contains appropriate cis-regulatory elements (see Example 6).

[0575] To facilitate stable genomic integration of component B into the genomic safe harbor locus AAVS1, a plasmid was constructed in which the DNA elements of component B were flanked by left and right AAVS1 homology arms. Each arm contained >500 bp of sequence homologous to the AAVS1 genomic locus.

[0576] Stable integration of component B was achieved through a homology-directed recombination (HDR) process at the genomic safe harbor locus AAVS1. The ACL-414 cell line was transfected with a plasmid encoding an optimal gRNA targeting the AAVS1 locus, a plasmid encoding Cas9-P2A-GFP, and a plasmid encoding the genetic element of component B flanked by the left and right homology arms of AAVS1. Cells positive for uptake of the Cas9-P2A-GFP plasmid were FAC-sorted based on GFP fluorescence 2 days after transfection ( Fig.31 A). The cells sorted by GFP were further expanded more than 7 days, allowing enough time for HDR to occur and forfeiture of the transient expression of the selection marker BFP. After this growth period, cells were analyzed on a FACS instrument, and single BFP positive cells were sorted and expanded to represent a monoclonal collection ( Fig.31 c).

[0577] Based on their sustained BFP expression and to allow for the mono-integration of component B into the desired AAVS1 gene location, individual monoclonal lines were selected as eAPCs. Cell lines ACL-469 and ACL-470 represent monoclonal lines with predominant BFP expression ( Fig.32 a and b). Genetic characterization of DNA extracted from monoclonal ACL-469 and ACL-470 demonstrated that their genomes had integrated component B, and that component B had integrated into the AAVS1 locus ( Fig.33 Genomic integration was confirmed by detecting a PCR amplicon of the expected size using primers specific for component B ( Fig.33 a). Confirmation of component B integration into the AAVS1 locus was determined by detection of a PCR amplicon of the expected size using primers designed to the AAVS1 genomic sequence distal to the region encoded by the homology arms and a primer unique to the SV40 pA terminator encoded by component B. Fig.33 b). Determination of the copy number of component B by digital droplet PCR, in which the number of component B and reference gene DNA molecules is measured and the ratio is calculated ( Fig.42 , Table 1). Monoclonal ACL-469 and ACL-470 contained a ratio of 1 component B molecule to 3 reference gene molecules. When considering that the established HEK293 cell line has a nearly triploid karyotype, this demonstrates a single integration of component B in the ACL-469 and ACL-470 cell lines.

[0578] In conclusion, the genetically modified ACL-469 and ACL-470 cell lines are HLA-ABC null and contained a single copy of a synthetic genomic recipient site designed for RMCE, thus demonstrating the creation of eAPCs with a single synthetic integration recipient site.

[0579] Example 3: Generation of eAPCs containing component B and component D

[0580] This article describes how components B and D are stably integrated into HLA-ABC null The monoclonal line ACL-414 was used to generate a second trait of eAPC. The second trait contained two genomic receiver sites for integration of at least one ORF, wherein the genomic receiver sites were synthetic constructs designed for recombinase-mediated cassette exchange (RMCE).

[0581] This example uses the same methods and components as described in Example 2, but adds a second genomic receiving site, Component D. The Component D genetic element consists of two unique heterologous specific recombinase sites, F14 and F15, which are different from Component B. These sites flank the ORF encoding the selectable marker red fluorescent protein (RFP). The 5' of the F14 site encoding is the EF1a promoter, and the 3' of the F15 site is the SV40 polyadenylation signal terminator. As in Example 2, the Component D genetic element is flanked by left and right homology arms of AAVS1, each containing >500 bp of sequence homologous to the AAVS1 genomic locus.

[0582] Components B and D were integrated into AAVS1 as described in Example 2, but the plasmid encoding the component D element was added to the transfection mixture. Two days after transfection, cells positive for Cas9-P2A-GFP plasmid uptake were FAC-sorted based on GFP fluorescence ( Fig.31 a). GFP sorted cells were further expanded for more than 7 days, after which the cells were analyzed on a FACS machine and single BFP and RFP positive cells were sorted and expanded to represent a pool of monoclonal clones ( Fig.31 b).

[0583] Individual monoclonal lines were selected as eAPCs based on their sustained expression of BFP and RFP and for single integration of component B and single integration of component D into different AAVS1 alleles. Cell line ACL-472 is a representative monoclonal line with sustained expression of BFP and RFP ( Fig.32 c). As described in Example 2, DNA extracted from monoclonal ACL-472 was genetically characterized and demonstrated that their genomes had integrated both component B and component D, and that both components were integrated into the AAVS1 locus ( Fig.33). The copy number of components B and D was determined by digital droplet PCR, in which the number of component B, D and reference gene DNA molecules was measured and the ratio was calculated. Monoclonal ACL-472 contained 2 components B and D molecules to 3 reference gene molecules in a ratio of ( Fig.42 , Table 2). When considering that the established HEK293 cell line has a nearly triploid karyotype, this demonstrates a single integration of component B and a single integration of component D into the ACL-472 cell line.

[0584] In conclusion, the genetically modified ACL-472 cell line is HLA-ABC null and contained a single copy of component B and component D, a synthetic genomic recipient site designed for RMCE, thus demonstrating the creation of eAPCs with two unique synthetic integration recipient sites.

[0585] Example 4: eAPC-p constructed in one step with one integration pair, where component C' encodes a single HLAIORF

[0586] Here we describe how eAPC-p is constructed in one step using an integration pair, where the genomic recipient site component B is the native genomic site and the genetic donor vector component C' contains a single ORF encoding an analyte antigen presenting complex (aAPX).

[0587] In this embodiment, eAPC is a genetically modified ARH-77 cell line, called ACL-128, in which two APX families, major HLA class I families and HLA class II mutations. The founding cell line ARH-77 is a B lymphoblast derived from plasmid cell leukemia, which shows strong HLA-A, B, C and HLA-DR, DP, DQ cell surface expression. Cytogenetic analysis showed that the founding ARH-77 cell line has a near diploid karyotype, but also shows a deletion in chromosome 6p21, which encodes the HLA locus. DNA sequencing of the ARH-77 locus confirmed that ARH-77 encodes only a single allele of the HLA-A, HLA-B and HLA-C and HLA-DRA, HLA-DRB, HLA-DQA, HLA-DQB, HLA-DPA and HLA-DPB gene families.

[0588] Using the method described in Example 1, HLA-ABC was generated by CRISPR / cas9 targeted mutagenesis using gRNA targeting HLA-A, HLA-B and HLA-C and HLA-DRA, HLA-DRB, HLA-DQA, HLA-DQB, HLA-DPA and HLA-DPB gene families. null and HLA-DR, DP, DQ nullCell line ACL-128. Surface labeling with pan-anti-HLA-ABC or pan-anti-HLA-DR, DP, DQ confirmed that ACL-128 lacks surface expression of two APX families, respectively. Fig.34 b and 35 and Fig.37 b.

[0589] In this example, the genomic recipient site component B is the native AAVS1 genomic site, and targeted integration is achieved by HDR. The genetic donor vector component C is matched to component B by component C encoding the left and right homology arms of AAVS1, each homology arm containing >500bp of sequence homologous to the AAVS1 genomic locus. Between the left and right AAVS1 homology arms, the plasmid encodes a CMV promoter and an SV40 terminator. The target aAPX is cloned between the promoter and terminator, generating component C'. In this example, component C' contains a single ORF encoding one aAPX, HLA-A*24:02 or HLA-B*-07:02, representing component C', respectively. HLA-A*24:02 and component C' HLA-B*-07:02 .

[0590] The process of constructing eAPC-p is to integrate component C' into component B by HDR induction to produce component B'. The cell line ACL-128 was electroporated with a plasmid encoding the optimal gRNA targeting the AAVS1 locus, Cas9-P2A-GFP, and component C'. Two days after electroporation, cells positive for Cas9-P2A-GFP plasmid uptake were FAC-sorted based on GFP fluorescence ( Fig.34 a). GFP sorted cells were further expanded for more than 7 days, allowing sufficient time for HDR to occur and for the loss of transient expression of aAPX. After this growth period, cells were stained with pan-HLA-ABC antibodies, resulting in the identification of cells that had acquired analyte HLA expression on their surface ( Fig.34 b) The presence of pan-HLA-ABC antibody staining suggests that the analyte HLA ORF encoded in component C' has integrated into the genome. Individual HLA-ABC positive staining cells were sorted and expanded to represent a pool of eAPC-p monoclones.

[0591] Based on their maintained analyte HLA surface expression and integration of the analyte ORF into the genomic recipient site, individual monoclonal lines were selected as eAPC-p, producing component B'. Cell lines ACL-321 and ACL-331 are representative monoclonal lines that maintain analyte HLA surface expression of HLA-A*24:02 or HLA-B*-07:02, respectively ( Fig.35). Genetic characterization was performed on DNA extracted from selected monoclonal clones ACL-321, ACL-327, ACL-331 and ACL-332, and it was demonstrated that their genomes had integrated component C', and that integration occurred at the AAVS1 genomic receiving site, producing component B' ( Fig.36 Confirmation of genomic integration was determined by detection of a PCR amplicon of the expected size using primers specific for component C' ( Fig.36 a). The presence of component B' was confirmed by detecting a PCR amplicon of the expected size using primers designed to target AAVS1 genomic sequences distal to the region encoded by the homology arms and primers unique to the SV40 pA end linked to the analyte HLA ORF ( Fig.36 b).

[0592] In summary, the generation of genetically modified ACL-321 and ACL-331 cell lines, which contain a copy of the aAPX HLA-A*24:02 or HLA-B*-07:02 ORF, respectively, located in the genome receptor locus component B', resulted in the analyte aAPX becoming the only major HLA class I member expressed on the cell surface. Thus, this demonstrates the creation of two defined eAPC-p cell lines using the multicomponent system.

[0593] Example 5: eAPC-p constructed using an integration pair in one step, where component C' encodes a pair of HLA I ORFs

[0594] This article describes how eAPC-p is constructed in one step using one integration pair, where the genomic recipient site component B is the native genomic site and the genetic donor vector component C' contains a single ORF encoding two aAPX chains.

[0595] This example uses eAPC, ACL-128 and component B, both of which are defined in Example 4. Component C', however, contains a single ORF encoding either the HLA-DRA*01:01 allele linked to the HLA-DRB1*01:01 allele via a viral self-cleaving peptide element or the HLA-DPA1*01:03 allele linked to the HLA-DPB1*04:01 allele via a viral self-cleaving peptide element, denoted as component C', respectively. HLA-DRA*01:01 / HLA-DRB1*01:01 and component C' HLA-DPA1*01:03 / HLA-DPB1*04:01 The viral self-cleaving peptide element encodes a peptide sequence that, when transcribed, results in self-cleavage of the synthetic peptide and produces two polypeptides that define each HLA chain.

[0596] In Example 4, the process of constructing eAPC-p is described, except that the identification of cells that acquire analyte HLA expression on their surface is assessed by cell surface labeling with pan-anti-HLA-DR, DP, DQ antibodies ( Fig.37 ). The presence of pan-anti-HLA-DR, DP, DQ antibody staining suggests that the analyte HLA ORF encoded in component C' has integrated into the genome. Individual HLA-DR, DP, DQ positive staining cells were sorted and expanded to represent a pool of eAPC-p monoclonals.

[0597] Based on maintained analyte HLA surface expression and integration of the analyte ORF into the genomic recipient site, individual monoclonal lines were selected as eAPC-p and component B' was produced as described in Example 4. Cell lines ACL-341 and ACL-350 are representative monoclonal lines with maintained analyte HLA surface expression of HLA-DRA*01:01 / HLA-DRB1*01:01 or HLA-DPA1*01:03 / HLA-DPB1*04:01 ( Fig.38 ).

[0598] In summary, the generation of genetically modified ACL-341 and ACL-350 cell lines, which contain a copy of the aAPX HLA-DRA*01:01 / HLA-DRB1*01:01 or HLA-DPA1*01:03 / HLA-DPB1*04:01 ORFs, respectively, within the genomic receptor site component B', resulted in the analyte aAPX becoming the only major HLA class II member expressed on the cell surface. Thus, this demonstrates the use of a multi-component system to generate two defined eAPC-p cell lines.

[0599] Example 6: eAPC-p constructed with one integration pair in one step, where component B is a synthetic construct

[0600] This article describes how eAPC-p is constructed in one step using one integration pair, where the genomic receiver site component B is a synthetic construct designed for the RMCE genomic site and the genetic donor vector component C' includes a single ORF encoding one aAPX.

[0601] In this embodiment, genomic integration site component B is composed of selected genetic elements. Two unique heterologous specific recombinase sites, FRT and F3, are flanked by the ORF of the coding selection marker blue fluorescent protein (BFP). The 5' of the coded FRT site is the EF1a promoter, and the 3' of the F3 site is the SV40 polyadenylation signal terminator. The genetic elements of component B are integrated into the cell line ACL-128 by electroporation with the same plasmid as described in Example 2. Single monoclonal lines are selected according to the BFP expression maintained by it, and genetic characterization is performed to contain a single integration ( Fig.39a). The obtained eAPC cell line ACL-385 is HLA-ABC null and HLA-DR, DP, DQ null and contains a single copy of synthetic genomic receiver site component B designed for RMCE.

[0602] The genetic donor vector, component C, matches component B because component C encodes the same heterologous specific recombinase sites FRT and F3. The target aAPX ORF, which additionally encodes a kozak sequence before the start codon, is cloned between the two heterologous specific recombinase sites and generates component C'. In this example, component C' contains a single ORF encoding one aAPX: HLA-A*02:01, referred to as component C' FRT:HLA-A*02:01:F3 .

[0603] Using a plasmid encoding the Tyr-recombinase Flp, and component C' FRT:HLA-A*02:01:F3 Together, eAPC-p was generated by RMCE through electroporation of the cell line ACL-385. 4-10 days after electroporation, single cells that were positive for HLA I surface expression and negative / reduced for the fluorescent protein marker BFP encoded by the component B selection marker were sorted. The monoclonal lines grown from individuals were selected based on their maintained HLA I allele expression and the loss of BFP fluorescence, which indicated that the expected RMCE occurred. In order to identify such monoclones, both phenotypic and genetic tests were performed. First, all monoclonal cell lines were screened for cell surface HLA-ABC expression and BFP fluorescence deficiency ( Fig.39 ). Genomic DNA was extracted from these cell lines (e.g., ACL-421 and ACL-422), and integration of component C' into component B was confirmed by detection of a PCR product specific for component B', resulting in component B' ( Fig.40 ).

[0604] In summary, the generation of genetically modified ACL-421 and ACL-422 cell lines containing aAPX HLA-A*02:01 ORF copy in the synthetic genomic receptor site B' module, respectively, resulted in the analyte aAPX being the only major HLA class I member expressed on the cell surface. Thus, this demonstrated the use of a multi-module system to generate two defined eAPC-p cell lines.

[0605] Example 7: eAPC-pa constructed with two integration pairs in two steps

[0606] Herein, it is described how to construct eAPC-pa in two steps. Step 1, where the genomic receiving site component B is the native genomic site and the genetic donor vector component C' contains a single ORF encoding one aAPX. Step 2, where the genomic receiving site component D is a second native genomic site and the genetic donor vector component E' contains a single ORF encoding one analyte antigen molecule (aAM).

[0607] In this embodiment, step 1 is performed, wherein the eAPC is ACL-128, the genomic receptor site, component B, is the mutant HLA-A allele genomic site, referred to as HLA-A null , and targeted integration is achieved through HDR. Genetic donor vector, component C is encoded by HLA-A null Component C, with left and right homology arms, matches component B, and each homology arm contains >500 bp of HLA-A null Sequences homologous to genomic loci. null Between the left and right homology arms, the plasmid encodes a CMV promoter and an SV40 terminator. The target aAPX is cloned between the promoter and the terminator to generate component C'. In this embodiment, component C' contains a single ORF encoding one aAPX, HLA-A*02:01 or HLA-B*-35:01, respectively, denoting component C'. HLA-A*02:01 Component C' HLA-B*-35:01 .

[0608] Component C' was integrated into component B and monoclonal eAPC-p cell lines were selected as described in Example 4, except that HLA-A was targeted null The gRNA of the genomic locus was used to promote HDR integration of component C' into component B. Monoclonal eAPC-pACL-191 and ACL-286 expressed HLA-A*02:01 or HLA-B*-35:01 on the cell surface, respectively. Fig.41 a).

[0609] In this example, step 2 is performed wherein the genomic recipient site, component D, is the native AAVS1 genomic site and targeted integration is achieved via HDR. The genetic donor vector component E is matched to component D via component E encoding the AAVS1 left and right homology arms, each containing >500 bp of sequence homologous to the AAVS1 genomic locus. Between the AAVS1 left and right homology arms, the plasmid encodes the CMV promoter and the SV40 terminator. The target aAM is cloned between the promoter and terminator, yielding component E'. In this example, component E' comprises a single ORF encoding the selectable marker GFP linked to the aAM ORF encoding hCMV-pp65, denoted as component E' GFP:2A:pp63The viral self-cleavage peptide element encodes a peptide sequence that, when transcribed, results in self-cleavage of the synthetic peptide and produces two polypeptides, GFP and the intracellular hCMV-pp65 protein.

[0610] Component E' was integrated into component D as described in Example 4. Individual monoclonal lines, ACL-391 and ACL-395, were selected as eAPC-pa ( Fig.41 B).

[0611] In summary, genetically modified ACL-391 and ACL-395 cell lines were generated that contain a copy of the aAPX HLA-A*02:01 or HLA-B*-35:01 ORF, respectively, within the genome receptor site component B' and the aAM ORF pp65 within the genome receptor site component D'. These genetic modifications result in the aAPX being the only major HLA class I member expressed on the cell surface of cells that also express the aAM. Thus, this demonstrates the use of a multi-component system to generate two defined eAPC-pa cell lines.

[0612] Example 8: eACP-p constructed in one step, wherein component C' encodes a single HLAIORF.

[0613] This article describes the conversion of eAPCs to eAPC-p in a single step via a single integration pair event to integrate a single HLAIORF encoding an analyte antigen presenting complex (aAPX), and wherein the eAPCs contain two synthetic genomic receptor sites designed for RMCE-based genomic integration, component B and component D. The resulting eAPC-p has one genomic receptor site occupied by the HLAIORF (component B'), while the remaining component D can be used for additional integration pair events ( Figure 6 ).

[0614] This example uses eAPC (ACL-402) containing components B and D produced in Example 3, wherein component B contains two unique heterologous specific recombinase sites F14 and F15, which are located on the sides of the ORF encoding the selection marker red fluorescent protein (RFP). The 5' of the encoded F14 site is the EF1a promoter, and the 3' of the F15 site is the SV40 polyadenylation signal terminator. Component D contains two unique heterologous specific recombinase sites FRT and F3, which are located on the sides of the ORF encoding the selection marker blue fluorescent protein (BFP). The 5' of the encoded FRT site is the EF1a promoter, and the 3' of the F15 site is the SV40 polyadenylation signal terminator.

[0615] This example utilizes a component C genetic donor vector that contains heterologous recombinase sites F14 and F15 and is therefore compatible with component B. Two separate components C' are generated from component C, wherein one vector (V4.H.5) contains the Kozak sequence, the start codon and the aAPX ORF encoding HLA-A*02:01 between the F14 / F15 sites, and wherein the second vector (V4.H.6) contains the Kozak sequence, the start codon and the aAPX ORF encoding HLA-A*24:02 between the F14 / F15 sites.

[0616] eAPC (ACL-402) were independently combined by electroporation with vectors encoding the expression of RMCE recombinase (Flp, V4.1.8) and either component C' of V4.H.5 or V4.H.6. The cells were cultured for 4-10 days and then selected and sorted based on the loss of the integrated selection marker RFP and the increase in HLA I on the cell surface. Subsequently, each grown monoclonal line was characterized, confirmed and selected based on the increase in HLA I surface expression and the loss of RFP fluorescence, indicating that the expected conversion of component B to B' had occurred. Compared to the parental ACL-402 cell line, the selected eAPC-p monoclonal ACL-900 (V4.H.5, HLA-A*02:01) and ACL-963 (V4.H.6, HLA-A*24:02) were both negative for RFP and maintained HLA I surface expression ( Fig.43 In addition, both monoclones retained expression of the integrated BFP selectable marker, indicating that component D remained uncoupled and separated from the component B integration pair event. To further characterize the eAPC-p monoclonal clones, genomic DNA was extracted from the cells and the integration pair between component C' and component B was confirmed by detecting a PCR product specific for component B', generating component B'( Fig.43 b, Table 5 lists the primers used for genotyping). Primers were designed to target the region adjacent to the genomic recipient site (primer ID 8.B.3), as well as the region within the integration pair event (primer ID 15.H.2). Amplification occurred only in the case of specific integration, without generating products from the control (ACL-3) or from off-target recombination.

[0617] In summary, this example illustrates two specific examples of the conversion of eAPCs to eAPC-p using a multi-component system, in which two different aAPXs were delivered separately (component C') and integrated into a single genomic recipient site (component B) via the RMCE genomic integration method, subsequently creating a limited pool containing two discrete eAPC-p. In addition, it was demonstrated that the second genomic recipient site (component D) was insulated and unaffected by the component B / component C' integration pair.

[0618] Example 9: eAPC-pa constructed from eAPC-p in one step, wherein component D' encodes a single analyte antigen molecule (aAM) ORF.

[0619] This example describes how multiple eAPC-pa were constructed in parallel from the parental eAPC-p (described in Example 8), where the genomic receiver site component D was targeted for integration via a primed genetic donor vector component E' containing a single ORF encoding aAM.

[0620] In this example, the parental eAPC-p line used was ACL-900, which expresses a single aAPX (HLA-A*02:01) integrated in component B' (described in Example 8). The eAPC-p component D remained open and consisted of two unique heterologous specific recombinase sites, FRT and F3, which flanked the ORF encoding the selection marker blue fluorescent protein (BFP). 5' to the encoded FRT site was the EF1a promoter, and 3' to the F15 site was the SV40 polyadenylation signal terminator. In this example, a genetic donor vector, component E, was used, which contained two heterologous specific recombinase sites, F14 and F15, and thus matched component D. In this example, component E was further primed with a target aAM ORF selected from HCMVpp28 (V9.E.6), HCMVpp52 (V9.E.7) or HCMVpp65 (V9.E.8), each of which also encoded a C-terminal c-myc tag. In addition, each component E' further contained a Kozak sequence and a start codon immediately 5' of the aAM ORF. Thus, a small discrete pool of components E' was generated, which included three vectors.

[0621] eAPC-p (ACL-900, Example 8) were combined with vectors encoding the expression of each component E' of RMCE recombinase (Flp, V4.1.8) and V9.E.6, V9.E.7 or V9.E.8 independently by electroporation. The cells were incubated for 4-10 days to allow integration to occur, followed by selection of single eAPC-pa and single cell sorting (monocloning) based on the reduction of the signal of the selection marker of the integrated BFP encoded by component D ( Fig.44 a). Subsequently, individual outgrowths of monoclonal eAPC-pa, ACL-1219 (pp28), ACL-1227 (pp52), and ACL-1233 (pp65) were characterized and selected based on loss of BFP expression and maintained surface expression of HLA I (aAPX at component B') ( Fig.44b), indicating that the expected conversion of component D to D' occurred. Furthermore, the maintained surface expression of aAPX indicated that component B' was unaffected and segregated from the integration pair event between component D and component E'. To further characterize the selected eAPC-pa monoclonals, genomic DNA was extracted and the integration pair between component E' and component D, resulting in component D', was confirmed by detecting a polymerase chain reaction (PCR) amplicon product specific for component D'. Fig.44 In c, two single clones representing each of the three eAPC-pa are shown, in which amplicon products of the expected sizes for aAM ORFs pp28 (0.8 kb), pp52 (1.5 kb), and pp65 (1.9 kb) were observed, further confirming that the expected integration events had occurred.

[0622] In summary, this example illustrates three specific examples of the conversion of eAPC-p to eAPC-pa using a multi-component system, in which three different aAMs were delivered individually (component E') and integrated into a single genomic recipient site (component D) by the RMCE genomic integration method, followed by the generation of three discrete mini-pools of eAPC-pa carrying three different aAM ORFs. In addition, it was demonstrated that the second genomic recipient site (component B') loaded was insulated and unaffected by the component D / component E' integration pair.

[0623] Example 10: Shotgun integration of multiple analyte antigen molecules ORFs into eAPC-p to generate a pooled eAPC-pa library in one step

[0624] This article describes how to integrate a pool of primed component E vectors (component E') encoding multiple aAM ORFs (HCMVpp28, HCMVpp52 and HCMVpp65) into parental eAPC-p (described in Example 8) in one step to generate a pooled pool of eAPC-pa, where each individual cell integrates a single random analyte antigen ORF from the original vector pool at component D', so that each eAPC-pa expresses a single random aAM, but the pooled pool of eAPC-pa collectively represents all aAM ORFs encoded in the original pooled vector pool. This method of generating a pool of eAPC-pa, each eAPC-pa expressing a single random ORF from the vector pool, is called shotgun integration.

[0625] In this example, the parental eAPC-p line used was ACL-905 (cell line construction is described in Example 8) expressing aAPX (HLA-A*02:01) on the cell surface, and component D and component E' were as described in Example 9. In this example, the individual component E' vectors of Example 9, V9.E.6, V9.E.7 and V9.E.8 (containing aAM ORFs encoding HCMVpp28, HCMVpp52 and HCMVpp65, respectively) were mixed together in a 1:1:1 molar ratio to produce a vector pool. eAPC-p (ACL-905) was combined with the vector pool and a vector encoding the expression of RMCE recombinase (Flp, V4.1.8) by electroporation. The cells were incubated for 4-10 days and then based on the vectors with the vectors consisting of component D ( Fig.45 a) Bulk sorting of cells by reducing the signal of the integrated selection marker BFP encoded by ACL-1050 ( Fig.45 b).

[0626] To confirm that the eAPC-pa pool ACL-1050 consisted of a mixture of eAPC-pa encoding one of HCMVpp28, HCMVpp52, or HCMVpp65 at component D', individual cells were single-cell sorted from the polyclonal population and 12 were randomly selected for genetic characterization. Primers spanning each aAM were used (Table 5, Fig.45 c) Amplification of component D'. Fig.45 In c, amplicons generated for 12 cells are shown with controls where for all 12 cells a single amplicon product was observed consistent with the expected size of one of the aAM ORFs pp28 (0.8 kb), pp52 (1.5 kb), and pp65 (1.9 kb). In addition, each aAM ORF was identified at least once, indicating that the eAPC-pa pool consisted of a mixture of eAPC-pa, where each eAPC-pa in the pool had integrated a single random aAM ORF from the original pool of three vectors.

[0627] In summary, this example demonstrates the use of a multi-component system to convert eAPC-p into a pooled pool of eAPC-pa in a single step by combining eAPC-p with a pooled pool of three vectors encoding three different analyte antigen molecules (component E') and utilizing a shotgun integration approach based on RMCE. In addition, this example demonstrates that each eAPC-pa in the resulting pool of eAPC-pa has integrated a single random aAM ORF from the original vector pool via an integration pair event between component D and component E', and that all three aAM ORFs are represented in the resulting pooled eAPC-pa pool.

[0628] Example 11: Demonstration of two eAPC:T systems for antigen-specific outgrowth of primary CD8 cells induced by eAPC-pa

[0629] This example describes the compilation and use of two different eAPC:T systems, wherein the first system consists of eAPC-p, exogenously provided aAM (used to create aAPX:aAM presented by eAPC-p), and analyte primary T cells (analyte TC). The second system consists of eAPC-pa presenting aAPX:aAM and analyte primary T cells (analyte TC). The eAPC:T system is used to identify and select analyte TCs with TCRs that are able to respond to the analyte antigen (aAPX:aAM) by detecting the proliferation and outgrowth of specific analyte TCs.

[0630] In this example, the induced outgrowth of antigen-specific CD8+T cells from a population of CD8+T cells was monitored, where aAPX was HLA-A*02:01 (HLA class I) and aAM was the peptide NLVPMVATV. In a system consisting of eAPC-p, aAM was provided exogenously, and in a system consisting of eAPC-pa, aAM was naturally processed from an integrated analyte antigen ORF (HCMVpp65). The cell lines used were eAPC-p (ACL-191) and eAPC-pa (ACL-390), described in Examples 8 and 9, respectively. As described in Materials and Methods, analyte TC, CD8+T cells were isolated from healthy blood donors known to have CD8+T cells specific for the NLVPMVATV peptide.

[0631] In the first eAPC:T system, eAPC-p (ACL-191) were pulsed with exogenous NLVPMVATV (SEQ ID NO: 3) peptide at a peptide concentration of 1 μM for 4 hours as described in Materials and Methods. The eAPC:T system was then edited by combining the pulsed eAPC-p cells with analyte TC (bulk sorted CD8+ T cells) and co-culturing under standard conditions. After 9 days of co-culture, cells were analyzed for the formation of cooperative complexes between analyte antigen and analyte TCR by specific staining with CMV-A.0201-NLVP tetramer (aAPX:aAM as soluble reagent) to detect the outgrowth of antigen-specific T cells by flow cytometry. The eAPC:T system comprising unpulsed ACL-191 cells (without aAM) or pulsed HLA-null ACL-128 (without aAPX) cells or unpulsed HLA-null ACL-128 cells (without aAPX:aAM) was compared. Significant outgrowth of analyte TC (CD8+ T cells) specific for the NLVPMVATV (SEQ ID NO: 3) peptide was confirmed by HLA-A*02:01-NLVP tetramer staining, and was only observed in the eAPC:T system containing eAPC-p cells pulsed with NLVPMVATV ( Fig.46 a).

[0632] A second eAPC:T system was compiled by combining eAPC-pa (ACL-390) cells with analyte TC (bulk sorted CD8+ T cells) and co-culturing under standard conditions (see Materials and Methods). As with the first system, the co-cultured cells were harvested and analyzed for cells induced by analyte antigen and analyte TCR by specific staining with CMV-A.0201-NLVP tetramer (aAPX:aAM as soluble reagent). Fig.46 b shows antigen-specific outgrowth of primary CD8+ T cells co-cultured with eAPC-pa(ACL-390) cells, which have stable expression of pp65 ORF (aAM) and aAPX(HLA-A*02:01), thus presenting aAPX:aAM. Comparison was made with eAPC-p(ACL-191) cells, two other eAPC:T systems without stable expression of pp65 ORF, and HLA-null ACL-128 cells. Outgrowth of CD8+ T cells specific for aAPX:aAM presented by eAPC-pa was identified by CMV-A.0201-NLVP tetramer staining only in the eAPC:T system with eAPC-pa(ACL-390).

[0633] In summary, this example demonstrates that the use of eAPC-p and eAPC-pa cells in an edited eAPC-T system enables stimulation of T cells by presented analyte antigen (aAPX:aAM), which can selectively grow analyte TCs (CD8+ T cells) for recognition and selection of analyte TCs bearing the analyte TCR. In addition, two eAPC:T systems demonstrate the use of different forms of aAPX:aAM, in one system the aAM is provided exogenously, and in the second system the aAM is provided by the expression of the integrated analyte antigen ORF of the eAPC-pa through processing by natural cellular mechanisms.

[0634] Example 12: Demonstration of antigen-specific outgrowth of primary CD4 cells induced by the eAPC:T system for eAPC-pa

[0635] This example describes the compilation and use of an eAPC:T system, which consists of eAPC-p, exogenously provided aAM (used to generate aAPX:aAM presented by eAPC-p), and analyte primary T cells (analyte TCs). The eAPC:T system is used to identify and select analyte TCs with TCRs by detecting the proliferation and outgrowth of specific analyte TCs that enhance responses to analyte antigens (aAPX:aAM) and analyte TCRs.

[0636] In this example, outgrowth of antigen-specific CD4+ T cells from a CD4+ T cell population was induced by specific aAPX:AM, where aAPX is HLA-DRB1*01:01 (HLA class II) and aAM is an externally provided peptide PKYVKQNTLKLAT (SEQ ID NO: 1). The cell line used was eAPC-p (ACL-341) constructed in a similar manner as described in Examples 8 and 9. Analyte TC, CD4+ T cells, were isolated from healthy blood donors known to have CD4+ T cells specific for the PKYVKQNTLKLAT peptide, as described in the Materials and Methods section.

[0637] In this example, eAPC-p (ACL-341) was pulsed with exogenous PKYVKQNTLKLAT (SEQ ID NO: 1) peptide at a peptide concentration of 1 μM for 2 hours as described in the Materials and Methods section. The eAPC:T system was edited by combining the pulsed eAPC-p cells with the analyte TC (mass sorted CD4+ T cells) and co-culturing under standard conditions. After 7 days of co-culture, cells induced by the presented aAPX:aAM were analyzed by specific staining with INFL-DRB1*01:01-PKYV tetramer (aAPX:aAM as a soluble reagent) to detect the outgrowth of antigen-specific T cells by flow cytometry. The eAPC:T system containing unpulsed ACL-341 cells (aAPX:CM) was compared. The significant outgrowth of analyte TC (CD4+ T cells) specific for the PKYVKQNTLKLAT (SEQ ID NO: 1) peptide was confirmed by CMV-A.0201-NLVP tetramer staining and was only observed in the eAPC:T system containing eAPC-p cells pulsed with PKYVKQNTLKLAT ( Fig.47 ).

[0638] In summary, this example demonstrates the use of HLA class II-based eAPC-p editing into the eAPC:T system, which can selectively grow analyte TCs (CD4+ T cells) for recognition and selection of analyte TCs bearing analyte TCRs that form cooperative complexes with the presented analyte antigen (aAPX:aAM).

[0639] Example 13: Demonstration of antigen-specific cytotoxicity induced by eAPC-pa of eAPC:T by co-cultured primary CD8 cells

[0640] This example describes the compilation and use of two different eAPC:T systems, wherein the first system consists of eAPC-p, exogenously provided aAM (used to produce aAPX:aAM presented by eAPC-p), and analyte primary T cells (analyte TC). The second system consists of eAPC-pa presenting aAPX:aAM and analyte primary T cells (analyte TC). The eAPC:T system is used to determine the specificity of the analyte TC for the presented analyte antigen (aAPX:aAM) by detecting cytotoxic effects against eAPC-p or -pa by the analyte TC.

[0641] In this example, the cytotoxic effect of antigen-specific CD8+ T cells from a CD8+ T cell population is demonstrated, forming a cooperative complex between the analyte TCR and aAPX:AM, where aAPX is HLA-A*02:01 (HLA class I) and aAM is the peptide NLVPMVATV (SEQ ID NO: 3). In the system composed of eAPC-p, aAM is exogenously provided, and in the system composed of eAPC-pa, aAM is naturally processed from the integrated analyte antigen ORF (HCMVpp65). The cell lines used are eAPC-p (ACL-191) and eAPC-pa (ACL-390) described in Examples 8 and 9. The analyte TC, CD8+ T cells, were isolated from healthy blood donors known to have CD8+ T cells specific for the NLVPMVATV peptide, as described in the Materials and Methods section.

[0642] In the first eAPC:T system, as described in the Materials and Methods section, eAPC-p (ACL-191) was pulsed with exogenous NLVPMVATV peptide at a peptide concentration of 1 μM for 2 hours. The eAPC:T system was then edited by combining the pulsed eAPC-p cells with analyte TCs (large amounts of sorted CD8+ T cells) and co-culturing under standard conditions. Killing of eAPC-p cells was assessed by Annexin V and PI staining and flow cytometry, and the cooperative complex between the analyte antigen and the analyte TCR of the co-cultured cells was analyzed. The eAPC:T system was compared, which contained pulsed HLA-null ACL-128 cells (without aAPX) or unpulsed HLA-null ACL-128 cells (without aAPX:aAM). The significant cytotoxic effect of the analyte TCs (CD8+ T cells) was confirmed only in the eAPC:T system containing eAPC-p cells pulsed with NLVPMVATV ( Fig.48 a).

[0643] The second eAPC:T system was compiled by combining eAPC-pa (ACL-390) cells with analyte TC (mass sorted CD8+ T cells) and co-culturing under standard conditions. As with the first system, killing of eAPC-pa cells was assessed by Annexin V and PI staining and flow cytometry, and the co-cultured cells were harvested and analyzed for cooperative complexes between analyte antigen and analyte TCR. Fig.48b Demonstration of antigen-specific cytotoxicity of primary CD8+ T cells co-cultured with eAPC-pa (ACL-390) cells that have stable expression of pp65 ORF (aAM, component D') and aAPX (HLA-A*02:01, component B') and therefore present aAPX:aAM. Two other eAPC:T systems with eAPC-p (ACL-191) cells without stable expression of pp65 ORF (no aAM) and with HLA-null ACL-128 cells (no aAPX:aAM) were compared. Antigen-specific cytotoxicity of CD8+ T cells specific for aAPX:aAM presented by eAPC-pa was observed only in the eAPC:T system with eAPC-pa (ACL-390).

[0644] In summary, this example demonstrates the use of eAPC-p and eAPC-pa cells in an edited eAPC-T system that can selectively induce cytotoxicity by analyte TC (CD8+ T cells) for the recognition and selection of analyte TC bearing analyte TCRs that form a cooperative complex with the presented analyte antigen (aAPX:aAM). In addition, two eAPC:T systems demonstrate the use of different forms of aAPX:aAM, in one system the aAM is provided exogenously, and in the second system the aAM is provided by the expression of the integrated analyte antigen ORF of the eAPC-pa through natural cellular mechanisms.

[0645] Example 14: Identification of aAM loaded into eAPC-p by mass spectrometry

[0646] This example describes the use of eAPC-p dosed with exogenous analyte antigen molecules (aAM), where the aAPX:aAM complexes are subsequently captured by metal affinity chromatography and the aAM cargo identified by mass spectrometry, thereby identifying the aAPX:aAM context of the aAM, i.e., the HLA-restricted presentation of the antigenic peptide.

[0647] This example uses the eAPC-p cell line from Example 8, where the eAPC-p has integrated aAPx in module B', ACL-900 (HLA-A*02:01) and ACL-963 (HLA-A*24:02). The aAPX ORF also encodes a C-terminal 6x histidine tag for capture by metal affinity chromatography. The eAPC-p were combined with exogenous aAM and pulsed at a concentration of 1 μM for 2 hours, with four discrete pulses consisting of one of the following aAMs as the peptide; NLVPMVATV (APD-2, SEQ ID NO: 3), NLGPMAAGV (APD-21, SEQ ID NO: 4) or VYALPLKML (APD-11, SEQ ID NO: 5), or no peptide.

[0648] After pulsing, eAPC-p were harvested, lysed and subsequently captured by metal affinity chromatography as described in Materials and Methods. Once the captured peptides (aAM and CM) were separated from aAPX, they were acid washed and filtered. Subsequently, the peptide fractions were subjected to liquid extraction and the organic phase was removed, followed by solid phase extraction and submitted to mass spectrometry to identify the peptide fractions.

[0649] Fig.49 A table summarizing the mass spectrometry results for different eAPC-p / aAM pulse combinations is presented. The results identified peptides NLVPMVATV binding and forming a complex with aAPX HLA-A*02:01, and VYALPLKML complexing with APX HLA-A*24:01, while all other combinations of aAPX:aAM showed no formation of detectable aAPX:aM complexes. These results are consistent with the known peptide-HLA binding affinities of the three peptides.

[0650] In summary, this example demonstrates that eAPC-p can be used to identify the selective binding of aAM to aAPX by capturing aAPX:aAM and subsequently releasing and enriching aAM for identification by mass spectrometry. Thus, this demonstrates that eAPC-p can be used to determine HLA-restricted expression of analyte antigen molecules.

[0651] Sequence Listing

[0652] <110> Genovie AB

[0653] <120> An engineered multicomponent system for identifying and characterizing T cell receptors and T cell antigens

[0654] <130> P018243PCT1

[0655] <160> 72

[0656] <170> BiSSAP 1.3

[0657] <210> 1

[0658] <223> Analyte Antigen Molecule

[0659] <210> 2

[0660] <223> Analyte Antigen Molecule

[0661] <210> 3

[0662] <223> Analyte Antigen Molecule, APD-2

[0663] <210> 4

[0664] <223> Analyte Antigen Molecule, APD-21

[0665] <210> 5

[0666] <223> Analyte Antigen Molecule, APD-11

[0667] <210> 6

[0668] <223> V1.A.4pcDNA3.1_GFP

[0669] <210> 7

[0670] <223> SpCas9-2A-GFP vector V1.A.8

[0671] <210> 8

[0672] <223> pMA-SV40pA vector V1.C.2

[0673] <210> 9

[0674] <223> HLA-A 02:01 6xHis+Exon 2 / 3-HA-L+R Vector V1.C.6 <210> 10

[0675] <223> HLA-B 35:01 6xHis+Exon 2 / 3-HA-L+R Vector V1.C.9 <210> 11

[0676] <223> AAVS1-S_A24_6xH vector V1.F.8

[0677] <210> 12

[0678] <223> AAVS1-L_B07_6xH vector V1.F.10

[0679] <210> 13

[0680] <223> AAVS1-l_GFP_HCMVpp65_WT vector V1.G.10

[0681] <210> 14

[0682] <223> AAVS1-l_GFP_HCMVpp65 ANET vector V1.G.9

[0683] <210> 15

[0684] <223> AAVS1-l_GFP_HCMVpp65 AIN vector V1.H.1

[0685] <210> 16

[0686] <223> AAVS1_DRA_Flag-DRB1_6xHis vector V1.I.5

[0687] <210> 17

[0688] <223> AAVS1_DPA1_Flag-DPB1_6xHis vector V1.I.7

[0689] <210> 18

[0690] <223> HLA-A-sg-sp-opti1 vector V2.A.1

[0691] <210> 19

[0692] <223> HLA-B-sg-sp-3 vector V2.A.7

[0693] <210> 20

[0694] <223> HLA-C-sg-sp-4 vector V2.B.3

[0695] <210> twenty one

[0696] <223> HLA-A-ex2-3_sg-sp-opti_1 vector V2.I.10

[0697] <210> twenty two

[0698] <223> HLA-A-ex2-3_sg-sp-opti_2 vector V2.J.1

[0699] <210> twenty three

[0700] <223> AAVSI_sg-sp-opti_3 vector V2.J.6

[0701] <210> twenty four

[0702] <223> AAVS_Efla-intron_F14_RFPnls_F15 vector V4.B.2

[0703] <210> 25

[0704] <223> AAVS_Efla-Intron_FRT_BFPnls_F3 vector V4.B.3

[0705] <210> 26

[0706] <223> pMA_FRT_HLA-A*02:01-6xHis_F3 vector V4.D.2

[0707] <210> 27

[0708] <223> pMA_F14_HLA-A*02:01-6xHis_F15 vector V4.H.5

[0709] <210> 28

[0710] <223> pMA_F14_HLA-A*24:02-6xHis_F15 vector V4.H.6

[0711] <210> 29

[0712] <223> pMA_F14_HLA-B*07:02-6xHis_F15 vector V4.H.7

[0713] <210> 30

[0714] <223> pMA_F14_HLA-B*35:01-6xHis_F15 vector V4.H.8

[0715] <210> 31

[0716] <223> CMVpro_FLP_Sv40pA_V2 vector V4.1.8

[0717] <210> 32

[0718] <223> FRT_HCMVpp28-3xMYC_F3 vector V9.E.6

[0719] <210> 33

[0720] <223> FRT_HCMVpp52-3xMYC_F3 vector V9.E.7

[0721] <210> 34

[0722] <223> FRT_HCMVpp52-3xMYC_F3 vector V9.E.8

[0723] <210> 35

[0724] <223> pMA-sv40_OE_F1 Primer 1.C.2

[0725] <210> 36

[0726] <223> pMA-sv40_OE_R1 Primer 1.C.3

[0727] <210> 37

[0728] <223> HLA-A-GT-Rg3 Primer 4.A.31

[0729] <210> 38

[0730] <223> HLA-A-GT-Fg2 Primer 4.A.4

[0731] <210> 39

[0732] <223> HLA-B-GT-Fg2 Primer 4.A.7

[0733] <210> 40

[0734] <223> HLA-B-GT-Rg2 Primer 4.B.1

[0735] <210> 41

[0736] <223> HLA-C-GT-Fg2 Primer 4.B.5

[0737] <210> 42

[0738] <223> HLA-A-02_GT_Rg4 Primer 4.I.9

[0739] <210> 43

[0740] <223> HLA-A-exon3_HA-RE-BglII_F1 Primer 6.I.9

[0741] <210> 44

[0742] <223> HLA-C-04-GT-Rg1 Primer 8.A.1

[0743] <210> 45

[0744] <223> CMV-pA-HLA-Ex3_probe_F1 primer 8.B.2

[0745] <210> 46

[0746] <223> CMV-pro_GT_R1 Primer 9.C.3

[0747] <210> 47

[0748] <223> sv40pA_GT_F1 Primer 9.C.4

[0749] <210> 48

[0750] <223> AAVS1_GT_F1 Primer 9.C.5

[0751] <210> 49

[0752] <223> AAVS1_GT_F3 Primer 9.C.7

[0753] <210> 50

[0754] <223> AAVS1_GT_F4 Primer 9.C.8

[0755] <210> 51

[0756] <223> AAVS1_GT_R2 Primer 9.C.10

[0757] <210> 52

[0758] <223> AAVS1_GT_R3 Primer 9.D.1

[0759] <210> 53

[0760] <223> AAVS1_GT_R4 Primer 9.D.2

[0761] <210> 54

[0762] <223> HLA-A-intron4_GT_R1 Primer 9.D.6

[0763] <210> 55

[0764] <223> sv40pA-GT Primer 9.D.7

[0765] <210> 56

[0766] <223> sv40pA-AAVS1-probe-FAM-F1 primer 9.J.2 <210> 57

[0767] <223> TRAC_TCRA-ex1_R1 Primer 10.A.9

[0768] <210> 58

[0769] <223> TRAC_TCRA-promoter_F1 Primer 10.A.10

[0770] <210> 59

[0771] <223> TRAC_probe (HEX) primer 10.B.6

[0772] <210> 60

[0773] <223> Pan-HLA_GT_F1 Primer 8.B.3

[0774] <210> 61

[0775] <223> SV40pA_GT_R1 Primer 15.H.2

[0776] <210> 62

[0777] <223> 3xMyc_OE_R1 Primer 10.C.4

[0778] <210> 63

[0779] <223> CtermCysLink_OE_R1 Primer 10.D.1

[0780] <210> 64

[0781] <223> Ef1a_intron_GT_F2 Primer 15.H.4

[0782] <210> 65

[0783] <223> HCMVpp65_GT_F2ddPCR primer / probe 21.I.1

[0784] <210> 66

[0785] <223> HCMVpp28_GT_F1 ddPCR primer / probe 21.I.2

[0786] <210> 67

[0787] <223> HCMVpp52_GT_F1 ddPCR primer / probe 21.I.3

[0788] <210> 68

[0789] <223> Myc-Tag_GT_R1 ddPCR primer / probe 20.H.10

[0790] <210> 69

[0791] <223> Linker-Myc_probe_Fam ddPCR primer / probe 20.H.9

[0792] <210> 70

[0793] <223> TRAC-TCRA-ex1-F1 ddPCR Primer / Probe 10.A.9

[0794] <210> 71

[0795] <223> TRAC-TCRA-ex1-F1 ddPCR Primer / Probe

[0796] <210> 72

[0797] <223> TRAC-probe (HEX) ddPCR primers / probes

[0798] Abbreviations

[0799] aAPX Analyte Antigen Presentation Complex

[0800] aAM analyte antigen molecule

[0801] APC antigen presenting cells

[0802] APX antigen presenting complex

[0803] BFP blue fluorescent protein

[0804] CAR-T CAR T cells

[0805] CM cargo molecules

[0806] CRISPR clustered regularly interspaced short palindromic repeats

[0807] gRNA Cas9 guide RNA

[0808] CAR Chimeric Antigen Receptor

[0809] CDR complementarity determining region

[0810] C-region constant region

[0811] CMV Cytomegalovirus

[0812] DAMPS Danger-associated molecular patterns

[0813] DC

[0814] DNA deoxyribonucleic acid

[0815] D-Diversity Zone

[0816] eAPC Engineered Antigen Presenting Cells

[0817] eAPC-p Engineered antigen presenting cells that present analyte antigen presenting complexes

[0818] eAPC-pa Engineered antigen presenting cells presenting analyte antigen presenting complex and analyte antigen molecule

[0819] eAPC-a Engineered antigen presenting cells expressing analyte antigen molecules

[0820] eAPC:T eAPC:TCR system, where analyte eAPC is combined with analyte TCR

[0821] FACS fluorescence activated cell sorting

[0822] GEM T cell germline-encoded mycoacyl-reactive T cells

[0823] GFP Green Fluorescent Protein

[0824] HLA class I

[0825] HLA class II

[0826] HDR Homology-Directed Recombination

[0827] HLA Human Leukocyte Antigen

[0828] IgSF immunoglobulin superfamily

[0829] IRES internal ribosome entry site

[0830] iNK T cellsInvariant natural killer T cells

[0831] J Zone Connection Area

[0832] MACS Magnetic Activated Cell Sorting

[0833] MAGE melanoma-associated antigen

[0834] MAIT Mucosa-associated unchanged T

[0835] NCBP Non-cell-based particles

[0836] ORF Open Reading Frame

[0837] PAMPS pathogen-associated molecular patterns

[0838] PCR polymerase chain reaction

[0839] RMCE recombinase-mediated cassette exchange

[0840] RFP Red Fluorescent Protein

[0841] DNA RNA

[0842] SH2 Src homology 2

[0843] T cells T lymphocytes

[0844] TC TCR or TCR mimic affinity reagent presenting cells

[0845] TCR T cell receptor

[0846] TRA TCRα

[0847] TRB TCRβ

[0848] TRD TCRδ

[0849] TCRsp TCR surface protein complexed with CD3

[0850] TALEN transcription activator-like effector nuclease

[0851] TRG TRCγ

[0852] TAA Tumor-associated antigen

[0853] V-region variable region

[0854] β2M β2 microglobulin

[0855] ZAP-70 zeta chain associated protein of 70 kDa

[0856] definition

[0857] A pair of complementary TCR chains: two TCR chains, the translated proteins of which are able to form a TCRsp on the surface of a TCR presenting cell.

[0858] Affinity: A kinetic or equilibrium parameter of an interaction between two or more molecules or proteins

[0859] Affinity reagent: Any reagent designed to have a specific affinity for an analyte. Often used in the context of affinity for HLA-antigen complexes

[0860] Allele: A variant form of a given gene

[0861] AM: Analyte Antigen Molecule. In general, proteins can also be metabolites expressed by cells from their genomic DNA and / or specifically introduced gene sequences. AMs are expressed in cells and the fragments can then be presented on the cell surface by APX as cargo or alone. Whether as cargo or not, AMs can be targets for T cell receptor-bearing cells or related affinity reagents.

[0862] Amplicon: A DNA or RNA that is the source and / or product of artificial amplification using various methods including PCR.

[0863] Analyte: The entity of interest to be identified and / or measured and / or queried in a combined system

[0864] Analyte TC: An analyte cell presenting an analyte TCR on its surface, wherein the cell may be a primary T cell, a recombinant T cell, or an engineered TCR presenting cell.

[0865] Analyte TCR: TCRsp or TCR-mimicking affinity reagent provided as a soluble reagent, immobilized reagent, presented by NCBP or presented on the cell surface.

[0866] Antigen: Any molecule that can be engaged by the TCR and result in signal transduction within a T cell, usually presented by an antigen-presenting complex.

[0867] Analyte Antigen: Collectively referred to as the eAPC:T system, this represents any entity that presents an antigen for analytical determination

[0868] Antibody: Affinity molecule, expressed by specialized cells of the immune system called B cells, and containing two chains. B cells express a very large and very diverse repertoire of antibodies that do not normally bind self-proteins but can bind and neutralize pathogens or toxins that would threaten the host. Natural or artificially engineered antibodies are often used as affinity reagents.

[0869] APC: Antigen presenting cell. Cells that carry AM, APX, APX on their cell surface

[0870] APX: Antigen Presenting Complex. A protein expressed and presented on the cell surface by nucleated cells from genomic DNA of genes / coding ORFs and / or specifically introduced gene sequences. APX presents cargo, either peptides or other metabolite molecules.

[0871] C-region: Constant region. One of the gene segments used to assemble the T cell receptor. The C-region is the only segment that, rather than driving the diversity of the TCR, defines its general function in the immune system.

[0872] Cargo loading machinery: The cellular proteome that produces and loads cargo molecules onto APXs from proteins or other presenting molecules found in the cell.

[0873] CDR: Complementarity Determining Region. A short sequence at the antigenic end of TCRs and antibodies that performs most of the target binding function. Each antibody and TCR contains 6 CDRs, and they are often the most variable part of the molecule, allowing for the detection of a large number of different target molecules.

[0874] CM: Cargo molecule. A peptide or metabolite presented by an antigen presenting complex such as HLA I or HLA II. CMs can be expressed endogenously by cells from genomic DNA, introduced into the culture medium, or by specifically introduced gene sequences.

[0875] Copy number: the integer number of occurrences of a defined sequence encoded within the genome of a cell

[0876] Cytogenetics: the study of heredity concerned with the structure and function of chromosomes, i.e., determining the karyotype of cells.

[0877] Cytotoxic / Cytotoxicity: The process by which T cells release factors that directly and specifically damage target cells.

[0878] D-region: Diversity region. One of the gene segments used to assemble the T cell receptor. Each individual has a large number of different variants of these regions, allowing each individual to equip T cells with a very large variety of different TCRs.

[0879] DNA: Deoxyribonucleic acid. The chemical name for the molecule that forms the genetic material that codes for genes and proteins

[0880] eAPC:TCR System: eTPC:T, system, where the analyte eAPC is combined with the analyte TCR to obtain primary and terminal outputs

[0881] Endogenous: substances originating from within cells

[0882] Engineered cells: Cells whose genomes have been engineered through genetic modification.

[0883] Eukaryotic conditional regulatory element: a DNA sequence that affects promoter activity and can be induced or repressed under defined conditions.

[0884] Eukaryotic promoter: A DNA sequence that encodes RNA polymerase binding sites and response elements. The sequences in the promoter region control the binding of RNA polymerase and transcription factors, and thus the promoter plays a role in determining when and where the target gene will be expressed.

[0885] Eukaryotic terminator / signal terminator: A DNA sequence recognized by a protein factor that associates with RNA polymerase II and triggers the termination process of transcription. It also encodes a poly-A signal

[0886] FACS / Flow Cytometry: Fluorescence Activated Cell Sorting. An analytical technique by which single cells can be analyzed for the expression of specific cell surface and intracellular markers. A variation of this technique, cell sorting, allows the retrieval of cells carrying a defined set of markers for further analysis.

[0887] APX family: a group of several similar genes encoding functionally related proteins that constitute the antigen presentation complex

[0888] Fluorescent (protein) label: A molecule that has specific extinction and emission characteristics and can be detected by microscopy, FACS and related techniques.

[0889] Genetic Donor Vector: A genetically based vector used to deliver genetic material to a genomic recipient site

[0890] Genomic Recipient Site: The site within the genome used for targeted integration of donor genetic material encoded within a Genetic Donor Vector.

[0891] Heterospecific recombinase site: a DNA sequence recognized by a recombinase to facilitate the exchange of two DNA molecules

[0892] HLA I: Human Leukocyte Antigen Class I. A gene that is expressed in all nucleated cells in humans and exported to the cell surface where it presents short fragments of internal proteins, peptides, as cargo to the T-cell receptor. It therefore presents fragments of potential persistent infections as well as internal proteins. HLA I can also present as cargo peptides that are added to the culture medium, produced by proteins expressed from introduced genetic elements, or produced by proteins taken up by the cells. HLA class I genes are polymorphic, meaning that different individuals may have variations in the same gene, resulting in variations in presentation. Related to HLA class II.

[0893] HLA II: Human Leukocyte Antigen Class II. Genes expressed in specific cells in the human body that coordinate and help the adaptive immune response for example dendritic cells. Associated with HLA class I. HLA class II proteins are exported to the cell surface, where they present short fragments of external proteins, peptides, as cargo to the T-cell receptor. Thus, it presents fragments of potential persistent infections as well as internal proteins. HLA II can additionally present peptides as cargo that are added to the culture medium, produced by proteins expressed from introduced genetic elements or produced by proteins taken up by the cells. HLA class II genes are polymorphic, meaning that different individuals may have variations in the same gene, resulting in variations in presentation.

[0894] Homology arm: A stretch of DNA that has nearly identical sequence identity to the complement homology arm and thus facilitates the exchange of two DNA molecules by the cellular process - homology directed repair.

[0895] Immune surveillance: The process by which the immune system detects and is activated by infection, malignancy, or other potentially pathogenic changes.

[0896] Insulator: A DNA sequence that prevents a gene from being affected by the activation or repression of nearby genes. Insulators also prevent the spread of heterochromatin from silent genes to actively transcribed genes.

[0897] Integration: Physical attachment of a DNA sequence to a cell's chromosomes

[0898] Integration pairs: pairs of genetic donor vectors and genomic recipient sites

[0899] Internal ribosome entry site (IRES): a DNA sequence that, once transcribed, encodes an RNA element that allows translation to be initiated in a cap-independent manner

[0900] J region: Joining region. One of the gene segments used to assemble the T cell receptor. Each individual has a large number of different variants of these regions, allowing each individual to equip T cells with a very large variety of different TCRs.

[0901] Karyotype: the chromosomal makeup of a cell

[0902] Kozak sequence: a short sequence required for efficient initiation of translation

[0903] Major HLA class I: APX family containing HLA-A, HLA-B, and HLA-C genes

[0904] Matched: When two components encode genetic elements that direct and restrict the interaction between complementary components

[0905] Meganuclease recognition site: a DNA sequence recognized by endodeoxyribonucleases (often called meganucleases)

[0906] Metabolites: molecules produced or altered by metabolic pathways in cells

[0907] Mobile genetic elements: DNA sequences that allow DNA to integrate with the activity of transposases

[0908] Monoclonal cell line: a defined group of cells derived from a single progenitor cell by repeated cell replication

[0909] Native: An entity that occurs naturally in cells

[0910] Noncoding genes: non-protein coding DNA sequences that are transcribed into functional noncoding RNA molecules

[0911] ORF: Open Reading Frame. A segment of genetic material that encodes the translation framework for protein (polypeptide) synthesis by ribosomes. Paracrine: Signaling by soluble factors acting directly on neighboring cells.

[0912] PCR: polymerase chain reaction, in which specific target DNA molecules are exponentially amplified

[0913] Peptide: A short chain of amino acids between 6 and 30 amino acids in length

[0914] Phenotypic analysis: Analysis of observable characteristics of cells.

[0915] Polymorphism: The presence of different alleles of the same gene, which can exist in different forms in individuals of the same species.

[0916] Polypeptide: A protein composed of a segment of peptides that forms a three-dimensional structure.

[0917] Primary output: eAPC cells, analyte TC cells, NCBP or other analyte TCR formats, from which terminal outputs can be derived and / or determined

[0918] Primer: A short DNA sequence that allows specific recognition of a target DNA sequence, such as during PCR.

[0919] Promoter: A regulatory DNA element that provides for the controlled initiation of gene expression

[0920] Selectable marker: a DNA sequence that confers a trait suitable for artificial selection methods.

[0921] Shotgun integration: The process of introducing a library of vectors into a cell population so that only a single copy of any given vector insert can be integrated into the genome of each single cell. Used to refer to the integration of pooled vectors into a given cell population via integration pairs.

[0922] Splice acceptor site: DNA sequence at the 3' end of intron AM, APX CM or affinity reagents for interaction with cells bearing TCRsp on their surface, or TCRsp-based reagents

[0923] Splice donor site: DNA sequence at the 5' end of an intron

[0924] Synthetic: An entity artificially created and introduced into a cell

[0925] T cell: T lymphocyte. A white blood cell that expresses the T cell receptor on its surface. Selected by the immune system to not react to self, but with the potential to recognize infection and malignancy, and to reject transplants from most members of the same species.

[0926] TCR: T cell receptor. Affinity molecule expressed by a subset of lymphocytes called T lymphocytes.

[0927] TCR-mimetic affinity reagents: proteins or molecules that interact and bind to analyte antigens in a mimetic of the natural TCRsp

[0928] TCRsp: A pair of complementary TCR chains expressing surface proteins in complex with CD3 or a pair of complementary TCR chains expressed as proteins in the form of a soluble reagent, an immobilized reagent or in the presence of NCBP.

[0929] Terminal output: analyte antigen and TCR sequence in the form of AM, APX, APX:CM, APX:AM, TCRsp or TCR-mimicking affinity reagent

[0930] TRA: TCRα encoding locus. One of four different loci encoding genes that can form VDJ recombined TCR chains. Translated TCRα chain proteins are usually paired with translated TCRβ chain proteins to form α / βTCRsp.

[0931] TRB: TCRβ encoding locus. One of four different loci encoding genes that can form VDJ recombined TCR chains. The translated TCRβ chain protein usually pairs with the TCRα chain protein to form the α / β TCRsp.

[0932] TRD: TCRδ encoding locus. One of four different loci encoding genes that can form VDJ recombined TCR chains. Translated TCRδ chain proteins usually pair with translated TCRγ chain proteins to form γ / δ TCRsp.

[0933] TRG: TCRγ encoding locus. One of four different loci encoding genes that can form VDJ recombined TCR chains. Translated TCRγ chain proteins are usually paired with translated TCRδ chain proteins to form γ / δ TCRsp.

[0934] V-region: variable region. One of the gene segments used to assemble the T cell receptor. Each individual has a large number of different variations in these regions, allowing each individual to equip T cells with a very large variety of different TCRs.

[0935] The present invention is further described in the following items:

[0936] project

[0937] 1. A multi-component system, wherein the first component is an engineered antigen presenting cell (eAPC), referred to as component A, and the second component is a genetic donor vector, referred to as component C, for delivering one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and / or an analyte antigen molecule (aAM).

[0938] 2. The multi-component system according to item 1, wherein component A

[0939] a. lack of endogenous surface expression of at least one family of aAPX and / or aAM and

[0940] b. Contains at least one genomic integration site, referred to as component B, for integrating at least one ORF encoding at least aAPX and / or aAM.

[0941] 3. A multi-component system according to item 1 or 2, wherein component C is matched with component B, and wherein component C is designed to deliver

[0942] a. A single ORF encoding at least one aAPX and / or aAM and / or

[0943] b. Two or more ORFs encoding at least one aAPX and / or aAM

[0944] And wherein a and / or b optionally encode an integrated selection marker, so that the ORF can be stably integrated into the B genome receiving site and express aAPX and / or aAM.

[0945] 4. A multi-component system according to any of the preceding items, which consists of an eAPC, referred to as component A, and a genetic donor vector, referred to as component C, for delivering one or more ORFs encoding aAPX and / or aAM, wherein

[0946] Component A

[0947] a. lack of endogenous surface expression of at least one family of aAPX and / or aAM and

[0948] b. Contains at least one genomic integration site, referred to as component B, for integrating at least one ORF encoding at least one aAPX and / or aAM

[0949] and component C matches component B, and where component C is designed to deliver

[0950] c. A single ORF encoding at least one aAPX and / or aAM or

[0951] d. Two or more ORFs encoding at least one aAPX and / or aAM

[0952] Wherein c and / or d optionally encode an integrated selection marker, so that the ORF can be stably integrated into the B genome receiving site and express aAPX and / or aAM.

[0953] 5. The multi-component system according to any of the preceding items, wherein component A comprises a further component, referred to as D, a genomic integration site for integration of one or more ORFs encoding at least one aAPX and / or aAM.

[0954] 6. A multi-component system according to item 5, wherein another component, called E, is a genetic vector that matches D, wherein component E is designed to deliver

[0955] a. A single ORF encoding at least one aAPX and / or aAM or

[0956] b. Two or more ORFs encoding at least one aAPX and / or aAM

[0957] Wherein a and / or b optionally encode an integrated selection marker, so that the ORF can be stably integrated into the D genome receiving site and express aAPX and / or aAM.

[0958] 7. The multi-component system according to any of the preceding items, wherein one or more additional genomic receiver sites and matching genetic donor vectors are added as additional components of the system.

[0959] 8. The multi-component system according to any of the preceding items, comprising a genomic receiving site B and / or D, and selected from

[0960] a. Design of synthetic constructs for recombinase-mediated cassette exchange (RMCE)

[0961] b. Design of synthetic constructs for site-directed homologous recombination

[0962] c. Natural genomic site for site-directed homologous recombination.

[0963] 9. The multi-component system according to any of the preceding items, wherein component A expresses a T cell co-stimulatory receptor.

[0964] 10. A multi-component system according to item 9, wherein component A expresses T cell co-stimulatory receptors CD80 and / or CD83 and / or CD86.

[0965] 11. A multi-component system according to any of the preceding items, wherein component A, when provided with genetic material encoding one or more ORFs encoding at least one or more aAPXs, allows aAPX to be expressed on the cell surface and can be loaded with a cargo molecule (CM), referred to as aAPX:CM.

[0966] 12. The multi-component system according to item 11, wherein aAPX can load CM via natural processing and cargo loading mechanisms.

[0967] 13. A multi-component system according to item 11 or 12, wherein aAPX can load aAM as CM, referred to as aAPX:aAM.

[0968] 14. A multi-component system according to any of the preceding items, wherein aAPX is any of the following

[0969] a. One or more members of HLA class I

[0970] b. One or more members of HLA class II

[0971] c. One or more non-HLA antigen presenting complexes

[0972] d. Or a combination of a, b and / or c.

[0973] 15. The multi-component system according to any of the preceding items, wherein aAM is selected from

[0974] a. Peptide or polypeptide complex provided as analyte antigen

[0975] b. Peptides derived from polypeptides provided as analyte antigens

[0976] c. Peptides provided as analyte antigens

[0977] d. Metabolites provided as analyte antigens

[0978] e. A polypeptide or polypeptide complex translated from the ORF of the analyte antigen molecule

[0979] f. Peptides derived from polypeptides translated from the ORF of the analyte antigen molecule

[0980] g. Peptides derived from altered component A proteome

[0981] h. Peptides derived from altered component A proteome

[0982] i. Metabolites derived from altered component A metabolites

[0983] and / or combinations thereof.

[0984] 16. The multi-component system according to any of the preceding items, comprising component B and / or D and comprising at least one of the following genetic elements

[0985] a. Heterologous specific recombinase site

[0986] b. Homology arms

[0987] c. Eukaryotic promoter

[0988] d. Eukaryotic conditional regulatory elements

[0989] e. Eukaryotic terminator

[0990] f. Selection marker

[0991] g. Splice acceptor site

[0992] h. Splice donor site

[0993] i. Non-protein coding genes

[0994] j.Insulator

[0995] k. Mobile genetic elements

[0996] 1. Meganuclease recognition sites

[0997] m. Internal ribosome entry site (IRES)

[0998] n. Viral self-cleaving peptide element

[0999] o.kozak consensus sequence

[1000] 17. The multi-component system according to any of the preceding items, comprising components C and / or E, and comprising at least one of the following genetic elements

[1001] a. Heterologous specific recombinase site

[1002] b. Homology arms

[1003] c. Eukaryotic promoter

[1004] d. Eukaryotic conditional regulatory elements

[1005] e. Eukaryotic terminator

[1006] f. Selection marker

[1007] g. Integrated selection marker

[1008] h. Splice acceptor site

[1009] i. Splice donor site

[1010] j. Non-protein coding genes

[1011] k.Insulator

[1012] l. Mobile genetic elements

[1013] m. Meganuclease recognition site

[1014] n. Internal ribosome entry site (IRES)

[1015] o. Viral self-cleaving peptide element

[1016] p. Antibiotic resistance cassette

[1017] q. Bacterial origin of replication

[1018] r. yeast origin of replication

[1019] s. Cloning site

[1020] t. Kozak consensus sequence

[1021] 18. The multi-component system according to any of the preceding items, comprising components B and / or D and for RMCE integration of a single ORF, and comprising:

[1022] a. Eukaryotic promoter

[1023] b. A pair of heterologous specific recombinase sites

[1024] c. Kozak consensus sequence

[1025] d.Selection marker

[1026] e. Eukaryotic terminator.

[1027] 19. The multi-component system according to any of the preceding items, comprising components B and / or D, and for RMCE integration of two or more ORFs and comprising the following genetic elements:

[1028] a. Eukaryotic promoter

[1029] b. A pair of heterologous specific recombinase sites

[1030] c. Two or more Kozak consensus sequences

[1031] d.Selection marker

[1032] e. Eukaryotic terminator

[1033] f. Second eukaryotic promoter

[1034] g. Second selection marker

[1035] h. Second eukaryotic terminator

[1036] 20. The multi-component system according to any of the preceding items, wherein components C and / or E are present for RMCE integration of a single ORF and comprise the following genetic elements:

[1037] a. A pair of heterologous specific recombinase sites

[1038] b. Kozak consensus sequence

[1039] c. Antibiotic resistance cassette

[1040] d. Bacterial origin of replication

[1041] e. Cloning site for introduction of a single ORF encoding one or more aAPX and / or aAM and / or integration of a selectable marker.

[1042] 21. The multi-component system according to any of the preceding items, wherein components C and / or E are present, for RMCE integration of two or more ORFs, and comprising the following:

[1043] a. A pair of heterologous specific recombinase sites

[1044] b. Two or more Kozak consensus sequences

[1045] c. Antibiotic resistance cassette

[1046] d. Bacterial or yeast origin of replication

[1047] e. A cloning site for the introduction of two or more ORFs with a eukaryotic terminator encoding one or more aAPX and / or aAM and / or an integrated selection marker.

[1048] 22. The multi-component system according to any of the preceding items, wherein component C and / or E is combined with at least one ORF encoding at least one aAPX and / or aAM to obtain component C' and / or E'.

[1049] 23. The multi-component system according to item 22, wherein said combining is performed multiple times to obtain a library of components C' and / or E'.

[1050] 24. A multi-component system according to any one of items 22 or 23, wherein one or more components C' and / or E' are combined with component A to integrate one or more aAPX ORFs encoded in components C' and / or E' into components B and / or D to obtain a cell called eAPC-p, wherein components B and / or D become components B' and / or D', so that eAPC-p expresses aAPx on the cell surface.

[1051] 25. A multi-component system according to any one of items 22 or 23, wherein one or more components C' and / or E' are combined with component A to integrate one or more aAM ORFs encoded in components C' and / or E' into components B and / or D to obtain a cell called eAPC-a, wherein components B and / or D become components B' and / or D', so that eAPC-a expresses aAM on the cell surface or inside the cell.

[1052] 26. A multi-component system according to any one of items 22 or 23, wherein one or more components C' and / or E' are combined with component A to integrate one or more aAPX ORFs and / or one or more aAMs encoded in components C' and / or E' into components B and / or D to obtain a cell called eAPC-pa, wherein components B and / or D become components B' and / or D', so that eAPC-pa expresses aAPX and aAM and / or aAPX:aAM.

[1053] 27. A multi-component system according to any one of item 24, wherein one or more components C' or E' are combined with eAPC-p to integrate one or more aAM ORFs encoded in component C' or E' into component B or D to obtain a cell called eAPC-pa, wherein component B or D becomes component B' or D', so that it expresses aAPX and aAM and / or aAPX:aAM.

[1054] 28. A multi-component system according to any one of item 25, wherein one or more components C' or E' are combined with eAPC-a to integrate one or more aAPX ORFs encoded in component C' or E' into component B or D to obtain a cell called eAPC-pa, wherein component B or D becomes component B' or D', so that it expresses aAPX and aAM and / or aAPX:aAM.

[1055] 29. A method for preparing eAPC-β as defined in item 24, the method comprising

[1056] a. Combining component A with at least one of components C' and / or E', wherein one or more components C' and / or E' encode one or more aAPXs, and combining with an integration factor and at least one

[1057] b. Loss of the selectable marker at the recipient locus of the selection genome

[1058] c. Selecting the surface expression of one or more aAPXs

[1059] d. Selecting for the acquisition of one or more integrated selectable markers.

[1060] 30. The method according to item 29, which comprises b, c and d.

[1061] 31. A method according to item 29 or 30, wherein the one or more components C' and / or E' are encoded in a single aAPx in step a of item 29.

[1062] 32. A method according to item 31, wherein the method is performed multiple times, wherein each time step a of item 29 is performed using a unique aAPX, so that a unique eAPC-p is obtained to obtain a discrete and defined eAPC-p library.

[1063] 33. A method according to item 29 or 30, wherein the one or more components C' and / or E' encode a mixed pool of two or more unique aAPXs in step a of item 29 to obtain a library, wherein the library comprises a mixed population of eAPC-p, each eAPC-p expressing a single aAPx in the pool used in step a of item 29.

[1064] 34. A method for preparing eAPC-a as defined in item 25, the method comprising:

[1065] a. Combining component A with at least one of components C' and / or E', wherein one or more components C' and / or E' encode one or more aAMs, and combining with an integration factor and at least one

[1066] b. Loss of the selectable marker at the recipient locus of the selection genome

[1067] c. Selecting the expression of one or more aAMs

[1068] d. Selecting for the acquisition of one or more integrated selectable markers.

[1069] 35. The method according to item 34, which comprises b and d.

[1070] 36. A method according to item 34 or 35, wherein said one or more components C' and / or E' encode a single aAM in step a of item 34.

[1071] 37. A method according to item 36, wherein the method is performed multiple times, wherein step a of item 34 is performed each time using a unique aAM so that a unique eAPC-a is obtained to obtain a discrete and defined library of eAPC-a.

[1072] 38. A method according to item 34 or 35, wherein the one or more components C' and / or E' encode a mixed pool of two or more unique aAMs in step a of item 34 to obtain a library, wherein the library comprises a mixed population of eAPC-a, each eAPC-a expressing a single aAM from the pool used in step a of item 34.

[1073] 39. A method for preparing eAPC-pa as defined in item 28, the method comprising

[1074] a. Combining eAPC-a with at least one of components C' or E', wherein one or more components C' or E' encode one or more aAPX ORFs, and in combination with an integration factor and at least one

[1075] b. Loss of the selectable marker at the recipient locus of the selection genome

[1076] c. Selecting the surface expression of one or more aAPXs

[1077] d. Selecting for the acquisition of one or more integrated selectable markers.

[1078] 40. The method according to item 39, which comprises b, c and d.

[1079] 41. A method according to item 39 or 40, wherein one or more components C' or E' are encoded in a single aAPx in step a of item 39.

[1080] 42. A method according to item 41, wherein the method is performed multiple times, wherein step a of item 39 is performed using a unique aAPX each time, so that a unique eAPC-pa is obtained to obtain a discrete and defined library of eAPC-pa.

[1081] 43. A method according to item 39 or 40, wherein the one or more components C' or E' encode a mixed pool of two or more unique aAPXs in step a of item 39 to obtain a library, wherein the library comprises a mixed population of eAPC-pa, each eAPC-pa expressing a single aAPx from the pool used in step a of item 39.

[1082] 44. A method for preparing eAPC-pa as defined in item 27, the method comprising

[1083] a. combining eAPC-p with at least one of components C' or E', wherein one or more components C' or E' encode one or more aAM ORFs, and in combination with an integration factor and at least one

[1084] b. Loss of the selectable marker at the recipient locus of the selection genome

[1085] c. Selecting the expression of one or more aAMs

[1086] d. Selecting for the acquisition of one or more integrated selectable markers.

[1087] 45. The method according to item 44, which comprises b and d.

[1088] 46. ​​A method according to item 44 or 45, wherein the one or more components C' or E' encode a single aAM in step a of item 44.

[1089] 47. A method according to item 46, wherein the method is performed multiple times, wherein step a of item 44 is performed using a unique aAM each time, so that a unique eAPC-pa is obtained to obtain a discrete and defined library of eAPC-pa.

[1090] 48. A method according to item 44 or 45, wherein the one or more components C' or E' encode a mixed pool of two or more unique aAMs in step a of item 44 to obtain a library, wherein the library consists of a mixed population of eAPC-pa, each eAPC-pa expressing a single aAM from the pool used in step a of item 44.

[1091] 49. A method for preparing eAPC-pa according to item 26, the method comprising:

[1092] a. combining eAPC with at least one of components C' or E', wherein one or more components C' and / or E' encode one or more aAM ORFs and one or more aAPX ORFs, and in combination with an integration factor and at least one

[1093] b. Loss of the selectable marker at the recipient locus of the selection genome

[1094] c. Selecting the expression of one or more aAMs and / or obtaining the surface expression of one or more aAPXs

[1095] d. Selecting for the acquisition of one or more integrated selectable markers.

[1096] 50. The method according to item 49, which comprises b, c and d.

[1097] 51. A method according to item 49 or 50, wherein the one or more components C' and / or E' encode a single aAM and a single aAPx in step a of item 49.

[1098] 52. A method according to item 51, wherein the method is performed multiple times, wherein step a of item 49 is performed each time using at least one of a unique aAM and / or a unique aAPX, so that a unique eAPC-pa is obtained to obtain a discrete and defined library of eAPC-pa.

[1099] 53. A method according to item 49 or 50, wherein the one or more components C' and / or E' encode a mixed pool of two or more unique aAMs and / or two or more unique aAPXs in step a of item 49 to obtain a library, wherein the library consists of a mixed population of eAPC-pa, each eAPC-pa expressing a single aAM and a single aAPx from the pool used in step a of item 49.

[1100] 54. An analyte eAPC obtained from a multi-component system according to any of the preceding items for characterizing

[1101] a. Specificity of the expressed analyte antigen for the analyte affinity reagent and / or

[1102] b. Affinity of the expressed analyte antigen for the analyte affinity reagent

[1103] c. Signal response of one or more analyte cells expressing analyte TCR (analyte TC) to expressed analyte antigen

[1104] wherein the analyte antigen is selected from aAPX:aAM and / or aAM and / or aAPX and / or aAPX:CM, and wherein the analyte eAPC is selected from eAPC-p and / or eAPC-a and / or eAPC-pa.

[1105] 55. A method of selecting one or more analyte eAPCs from an input analyte eAPC or a library of analyte eAPCs to obtain one or more analyte eAPCs that bind one or more analyte TCRs, wherein the method comprises

[1106] a. Combining one or more analyte eAPCs with one or more analyte TCRs, resulting in contact between the analyte antigen presented by the analyte eAPC and the analyte TCR

[1107] b. measuring the formation of a complex between one or more analyte antigens and one or more analyte TCRs (if any) and / or

[1108] c. measuring the signal response (if any) of one or more analyte eAPCs induced by the complex formed between the analyte antigen and one or more analyte TCRs and / or

[1109] d. measuring the signal response (if any) of one or more analyte TCs induced by the formation of a complex between the analyte antigen and one or more analyte TCRs expressed by the one or more analyte TCs,

[1110] e. Selecting one or more analytes eAPC from step b, wherein the selection is performed by positive and / or negative measurement

[1111] wherein the analyte antigen is selected from aAPX:aAM and / or aAM and / or aAPX and / or aAPX:CM, and wherein the analyte eAPC is selected from eAPC-p and / or eAPC-a and / or eAPC-pa and wherein the analyte TCR is a pair of TCR chains or a TCR-mimicking affinity reagent, in at least one of the following forms: a soluble reagent, an immobilized reagent, presented by a non-cell based particle (NCBP), presented on the surface of a cell (TC), wherein the cell can be selected from primary T cells and / or recombinant T cells and / or engineered cells.

[1112] 56. A method according to item 55, wherein the selection step e is performed by single cell sorting and / or cell sorting into pools.

[1113] 57. A method according to item 56, wherein sorting is followed by amplification of the sorted single cells.

[1114] 58. A method according to item 56, wherein sorting is followed by expansion of the sorted cell pool.

[1115] 59. The method according to any one of items 56 to 58, further comprising the step of sequencing component B' and / or component D' of the sorted and / or expanded cells.

[1116] 60. A method according to claim 59, wherein the sequencing step is preceded by the following

[1117] a. Extraction of genomic DNA and / or

[1118] b. Extracting component B' and / or component D' RNA transcripts and / or

[1119] c. Amplifying DNA and / or RNA transcripts of component B' and / or component D' by PCR and / or RT-PCR.

[1120] 61. A method according to item 59 or 60, wherein the sequencing step is destructive to the cells and wherein the sequencing information obtained is used to prepare the analyte eAPC selected in step e of item 55.

[1121] 62. A method according to any one of items 55, 56, 57, 58, 61, wherein the selected analyte eAPC is subjected to affinity analysis to determine the affinity of the analyte antigen to the analyte TCR, wherein the method further comprises

[1122] a. Labeling of selected analyte eAPCs with a range of analyte TCR concentrations

[1123] b. FACS analysis of the labeled analyte eAPC in step a

[1124] c. Determine the fluorescence labeling intensity of the analyte eAPC within the concentration range of the analyte affinity reagent

[1125] d. Calculate the affinity of the analyte antigen for the analyte TCR.

[1126] 63. A method according to item 62, wherein steps b to c are performed using a labeled reference and step d calculates affinity using the ratio of the fluorescence intensity of the analyte affinity reagent to the fluorescence intensity of the reference.

[1127] 64. A method according to item 63, wherein the labeled reference is selected from

[1128] a. Analyte eAPC labeled with an affinity reagent specific to the analyte antigen

[1129] b. Cells or particles presenting labeled reference analyte antigen.

[1130] 65. A method according to any one of items 55, 56, 57, 58, 61, wherein the selected analyte eAPC undergoes characterization of the signal response, wherein the method further comprises

[1131] a. Determine the native signaling response and / or

[1132] b. Determine the synthetic signaling response.

[1133] 66. A method according to item 65, wherein the induced signal response is determined by detecting an increase or decrease in one or more of the following compared to a non-induced signal response state:

[1134] a. Secreted biomolecules

[1135] b. Secreted chemicals

[1136] c. Intracellular biomolecules

[1137] d. Intracellular chemicals

[1138] e. Surface-expressed biomolecules

[1139] f. Cytotoxic effect of analyte TC on analyte eAPC

[1140] g. The paracrine effect of the analyte TC on the analyte eAPC, so as to induce a signal response in the analyte eAPC, and is determined by detecting an increase or decrease in any one of a to e

[1141] h. Amplification of analyte TC

[1142] i. Immune synapse formation between analyte TCs and analyte eAPCs.

[1143] 67. A method of selecting one or more analyte TCRs from an input analyte TCR or a library of analyte TCRs, wherein the analyte TCRs are combined with one or more analyte eAPCs to obtain the sequence of one or more pairs of TCR chains encoded in the analyte TCR, and / or to obtain the analyte TCR, wherein the method comprises

[1144] a. Combining one or more analyte eAPCs with one or more analyte TCRs, resulting in contact between an analyte antigen presented by the analyte eAPCs and one or more analyte TCRs

[1145] b. measuring the formation of a complex between the analyte antigen and one or more analyte TCRs (if any) and / or

[1146] c. measuring the signal response (if any) of one or more analyte TCs induced by the formation of a complex between the analyte antigen and one or more TCRs expressed by the one or more analyte TCs and / or

[1147] d. Measuring the signal response (if any) of one or more analyte eAPCs induced by complex formation between the analyte antigen and one or more analyte TCRs

[1148] e. Selecting one or more analyte TCRs from steps b, c and / or d, wherein the selection is performed by positive and / or negative measurement

[1149] wherein the analyte antigen is selected from aAPX:aAM and / or aAM and / or aAPX and / or aAPX:CM, and wherein the analyte eAPC is selected from eAPC-p and / or eAPC-a and / or eAPC-pa and wherein the analyte TCR is a pair of TCR chains or a TCR-mimicking affinity reagent, in at least one of the following forms: a soluble reagent, an immobilized reagent, presented by a non-cell based particle (NCBP), presented on the surface of a cell (TC), wherein the cell can be selected from primary T cells and / or recombinant T cells and / or engineered cells.

[1150] 68. A method according to item 67, wherein the selection step e is performed by single cell sorting and / or cell sorting into pools.

[1151] 69. A method according to item 68, wherein sorting is followed by amplification of the sorted single cells.

[1152] 70. A method according to item 68, wherein sorting is followed by expansion of the sorted cell pool.

[1153] 71. The method according to any one of items 67 to 70, further comprising the step of sequencing the analyte TCR chains of the sorted and / or amplified cells.

[1154] 72. A method according to claim 71, wherein the sequencing step is preceded by the following

[1155] a. Extraction of genomic DNA and / or

[1156] b. Extraction of analyte TCR chain RNA transcripts and / or

[1157] c. Amplify DNA and / or RNA transcripts of the analyte TCR chains by PCR and / or RT-PCR.

[1158] 73. A method according to any one of items 67, 68, 69, 70, wherein the signal response of the selected analyte TC is characterized, wherein the method further comprises

[1159] a. Determine the native signaling response and / or

[1160] b. Determine the synthetic signaling response.

[1161] 74. A method according to item 73, wherein the induced signal response is determined by detecting an increase or decrease in one or more of the following compared to a non-induced signal response state:

[1162] a. Secreted biomolecules

[1163] b. Secreted chemicals

[1164] c. Intracellular biomolecules

[1165] d. Intracellular chemicals

[1166] e. Surface-expressed biomolecules

[1167] f. Cytotoxic effect of analyte TC on analyte eAPC

[1168] g. The paracrine effect of the analyte TC on the analyte eAPC induces a signal response in the analyte eAPC, and is determined by detecting an increase or decrease in any of a to e.

[1169] h. Proliferation of analyte TC

[1170] i. Immune synapse between analyte TC and analyte eAPC.

[1171] 75. A method for selecting and identifying an aAM cargo or a CM cargo, wherein the cargo is a metabolite and / or a peptide, which is loaded into an aAPX of an analyte eAPC, wherein the method comprises

[1172] a. Isolate aAPX:aAM or aAPX:CM or cargo aM or cargo CM and

[1173] b. Identify the cargo being loaded.

[1174] 76. A method according to item 75, wherein step b comprises subjecting the separated aAPX:aAM or aAPX:CM to one or more

[1175] a. Mass spectrometry

[1176] b. Peptide sequencing analysis.

[1177] 77. A pair of TCR chain sequences or a library of TCR chain sequence pairs selected by the method defined in items 67 to 74, for at least one of the following

[1178] a. Diagnosis

[1179] b. Medicine

[1180] c. Cosmetics

[1181] d. Research and development.

[1182] 78. Antigenic molecules and / or ORFs encoding said antigenic molecules, or libraries selected by the methods defined in items 55 to 66 or 75, 76, for at least one of the following:

[1183] a. Diagnosis

[1184] b. Medicine

[1185] c. Cosmetics

[1186] d. Research and development.

[1187] 79. An antigen presenting complex loaded with an antigen molecule as cargo and / or an ORF encoding said complex, or a library thereof selected by a method as defined in items 55 to 66 or 75, 76, for at least one of the following:

[1188] a. Diagnosis

[1189] b. Medicine

[1190] c. Cosmetics

[1191] d. Research and development.

[1192] 80. An eAPC or eAPC library selected by the method defined in items 55 to 66, for at least one of the following

[1193] a. Diagnosis

[1194] b. Medicine

[1195] c. Cosmetics

[1196] d. Research and development.

[1197] 81. A cell expressing a TCR in complex with CD3 on the cell surface, or a library selected by the method defined in items 67-74, for at least one of the following:

[1198] a. Diagnosis

[1199] b. Medicine

[1200] c. Cosmetics

[1201] d. Research and development.

[1202] 82. A multi-component system according to any one of items 1 to 28, for use in at least one of the following

[1203] a. Diagnosis

[1204] b. Medicine

[1205] c. Cosmetics

[1206] d. Research and development.

[1207] 83. A TCR-mimicking affinity reagent sequence or a library of TCR-mimicking affinity reagent sequences selected by the method defined in items 67-74 for at least one of the following:

[1208] a. Diagnosis

[1209] b. Medicine

[1210] c. Cosmetics

[1211] d. Research and development.

[1212] 84. An NCBP with TCR pairs or TCR-mimicking affinity reagents or an NCBP library with TCR pairs or TCR-mimicking affinity reagents selected by the method defined in items 67 to 74 for at least one of the following:

[1213] a. Diagnosis

[1214] b. Medicine

[1215] c. Cosmetics.

[1216] The present invention is further described in the following items:

[1217] project

[1218] 1. A multi-component system, wherein the first component is an engineered antigen presenting cell (eAPC), referred to as component A, and the second component is a genetic donor vector, referred to as component C, for delivering one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and / or an analyte antigen molecule (aAM), wherein component A

[1219] a. lack of endogenous surface expression of at least one family of aAPX and / or aAM, and

[1220] b. comprising at least two genomic receiving sites, referred to as component B and component D, each for integrating at least one ORF encoding at least one aAPX and / or aAM,

[1221] and component C matches component B, and where component C is designed to deliver

[1222] c. a single ORF encoding at least one aAPX and / or aAM, or

[1223] d. two or more ORFs encoding at least one aAPX and / or aAM,

[1224] The genomic recipient sites B and D are synthetic constructs designed for recombinase-mediated exchange (RMCE).

[1225] 2. The multi-component system according to item 1, wherein c and / or d optionally encode an integrated selection marker, so that the ORF can stably integrate into the B genome receiving site and express aAPX and / or aAM.

[1226] 3. A multi-component system according to item 1 or 2, wherein the other component referred to as E is a genetic vector that matches D, wherein component E is designed to deliver

[1227] a. a single ORF encoding at least one aAPX and / or aAM, or

[1228] b. Two or more ORFs encoding at least one aAPX and / or aAM

[1229] And wherein a and / or b optionally encode an integrated selection marker, so that the ORF can stably integrate into the D genome receiving site and express aAPX and / or aAM.

[1230] 4. The multi-component system according to any of the preceding items, wherein one or more additional genomic receiver sites and matching genetic donor vectors are added as additional components of the system.

[1231] 5. A multi-component system according to any of the preceding clauses, wherein aAPX is any of the following

[1232] a. One or more members of HLA class I

[1233] b. One or more members of HLA class II

[1234] c. One or more non-HLA antigen presenting complexes, or

[1235] Any combination of da, b and c.

[1236] 6. A multi-component system according to any one of the preceding items, wherein aAM is selected from

[1237] a. Peptide or polypeptide complex provided as analyte antigen

[1238] b. Peptides derived from polypeptides provided as analyte antigens

[1239] c. Peptides provided as analyte antigens

[1240] d. Metabolites provided as analyte antigens

[1241] e. A polypeptide or polypeptide complex translated from the ORF of the analyte antigen molecule

[1242] f. Peptides derived from polypeptides translated from the ORF of the analyte antigen molecule

[1243] g. Peptides derived from altered component A proteome

[1244] h. Peptides derived from altered component A proteome

[1245] i. Metabolites derived from altered component A metabolites

[1246] and / or combinations thereof.

[1247] 7. The multi-component system according to any of the preceding items, wherein components B and / or D comprise at least one of the following genetic elements

[1248] a. Heterologous specific recombinase site

[1249] b. Homology arms

[1250] c. Eukaryotic promoter

[1251] d. Eukaryotic conditional regulatory elements

[1252] e. Eukaryotic terminator

[1253] f. Selection marker

[1254] g. Splice acceptor site

[1255] h. Splice donor site

[1256] i. Non-protein coding genes

[1257] j.Insulator

[1258] k. Mobile genetic elements

[1259] 1. Meganuclease recognition sites

[1260] m. Internal ribosome entry site (IRES)

[1261] n. Viral self-cleaving peptide element

[1262] o. Kozak consensus sequence.

[1263] 8. The multi-component system according to any of the preceding items, wherein components B and / or D are for RMCE integration of a single ORF and comprises:

[1264] a. Eukaryotic promoter

[1265] b. A pair of heterologous specific recombinase sites

[1266] c. Kozak consensus sequence

[1267] d.Selection marker

[1268] e. Eukaryotic terminator.

[1269] 9. The multi-component system according to any one of items 3 to 8, wherein component E is present and components C and / or E are used for RMCE integration of a single ORF and comprise the following genetic elements:

[1270] a. A pair of heterologous specific recombinase sites

[1271] b. Kozak consensus sequence

[1272] c. Antibiotic resistance cassette

[1273] d. Bacterial origin of replication

[1274] e. Cloning site for introduction of a single ORF encoding one or more aAPX and / or aAM and / or integration of a selectable marker.

[1275] 10. Multi-component system according to any one of items 3 to 9, wherein component C and / or E is combined with at least one ORF encoding at least one aAPX and / or aAM to obtain component C' and / or E'.

[1276] 11. The multi-component system according to item 10, wherein said combining is performed a plurality of times to obtain a library of components C' and / or E'.

[1277] 12. A multi-component system according to any one of items 10 or 11, wherein one or more components C' and / or E' are combined with component A to integrate one or more aAPX ORFs encoded in components C' and / or E' into components B and / or D to obtain a cell called eAPC-p, wherein components B and / or D become components B' and / or D', so that eAPC-p expresses aAPx on the cell surface.

[1278] 13. A multi-component system according to any one of items 10 or 11, wherein one or more components C' and / or E' are combined with component A to integrate one or more aAM ORFs encoded in components C' and / or E' into components B and / or D to obtain a cell called eAPC-a, wherein components B and / or D become components B' and / or D', so that eAPC-a expresses aAM on the cell surface or inside the cell.

[1279] 14. A multi-component system according to any one of items 10 or 11, wherein one or more components C' and / or E' are combined with component A to integrate one or more aAPX ORFs and / or one or more aAMs encoded in components C' and / or E' into components B and / or D to obtain a cell called eAPC-pa, wherein components B and / or D become components B' and / or D', so that eAPC-pa expresses aAPX and aAM and / or aAPX:aAM.

[1280] 15. A multi-component system according to item 12, wherein one or more components C' or E' are combined with eAPC-p to integrate one or more aAM ORFs encoded in component C' or E' into component B or D to obtain a cell called eAPC-pa, wherein component B or D becomes component B' or D' so that it expresses aAPX and aAM and / or aAPX:aAM.

[1281] 16. A multi-component system according to item 13, wherein one or more components C' or E' are combined with eAPC-a to integrate one or more aAPX ORFs encoded in component C' or E' into component B or D to obtain a cell called eAPC-pa, wherein component B or D becomes component B' or D' so that it expresses aAPX and aAM and / or aAPX:aAM.

[1282] 17. A method for preparing eAPC-p as defined in item 12, the method comprising:

[1283] a. Combining component A with at least one of components C' and / or E', wherein one or more components C' and / or E' encode one or more aAPXs, and combining with an integration factor and at least one

[1284] b. Loss of the selectable marker at the recipient locus of the selection genome

[1285] c. Selecting the surface expression of one or more aAPXs

[1286] d. Selecting for the acquisition of one or more integrated selectable markers.

[1287] 18. The method according to item 17, which comprises b, c and d.

[1288] 19. A method according to item 17 or 18, wherein said one or more components C' and / or E' encode a single aAPx.

[1289] 20. A method according to item 19, wherein the method is performed multiple times, wherein each time step a is performed using a different aAPX, so that different eAPC-p are obtained to obtain a discrete and defined eAPC-p library.

[1290] 21. A method according to item 17 or 18, wherein in step a said one or more components C' and / or E' encode a mixed pool of two or more different aAPXs to obtain a library, wherein said library comprises a mixed population of eAPC-p, wherein each eAPC-p expresses a single aAPx.

[1291] 22. A method for preparing eAPC-a as defined in item 13, the method comprising:

[1292] a. Combining component A with at least one of components C' and / or E', wherein one or more components C' and / or E' encode one or more aAMs, and combining with an integration factor and at least one

[1293] b. Loss of the selectable marker at the recipient locus of the selection genome

[1294] c. Selecting the expression of one or more aAMs

[1295] d. Selecting for the acquisition of one or more integrated selectable markers.

[1296] 23. The method according to item 22, comprising b and d.

[1297] 24. A method according to item 22 or 23, wherein in step a said one or more components C' and / or E' encode a single aAM.

[1298] 25. A method according to item 24, wherein the method is performed multiple times, wherein each step a is performed using a different aAM, so that different eAPC-a are obtained to obtain a discrete and defined eAPC-a library.

[1299] 26. A method according to item 22 or 23, wherein in step a said one or more components C' and / or E' encode a mixed pool of two or more different aAMs to obtain a library, wherein said library consists of a mixed population of eAPC-a, each of which expresses a single aAM.

[1300] 27. A method for preparing eAPC-pa as defined in item 16, the method comprising:

[1301] a. Combining eAPC-a with at least one of components C' or E', wherein one or more components C' or E' encode one or more aAPX ORFs, and with integration factors and at least one

[1302] b. Loss of the selectable marker at the recipient locus of the selection genome

[1303] c. Selecting the surface expression of one or more aAPXs

[1304] d. Selecting for the acquisition of one or more integrated selectable markers.

[1305] 28. The method according to item 27, which comprises b, c and d.

[1306] 29. A method according to item 27 or 28, wherein in step a said one or more components C' or E' encode a single aAPx.

[1307] 30. A method according to item 29, wherein the method is performed multiple times, wherein each step a is performed using a different aAPX so that different eAPC-pa are obtained to obtain a discrete and defined eAPC-pa library.

[1308] 31. A method according to item 39 or 40, wherein in step a of item 39 the one or more components C' or E' encode a mixed pool of two or more different aAPXs to obtain a library, wherein the library consists of a mixed population of eAPC-pa, each eAPC-pa expressing a single aAPx from the pool used in step a of item 39.

[1309] 32. A method for preparing eAPC-pa as defined in item 15, the method comprising:

[1310] a. Combining eAPC-p with at least one of components C' or E', wherein one or more components C' or E' encode one or more aAM ORFs, and with an integration factor and at least one

[1311] b. Loss of the selectable marker at the recipient locus of the selection genome

[1312] c. Selecting the expression of one or more aAMs

[1313] d. Selecting for the acquisition of one or more integrated selectable markers.

[1314] 33. The method according to item 32, which comprises b and d.

[1315] 34. A method according to item 32 or 33, wherein said one or more components C' or E' encode a single aAM in step a.

[1316] 35. A method according to item 34, wherein the method is performed multiple times, wherein each step a is performed using a different aAM so that different eAPC-pa are obtained to obtain a discrete and defined eAPC-pa library.

[1317] 36. A method according to item 32 or 33, wherein in step a said one or more components C' or E' encode a mixed pool of two or more different aAMs to obtain a library, wherein said library consists of a mixed population of eAPC-pa, each eAPC-pa expressing a single aAM from the pool used in step a.

[1318] 37. A method for preparing the eAPC-pa defined in item 14, the method comprising:

[1319] a. Combining eAPC with at least one of components C' or E', wherein one or more components C' and / or E' encode one or more aAM ORFs and one or more aAPX ORFs, and with integration factors and at least one

[1320] b. Loss of the selectable marker at the recipient locus of the selection genome

[1321] c. Selecting the expression of one or more aAMs and / or obtaining the surface expression of one or more aAPXs

[1322] d. Selecting for the acquisition of one or more integrated selectable markers.

[1323] 38. The method according to item 37, which includes b, c and d.

[1324] 39. A method according to item 37 or 38, wherein in step a said one or more components C' and / or E' encode a single aAM and a single aAPx.

[1325] 40. A method according to item 39, wherein the method is performed multiple times, wherein each time step a is performed using at least one of a different aAM and / or a different aAPX, thereby obtaining different eAPC-pa to obtain a discrete and defined library of eAPC-pa.

[1326] 41. A method according to item 37 or 38, wherein in step a the one or more components C' and / or E' encode a mixed pool of two or more different aAMs and / or two or more different aAPXs to obtain a library, wherein the library comprises a mixed population of eAPC-pa, each eAPC-pa expressing a single aAM and a single aAPx from the pool used in step a.

[1327] 42. An eAPC obtained from a multi-component system according to any preceding item for characterizing

[1328] a. Specificity of the expressed analyte antigen for the analyte TCR, and / or

[1329] b. the affinity of the expressed analyte antigen for the analyte TCR, or

[1330] c. Signaling response of one or more analyte cells expressing the analyte TCR (analyte TC) to the expressed analyte antigen

[1331] wherein the analyte antigen is selected from aAPX:aAM and / or aAM and / or aAPX and / or aAPX:CM, and wherein the analyte eAPC is selected from eAPC-p and / or eAPC-a and / or eAPC-pa.

[1332] 43. Use of a multi-component system as defined in any one of items 1 to 16 for producing one or more analyte eAPCs selected from eAPC-p and / or eAPCa and / or eAPC-pa.

[1333] 44. Use of one or more analyte eAPCs obtainable as defined in item 43 in a diagnostic device.

[1334] 45. A diagnostic device comprising one or more analyte eAPCs.

[1335] 46. ​​The diagnostic device according to item 45 further comprises one or more analyte TCRs.

[1336] 47. Use of one or more eAPCs for producing antigen-specific T cells.

Claims

1. A multi-component system, wherein the first component is an engineered antigen presenting cell (eAPC), referred to as component A, and the second component is a genetic donor vector, referred to as component C, for delivering one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and / or an analyte antigen molecule (aAM), wherein component A a. lack of endogenous surface expression of at least one family of aAPX and / or aAM, and b. contains at least one genomic receiving site, referred to as component B, for integrating at least one ORF encoding at least aAPX and / or aAM, The genomic recipient site B is a natural site for site-directed homologous recombination.

2. The multi-component system according to claim 1, wherein component A further comprises component D, wherein component D is a genomic receiving site for integrating one or more ORFs encoding at least one aAPX and / or aAM.

3. The multi-component system according to claim 2, wherein component D is a natural site or a synthetic construct designed for site-directed homologous recombination.

4. A multi-component system according to any one of the preceding claims, wherein component C is matched with component B, and wherein said component C is designed to deliver a. a single ORF encoding at least one of said aAPX and / or said aAM and / or b. Two or more ORFs encoding at least one of said aAPX and / or said aAM, and wherein a and / or b optionally encode an integrated selection marker, so that said ORF can stably integrate into the component B genomic receiving site and express said aAPX and / or said aAM.

5. The multi-component system according to any one of the preceding claims, wherein the multi-component system further comprises component E, wherein component E is a genetic vector that matches component D, wherein component E is designed to deliver a. a single ORF encoding at least one of said aAPX and / or said aAM, or b. two or more ORFs encoding at least one of said aAPX and / or said aAM, And wherein a and / or b optionally encodes an integrated selection marker, so that the ORF can stably integrate into the component D genome receiving site and express the aAPX and / or the aAM.

6. The multi-component system according to any one of the preceding claims, wherein one or more additional genomic receiver sites and matching genetic donor vectors are added as additional components of the system.

7. A multi-component system according to any one of the preceding claims, wherein the aAPX may be any of the following c. One or more members of HLA class I d. One or more members of HLA class II e. One or more non-HLA antigen presenting complexes f. Or a combination of ab and / or c.

8. The multi-component system according to any one of the preceding claims, wherein aAM is selected from a. a polypeptide or polypeptide complex provided as an analyte antigen, b. a peptide derived from a polypeptide provided as an analyte antigen, c. a peptide provided as an analyte antigen, d. metabolites provided as analyte antigens, e. a polypeptide or polypeptide complex translated from the ORF of the analyte antigen molecule, f. a peptide from a polypeptide translated from the ORF of an analyte antigen molecule, g. Peptides from the altered component A proteome, h. polypeptides from the altered component A proteome, and / or i. metabolites from the metabolite group that changes component A, and / or combinations thereof.

9. The multi-component system according to any one of the preceding claims, wherein component B and / or component D is included and comprises at least one of the following genetic elements a. Homology arms, b. Eukaryotic promoter, c. Eukaryotic conditional regulatory elements, d. Eukaryotic terminator, e. Selection marker, f. Splice acceptor site, g. Splice donor site, h. Non-protein coding genes, i. Insulators, j. Mobile genetic elements, k. Meganuclease recognition site, l. Internal ribosome entry site (IRES), m. A viral self-cleaving peptide element, or n. Kozak consensus sequence.

10. The multi-component system according to any one of the preceding claims, wherein the component C and / or component E is included, and the component C and / or component E comprises at least one of the following genetic elements a. Homology arms, b. Eukaryotic promoter, c. Eukaryotic conditional regulatory elements, d. Eukaryotic terminator, e. Selection marker, f. Integration of selection markers, g. Splice acceptor site, h. Splice donor site, i. Non-protein coding genes, j. Insulators, k. Mobile genetic elements, l. Meganuclease recognition site, m. Viral self-cleaving peptide element, n.Antibiotic resistance cassette, o. Bacterial origin of replication, p. yeast origin of replication, q. Cloning site, n.kozak consensus sequence, s. Internal ribosome entry site (IRES).

11. The multi-component system according to any one of the preceding claims, wherein component B and / or component D are included, and the components B and / or D are used for directed homologous recombination of a single ORF, and comprise: a. Eukaryotic promoter b. A pair of homology arms c. Kozak consensus sequence d.Selection marker e. Eukaryotic terminator.

12. The multi-component system according to any one of the preceding claims, wherein component B and / or component D are included and are used for directed homologous recombination of two or more ORFs comprising the following genetic elements: a. Eukaryotic promoter b. A pair of homology arms c. Two or more Kozak consensus sequences d.Selection marker e. Eukaryotic terminator f. Second eukaryotic promoter g. Second selection marker h. Second eukaryotic terminator.

13. The multi-component system according to any one of the preceding claims, wherein component C and / or component E are present, said component C and / or component E being used for directed homologous recombination of a single ORF and comprising the following genetic elements: a. A pair of homology arms b. Kozak consensus sequence c. Antibiotic resistance cassette d. Bacterial origin of replication e. Cloning site for introduction of a single ORF encoding one or more aAPX and / or aAM and / or integrated selection marker.

14. The multi-component system according to any one of the preceding claims, wherein component C and / or component E are present, said component C and / or component E being used for directed homologous recombination of two or more ORFs and comprising the following: a. A pair of homology arms b. Two or more Kozak consensus sequences c. Antibiotic resistance cassette d. Bacterial or yeast origin of replication e. A cloning site for the introduction of two or more ORFs, with a eukaryotic terminator, encoding one or more aAPX and / or aAM and / or an integrated selection marker.

15. The multi-component system according to any one of the preceding claims, wherein component C and / or component E further comprises at least one ORF encoding at least one aAPX and / or aAM to form component C' and / or component E'.

16. A multi-component system according to claim 15, comprising a library of components C' and / or components E'.

17. A multi-component system according to claim 15 or claim 16, wherein one or more components C' and / or component E' can be combined with component A to integrate one or more aAPX ORFs encoded in component C' and / or component E' into component B and / or component D to obtain a cell called eAPC-p, wherein component B and / or component D becomes component B' and / or component D', so that eAPC-p expresses aAPx on the cell surface.

18. A multi-component system according to claim 15 or claim 16, wherein one or more components C' and / or component E' can be combined with component A to integrate one or more aAM ORFs encoded in component C' and / or component E' into component B and / or component D to obtain a cell called eAPC-a, wherein component B and / or component D becomes component B' and / or component D', so that eAPC-a expresses aAM on the cell surface or inside the cell.

19. A multi-component system according to claim 15 or claim 16, wherein one or more components C' and / or component E' can be combined with component A to integrate one or more aAPX ORFs and / or one or more aAMs encoded in component C' and / or component E' into component B and / or component D to obtain a cell called eAPC-pa, wherein component B and / or component D becomes component B' and / or component D', so that eAPC-pa expresses aAPX and aAM and / or aAPX:aAM.

20. A multi-component system according to any one of claims 15 to 17, wherein one or more components C' or components E' can be combined with eAPC-p to integrate one or more aAM ORFs encoded in component C' or component E' into component B or component D to obtain a cell called eAPC-pa, in which component B or component D becomes component B' or component D', so that it expresses aAPX and aAM and / or aAPX:aAM.

21. A multi-component system according to any one of claims 15, 16 or 17, wherein one or more of said components C' or E' are combined with eAPC-a to integrate one or more aAPX ORFs encoded in component C' or component E' into component B or component D to obtain a cell called eAPC-pa, in which component B or component D becomes component B' or component D', so that it expresses aAPX and aAM and / or aAPX:aAM.

22. Use of the multi-component system according to any one of claims 1 to 16 for producing one or more analyte eAPCs selected from eAPC-p, eAPC-a and eAPC-pa.

23. A method for preparing an eAPC-p as defined in claim 17, the method comprising: a. Combining component A with at least one of component C' and / or component E', wherein one or more components C' and / or component E' encode one or more aAPXs, and combining with an integration factor, and at least one of the following b. Loss of the selectable marker at the receiving locus of the selection genome, c. selecting one or more aAPXs for surface expression, d. Selecting for the acquisition of one or more integrated selectable markers.

24. The method according to claim 23, comprising b, c and d.

25. A method for preparing eAPC-a as defined in claim 18, the method comprising: a. Combining component A with at least one of component C' and / or component E', wherein one or more components C' and / or component E' encode one or more aAMs, and combining with an integration factor, and at least one of the following b. Loss of the selectable marker at the receiving locus of the selection genome, c. selecting the acquisition of expression of one or more aAMs, d. Selecting for the acquisition of one or more integrated selectable markers.

26. The method of claim 25, comprising b and d.

27. The method for preparing eAPC-pa as defined in claim 21, comprising: a. Use of a multi-component system as defined in claim 15 for combining an eAPC-a as defined in claim 18 with at least one of component C' or component E', wherein one or more components C' or component E' encode one or more aAPXORFs, and in combination with an integration factor, and at least one of the following b. Loss of the selectable marker at the receiving locus of the selection genome, c. selecting one or more aAPXs for surface expression, d. Selecting for the acquisition of one or more integrated selectable markers.

28. A method for preparing eAPC-pa as defined in claim 20, the method comprising: a. A multi-component system as defined in claim 15 for combining an eAPC-p as defined in claim 18 with at least one of components C' or E', wherein one or more components C' or components E' encode one or more aAM ORFs, and in combination with an integration factor, and at least one of the following b. Loss of the selectable marker at the receiving locus of the selection genome, c. Select one or more aAMs for surface expression, d. Selecting for the acquisition of one or more integrated selectable markers.

29. The method according to claim 28, comprising b and d.

30. A method for preparing the eAPC-pa defined in claim 19, the method comprising: a. using a multi-component system as defined in claim 15 for combining an eAPC with at least one of component C' or component E', wherein one or more components C' and / or component E' encode one or more aAM ORFs and one or more aAPXORFs, and in combination with an integration factor, and at least one of the following b. Loss of the selectable marker at the receiving locus of the selection genome, c. selecting the surface expression of one or more aAMs and / or the surface expression of one or more aAPXs, d. Selecting for the acquisition of one or more integrated selectable markers.

31. The method according to claim 30, comprising b, c and d.

32. A multi-component system according to any one of claims 1, 3-21 and / or the use according to claim 22 and / or the method according to any one of claims 23-32, wherein the one or more natural sites for site-directed homologous recombination are each selected from the HLA locus and the AAVS1 locus.